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P R E F A C E 
This thesis results from a research project on inherited disorders of pyri-
midine and purine metabolism, and the influence of antimetabolites on this 
part of metabolism Up to a few years ago purine and pynmidine metabolism 
used to be regarded as separate entities, and this view is reflected in the 
way most biochemical textbooks deal with this part of intermediary metabo-
lism. Pyrimidine and purine metabolism, however, are closely interrelated. 
This interrelationship will be the main theme of this thesis, and is illus-
trated in three sections dealing with the role of phosphoribosylpyrophos-
phate (PRPP), the effects of the purine analog allopurinol on pynmidine 
metabolism, and the possible disturbances of pyrimidine metabolism secondary 
to deficiency of the purine enzymes adenosine deaminase and purine nucleo-
side Phosphorylase. The investigations were limited to mammalian blood cells 
and involved both intact cells and extracts of erythrocytes and lymphocytes. 
Chapter 1 deals with our current knowledge of pynmidine and purine 
metabolism, its regulation and the disturbances caused by enzyme deficien-
cies or enzyme inhibitors. 
In chapters 2-5 the role of PRPP in pyrimidine and purine metabolism is 
investigated. First the enzymes which utilize PRPP in mammalian erythrocytes 
were studied (chapter 2). The assays developed to measure the concentration 
and synthesis of PRPP are described in chapter 3. They were used to study 
PRPP metabolism in hyperuricemia and gout (chapter 4) and to investigate 
the synthesis and degradation of PRPP in erythrocytes from ten mammalian 
species (chapter 5) 
Chapter 6 deals with the effect of allopurinol administration on the 
urinary excretion of orotic acid and orotidine This effect can be ascribed 
to inhibition of orotate phosphoribosyltransferase and orotidine 5'-mono-
phosphate decarboxylase, as shown in chapter 7 This chapter also describes 
the allopurinol-mediated stabilization of these enzymes in erythrocytes 
The stability of enzymes of pyrimidine metabolism in aging erythrocytes is 
the main subject of chapter 8. Chapter 9 deals with the effect of several 
purine and pyrimidine nucleotides on the activities of orotate phosphoribo-
syltransf erase and orotidine 5'-monophosphate decarboxylase. 
The activities of adenosine deaminase and purine nucleoside phosphoryl-
1 
age were determined in lymphocytes and erythrocytes of man, horse and cattle 
(chapter 10). The activity of the former enzyme was very low in horse 
lymphocytes. Since deficiency of adenosine deaminase in man seems to inter-
fere with pyrimidine biosynthesis de novo, the relative contributions of 
the de novo and salvage pathways to the synthesis of pyrimidine nucleotides 
were evaluated for human and horse lymphocytes (chapter 11). 
Finally, in chapter 12 the main results of the preceding chapters are 
discussed in order to demonstrate the relationships between pyrimidine and 
purine metabolism. 
2 
C H A P T E R 1. 
GENERAL INTRODUCTION 
1.1. PYRIMIDINE METABOLISM 
Pyrimidine nucleotides are precursors of nucleic acids and of nucleotide co­
enzymes involved in carbohydrate and lipid metabolism. The biological and 
clinical aspects of pyrimidine metabolism have been reviewed by Levine et 
al. (1). During normal cell growth and functioning an adequate supply of 
pyrimidine nucleotides is ensured by self-balancing networks of enzymatic 
reactions. In most cells from multicellular organisms, pyrimidine nucleotide 
biosynthesis can proceed by two mechanisms, de novo synthesis and the sal­
vage pathway. 
De novo synthesis of UMP requires six enzymatic steps (Fig. 1.1). The 
first step is catalyzed by carbamoylphosphate synthetase II (EC 2.7.2.9), 
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Fig. 1.1. The interrelation of pyrimidine biosynthesis de novo and the bio­
synthesis of urea. The dotted tine represents the mitochondrial membrane. 
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a cytosol enzyme which utilizes glutamine as its nitrogen source. The enzyme 
is not present in mammalian erythrocytes (2). Carbamoylphosphate synthetase 
I (EC 2.7.2.5) which is located in the mitochondria of the liver utilizes 
ammonia and supplies carbamoylphosphate for the ornithine cycle. In hyper­
ammonemia due to enzyme deficiencies of the ornithine cycle or induced by 
administration of ammonium ions (3) there is an increase in pyrimidine syn­
thesis de novo indicating that intramitochondrial carbamoylphosphate is 
shunted from the ornithine cycle into pyrimidine synthesis. Recent evidence 
(4) suggests that also under normal conditions carbamoylphosphate synthe­
tase I is an important source of carbamoylphosphate for pyrimidine synthesis 
in the liver. Aspartate transcarbamylase (EC 2.1.3.2) and dihydroorotase 
(EC 3.5.2.3) are the second and third enzyme of the de novo pathway and form 
together with carbamoylphosphate synthetase II a multifunctional enzyme 
complex (5,6). Dihydroorotate dehydrogenase (EC 1.3.3.1), the next enzyme 
in the pathway, is located on the mitochondrial inner membrane (7). The en­
zyme is not present in erythrocytes (2). The terminal two enzymes of the 
pathway, orotate phosphoribosyltransferase (OPRT, EC 2.4.2.10) and orotidine 
5'-monophosphate decarboxylase (EC 4.1.1.23) are present in the cytosol as 
an enzyme complex (5). OPRT and ODC catalyze the conversion of orotate and 
phosphoribosylpyrophosphate (PRPP) to UMP and CO , with orotidine 5'-mono-
phosphate (OMP) as an intermediate (Fig. 1.2). As inherited disorders of 
pyrimidine synthesis de novo orotic aciduria types I and II are known, which 
are caused by deficiency of OPRT and/or ODC (8). 
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The salvage pathway for the synthesis of UMP (Fig. 1.2) involves the 
phosphorylation of uridine by uridine kinase (EC 2.7.1.48). Uridine may be 
derived from intracellular breakdown of nucleic acids. Cells may also use 
blood-borne nucleosides derived from dietary sources or synthesized in the 
liver by the de novo pathway (1). The reversible conversion of uridine to 
uracil is catalyzed by uridine Phosphorylase (EC 2,4.2.3). The significance 
of the salvage pathway in relation to cell division and differentiation has 
been reviewed by Roux (9). Uridine kinase also phosphorylates a number of 
pyrimldine analogues. The chemotherapeutic aspects of this enzyme have been 
reviewed by Cihak and Rada (10). 
Both de novo synthesis and the salvage pathway appear to be subject to 
feedback inhibition. UTP is an allosteric inhibitor of carbamoylphosphate 
synthetase II in mammalian cells (11). UTP and CTP inhibit purified uridine 
kinase. The inhibition appears to be competitive with respect to ATP (10). 
Uridine kinase was not inhibited, however, in intact cells which contained 
elevated concentrations of UTP or CTP (12). The regulatory role of PRPP in 
pyrimidine biosynthesis de novo is discussed in section 1.3. 
In human erythrocytes a pyrimidine-specific 5'-nucleotidase is present. 
Deficiency of this enzyme is associated with hemolytic anemia (13). 
1.2. PURINE METABOLISM 
Purine nucleotides are precursors of nucleic acids and important sources of 
stored metabolic energy. The cyclic nucleotides cAMP and cGMP are involved 
in regulatory processes. ATP is thought to be a neurotransmitter in "purin-
ergic" nerves. The significance of purine metabolism for cell physiology 
has extensively been reviewed by McKeran and Watts (14). The biosynthesis 
of purine nucleotides can be accomplished by de novo synthesis or by utili-
zation of preformed purine bases or nucleosides (Fig. 1.3). 
The de novo pathway is a sequence of ten enzymatic reactions leading 
to the synthesis of IMP. PRPP and glutamine are the substrates of the first 
enzyme, PRPP amidotransferase (EC 2.4.2.14). This enzyme is not present in 
mature erythrocytes (2,15). The synthesis of PRPP and its regulatory role 
are discussed in 1.3. IMP can be interconverted to AMP and GMP. 
5'-nucleotidase (EC 3.1.3.5) catalyzes the cleavage of orthophosphate 
from the 5'-position of nucleoside monophosphates. The enzyme is deficient 
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in lymphocytes of some patients with hypogammaglobulinemia (16). The nucleo­
sides guanosine and inosine can be converted to guanine and hypoxanthine, 
respectively, in a reversible reaction catalyzed by purine nucleoside Phos­
phorylase (PNP, EC 2.4.2.1). Deficiency of PNP is associated with defective 
T-lymphocyte function (17). Adenosine is not a substrate for PNP, but it can 
be deaminated by adenosine deaminase (ADA, EC 3.5.4.4). ADA deficiency is 
associated with a dysfunction of both B- and T-lymphocytes in one form of 
the severe combined immunodeficiency disease (18). The deficiencies of ADA 
and PNP will be discussed in more detail in 1.5. 
Adenosine can be salvaged by phosphorylation to AMP, a reaction catal-
6 
yzed by adenosine kinase (EC 2.7.1.20). The salvage of purine bases involves 
a reaction with PRPP to yield nucleotides, and is catalyzed by adenine phos-
phor ibosyltransf erase (APRT, EC 2.4.2.7) and hypoxanthine-guanine phospho-
ribosyltransferase (HfiPRT, EC 2.4.2.8). The liver may be an important source 
of preformed purines which are then transported by erythrocytes to the pe-
ripheral tissues (19). The transfer of adenosine from rabbit liver to ery-
throcytes has been demonstrated (20). The salvage pathway is also important 
for the conversion of purine antimetabolites to their nucleotide derivatives, 
which in many cases are the active forms of the drugs (19). Enzyme deficien-
cies of both APRT and HGPRT have been described. Deficiency of APRT leads to 
accumulation of 2,8-dihydroxyadenine (21). HGPRT deficiency can lead to the 
Lesch-Nyhan syndrome or to X-linked gout (22-24). Hyperuricemia and hyper-
uricosuria are common to both diseases, but in the Lesch-Nyhan syndrome 
there are also neurological disturbances (compulsive self-mutilation, choreo-
athetosis). 
Hyperuricemia may result from overproduction or underexcretion of uric 
acid. The renal contribution to hyperuricemia is outside the scope of this 
thesis and will not be discussed here. Excessive production of uric acid 
(primary metabolic gout) is usually associated with an accelerated rate of 
purine synthesis de novo. PRPP amidotransferase is the first and presumably 
rate-limiting enzyme of purine synthesis de novo. The activity of this en-
zyme is dependent on the concentrations of PRPP, purine ribonucleotides and 
orthophosphate (25-27). The role of PRPP is discussed in section 1.3. Purine 
ribonucleotides inhibit the purified enzyme (26), but enzyme activity in 
intact Ehrlich ascites cells was not inhibited even when purine nucleotide 
concentration was elevated threefold (28). 
1.3. PRPP AND THE REGULATION OF PYRIMIDINE AND PURINE METABOLISM 
PRPP plays a role in pyrimidine biosynthesis at two different sites. It is 
an allosteric activator of carbamoylphosphate synthetase II (11) and a sub-
strate for OPRT (Fig. 1.4). The first enzyme of pyrimidine synthesis de novo 
appears to be rate-limiting (11). The conversion of orotate to OMP seems to 
be the second limiting step of the de novo pathway. In hyperammonemia, the 
increased availability of carbamoylphosphate for pyrimidine synthesis re-
sults in the accumulation of orotate (3). In HGPRT-deficient lymphoblasts 
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the increased intracellular PRPP concentration was associated with an in­
creased concentration of pyrimidine nucleotides (29). This latter finding 
might also be explained by an activation of carbamoylphosphate synthetase 
14 
II, but there was no evidence of an increased incorporation of [ C]bicar-
bonate into pyrimidine nucleotides. 
PRPP is also a substrate for the purine phosphoribosyltransferases 
(APRT and HGPRT) and for PRPP amidotransferase, and it converts the cata-
lytically inactive form of PRPP amidotransferase to the active form (25). 
The intracellular concentration of PRPP is substantially lower than the К 
m 
values of PRPP for the amidotransferase and HGPRT (30), and PRPP concentra­
tion may therefore be rate-limiting for these enzymatic reactions. The 
regulatory role of PRPP concentration with respect to purine biosynthesis 
de novo has been confirmed in experiments with intact Ehrlich ascites cells 
(28) and liver slices (31). Therefore an increased availability of PRPP may 
cause an accelerated rate of purine biosynthesis de novo and overproduction 
of uric acid. Hyperuricemia and gout associated with HGPRT deficiency can 
be ascribed to a reduced consumption of PRPP leading to a surplus in the 
amount available for purine synthesis de novo (30, 32). An excess of PRPP 
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Fig. 1.5. Overall picture of the reactions involved in synthesis, utilization 
and degradation of PRPP. 
can also result from hyperactivity of the enzyme PRPP synthetase (EC 2.7.6. 
1). PRPP synthetase catalyzes the reaction between ATP and ribose 5-phosphate 
to form PRPP and AMP (Fig. 1.5). Orthophosphate is an essential allosteric 
activator of the enzyme (33, 34). Recent evidence indicates that PRPP syn­
thetase is X-linked (35). Several mutations in this enzyme leading to purine 
overproduction have been found in gouty patients. The mutations may affect 
the regulatory site or the catalytic site of the enzyme. Sperling et al. (36) 
identified a mutant PRPP synthetase enzyme which had a decreased sensitivity 
to inhibition by AMP, ADP, GDP and 2,3-DPG. Becker et al. (37) discovered a 
mutant PRPP synthetase with a threefold increase in catalytic activity per 
enzyme protein molecule. Becker also reported the occurrence of kinetic 
variants of PRPP synthetase in some gouty patients. In these cases the en­
zyme purified from erythrocytes had a normal activity but an increased 
affinity for one of its substrates (38). 
Ribose 5-phosphate, the precursor of PRPP, is a product of both the 
oxidative and the non-oxidative pentose phosphate pathways (Fig. 1.5). An 
alternative route is the phosphorolysis of ribonucleosides (39). The ribose 
9 
1-phosphate formed can be converted to ribose 5-phosphate by phosphoribo-
mutase. In some gouty patients the excessive purine synthesis appeared to 
result from an increased ribose 5-phosphate concentration, leading to an 
increased availability of PRPP (38). An increased supply of ribose 5-phos-
phate may also contribute to the hyperuricemia associated with deficiency 
of glucose 6-phosphatase (32). The decreased concentration of PRPP in cul-
tured lymphoblasts during glutamine limitation seems to result from a de-
creased availability of ribose 5-phosphate (39). 
Degradation of PRPP by enzymatic hydrolysis occurs in homogenates of 
several human tissues (40). The hydrolysis does not require magnesium ions, 
in contrast to the utilization of PRPP by the pathways discussed above. 
Alkaline phosphatase appears to be the responsible enzyme. 
1.4. EFFECTS OF ALLOPURINOL ON PURINE AND PYRIMIDINE METABOLISM 
Allopurinol (4-hydroxypyrazolo (3,4-d)-pyrimidine) is a structural analog 
of hypoxanthine (Fig. 1.6). Its oxidation product, oxipurinol, closely re-
sembles the pyrimidine compound orotic acid. Both allopurinol and oxipurinol 
can be converted to ribonucleotide derivatives, as shown in Fig. 1.7. They 
are mainly excreted as ribonucleosides. The metabolism of allopurinol and 
its effects on purine and pyrimidine metabolism have been reviewed (41). 
Allopurinol and oxipurinol are potent inhibitors of xanthine oxidase 
(EC 1.2.3.2). Xanthine oxidase catalyzes the oxidation of hypoxanthine to 
xanthine and of xanthine to uric acid. Allopurinol has proven to be a suit-
able chemotherapeutic agent to reduce serum uric acid concentration in hyper-
uricemia. In most patients the replacement of urinary uric acid by the oxy-
purines, hypoxanthine and xanthine, is less than stoichiometric. This may 
indicate that de novo purine synthesis is suppressed by allopurinol, pos-
sibly by allopurinol l-ribonucleotide (26). An alternative explanation 
would be that the oxypurines are not excreted but reutilized. Whatever the 
mechanism, this effect of allopurinol depends on HGPRT activity since in 
patients with HGPRT deficiency the oxypurine excretion increases during 
allopurinol therapy to the same extent as uric acid excretion decreases. 
The administration of allopurinol also 1 .-ads to interference with 
pyrimidine metabolism as indicated by an increased excretion of orotidine 
and orotic acid in urine (41). The increased excretion of orotidine can be 
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ascribed to inhibition of ODC by ribonucleotides of allopurinol and oxi-
purinol. The increased excretion of orotic acid suggested that allopurinol 
also causes inhibition of OPRT, but the mechanism of this inhibition had 
not yet been elucidated. Evidence will be presented in this thesis that 
the inhibition may be mediated by OMP, Allopurinol therapy also induces an 
apparent increase in the activities of OPRT and ODC in erythrocytes. Sev-
eral hypotheses have been proposed to explain this phenomenon. Evidence 
presented in this thesis suggests that the apparent increase of enzyme ac-
tivities is due to enzyme stabilization during the life-span of the ery-
throcytes. The effects of allopurinol on purine and pyrimidine metabolism 
and the presumable mechanisms of these effects are summarized in Table 1.1. 
TABLE 1.1 
EFFECTS OF ALLOPURINOL ON PURINE AND PYRIMIDINE METABOLISM 
Hypourlcernia 
Decreased punne 
biosynthesis 
Orotic aciduria 
Orotidinuna 
Increased act iv i ty 
of OPRT and ODC 
in erythrocytes 
Inhibition of xanthine oxidase Allopurinol 
Oxipurinol 
Inhibition of PRPP 
amidotransferase 
Inhibition of OPRT 
Inhibition of ODC 
StabilIzation of 
OPRT and ODC 
Allopunnol-l-r1bonucleot1de? 
OHP? 
Oxlpurinol-l-ribonucleotide 
Oxipijrinol-7-ribonucleotide 
Allopurinol-l-rlbonucleotide 
Allopurinol-l-r1bonucleotide? 
0x1 purl nol-7-ribonucleotide7 
OMP' 
1.5. PYRIMIDINE METABOLISM AND THE DEFICIENCIES OF ADENOSINE DEAMINASE AND 
PURINE NUCLEOSIDE PHOSPHORYLASE 
The association of severe combined immunodeficiency disease with deficiency 
of adenosine deaminase was first described by Giblett et al. (18). Sub-
sequently, deficiency of purine nucleoside Phosphorylase was detected in a 
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child with dysfunction of T-lymphocytes (17). The metabolic relationship 
of these sequential enzymes and the similar suppression of T-lymphocyte 
function suggest a common mechanism for impairment of the immune response. 
Furthermore, inosine which accumulates in PNP deficiency is a competitive 
inhibitor of ADA (42). 
The precise mechanism by which these enzyme deficiencies are related 
to immunodeficiency is not known but several hypotheses have been proposed 
(Table 1.2). Most of these hypotheses are based on the assumption that ADA 
normally detoxifies adenosine by converting it to inosine which is then 
catabolized by PNP. Accumulation of adenosine or inosine may inhibit the 
uptake of other nucleosides into lymphocytes. Intracellular accumulation of 
adenine nucleotides may interfere with some essential process in the lymph­
ocyte (e.g. synthesis of pyrimidine nucleotides, see below). The effects of 
adenosine on lymphoid cells have recently been reviewed by Seegmiller et al 
(43). Another possibility is that a product formed by the action of ADA and 
PNP is essential for normal lymphocyte function. Finally, recent evidence 
suggests that the immunodeficiency may be caused by accumulation of deoxy-
ribonucleotides (44, 45) leading to inhibition of the enzyme ribonucleotide 
reductase. 
TABLE 1.2 
POSSIBLE EFFECT OF ADA- OR PNP DEFICIENCY ON LYMPHOCYTES 
I . Inhibition of uptake other nucleosides 
I I Intracellular accumulation of adenine nucleotides or cyclic AMP, 
which may cause. 
a inhibition PPRP synthetase by adenine nucleotides, by cyclic 
AMP or by depletion of Ρ 
b. inhibition pyrimidine nucleotide synthesis de novo 
c. disturbance of energy charge 
d. inhibition of lymphocyte proliferation or transformation and 
cytotoxicity by cyclic AMP 
I I I . Deficiency of products (inosine, hypoxanthine, nbose 1-phosphate) 
IV. Trapping of punnedeoxynbonucleosides as phosphates. 
inhibition of pyrimidine deoxynbonucleotide synthesis. 
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Green and Chan (46) first suggested that ADA deficiency may cause an 
interference of pyrimidine biosynthesis de novo. The addition of adenosine 
to fibroblasts or lymphoid cells cultured in a medium free of ADA activity 
resulted in a depletion of cellular pyrimidine nucleotides and accumulation 
of orotic acid. These effects of adenosine could be prevented by uridine 
and were ascribed to an effect of adenine nucleotides on the activity of 
OPRT or the availability of PRPP (46, 47). Inhibition of cell growth, de­
pletion of cellular pyrimidine nucleotides and accumulation of orotic acid 
were also found when lymphoma cells (48, 49) or lymphoblasts (50) were 
cultured in the presence of adenosine and erythro-9-(2-hydroxy-3-nonyl)-
adenine (EHNA), an inhibitor of ADA. Again, uridine prevented the toxic 
effects of adenosine. The occurrence of orotic aciduria in two patients 
with deficiency of PNP (51) suggests that PNP deficiency also leads to in­
terference with pyrimidine biosynthesis de novo. 
Accumulation of orotic acid could be explained by a decreased intra­
cellular concentration of PRPP. The content of PRPP in liver and spleen 
slices of the rat was markedly decreased by the addition of adenosine (52). 
Addition of adenosine in combination with the ADA inhibitor EHNA resulted 
adenosine 
kindse 
adenosine 
deaminase 
purine nucleoside 
phosphorvlase 
PRPP - synthetase 
- > AMP > A D P »ATP 
Fig. Ι.β. The interrelation of adenosine metabolism and PRPP metabolism. 
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in a decreased PRPP concentration in lymphoma cells (49) and lymphoblasts 
(50). Inhibition of the enzyme PRPP synthetase by adenine nucleotides would 
offer an explanation for the decreased PRPP concentration. An alternative 
explanation would be a decreased availability of precursors of PRPP. Fig. 
1.8 shows that the consecutive action of ADA and PNP on adenosine results 
in the production of ribose 1-phosphate, which can be converted to ribose 
5-phosphate, the precursor of PRPP. The significance of PRPP for lymphocyte 
function is illustrated by the finding that an increase of the PRPP concen-
tration is one of the early events in the stimulation of lymphocytes by 
phytohemagglutinin (53). 
Whatever the mechanism of inhibition of pyrimidine biosynthesis de 
novo, it is obvious that the inhibition could be bypassed by means of the 
salvage pathway involving uridine. 
1.6. AIM AND SCOPE OF THIS STUDY 
The present investigation deals with the regulation of pyrimidine and purine 
metabolism, and the influence of inherited disorders and antimetabolites on 
this part of intermediary metabolism. In intact cells the pathways of pyrim-
idine and purine metabolism are not isolated entities but interact with 
each other and with the metabolism of amino acids and carbohydrates. Three 
aspects of the close interrelationship of pyrimidine and purine metabolism 
are investigated in detail. 
First, special attention is given to the role of phosphoribosylpyro-
phosphate in pyrimidine and purine metabolism. The activities of the phos-
phoribosyltransferases (OPRT, APRT and HGPRT) in mammalian hemolysates are 
reported in chapter 2. In chapter 3 simple methods are described for esti-
mating the concentration of PRPP and the activity of PRPP synthetase. These 
methods are used to investigate the role of PRPP in hyperuricemia and gout 
(chapter 4) and to measure the concentration, synthesis and degradation of 
PRPP in hemolysates from ten mammalian species (chapter 5). 
Secondly, the effects of the purine analog allopurinol on pyrimidine 
metabolism are investigated. An isotope dilution assay is described which 
is adequate for the accurate and specific measurement of orotic acid and 
orotidine. This assay is applied to evaluate the effect of allopurinol ad-
ministration on the urinary excretion of these compounds (chapter 6). In 
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chapter 7 mechanisms are proposed for the allopurinol-induced stabilization 
and inhibition of the enzymes OPRT and ODC. The stability of enzymes of 
pyrimidine metabolism in aging erythrocytes is the main subject of chapter 
8. Chapter 9 deals with the effect of several purine and pyrimidine nucleo-
tides on the activities of OPRT and ODC. 
Thirdly, the possible interference of pyrimidine biosynthesis de novo 
secondary to deficiencies of enzymes of purine metabolism (ADA and PNP) is 
the starting-point for an investigation of pyrimidine metabolism in lympho-
cytes of man and horse. Horse lymphocytes are included in this investigation 
since ADA activity appeared to be virtually absent in these cells as report-
ed in chapter 10. Chapter 11 deals with the relative contribution of the 
de novo pathway and the salvage pathway to the synthesis of pyrimidine nu-
cleotides in lymphocytes of man and horse. 
When studying metabolic pathways and their regulation, one must be very 
cautious in extrapolating the results of studies with cell extracts to the 
metabolism of intact cells or tissues. The conditions in which such studies 
are performed - high concentration of substrate, low concentration of enzyme 
and total protein, artificial ionic environment, etc. - are not at all like 
those that exist in intact cells. Furthermore, even if the results obtained 
with a cell extract reflect the intracellular metabolism, the conclusions 
drawn are not a priori valid for other cells than the particular type of 
cell that was studied. Whenever possible, the results obtained with cell 
extracts will be compared with measurements of the metabolism in intact 
cells. The red cell is a peculiar cell type since it contains no cell organ-
elles and lacks several important enzymes of pyrimidine and purine metabo-
lism (2 ). Therefore metabolic pathways are usually investigated both in 
erythrocytes and in leukocytes or lymphocytes. 
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C H A P T E R 2 
ACTIVITY OF PURINE PHOSPHORIBOSYLTRANSFERASES AND OF TWO ENZYMES OF 
PYRIMIDINE BIOSYNTHESIS IN ERYTHROCYTES OF TEN MAMMALIAN SPECIES 
W.J.M.Tax, J.H. Veerkamp and J.M.F.Tnjbels 
(Comp.Biochera.Physiol. (1976) 54 B, 209-212) 
2.1. SUMMARY 
1. Activities of HGPRT, APRT, OPRT and ODC have been determined in hemolys-
ates from man and nine other mammalian species. 
2. HGPRT was found to be nearly absent from horse erythrocytes, while low 
activities were found in dog and rat erythrocytes. 
3. OPRT and ODC activities appeared to be very low in sheep erythrocytes, 
and below detection limit in horse erythrocytes. 
4. OPRT and ODC activities were found to be coordinate in erythrocytes from 
all species studied. 
2.2. INTRODUCTION 
In our studies on the regulation of purine and pyrimidine metabolism we 
were looking for an animal which could serve as a suitable model for human 
purine and pyrimidine metabolism. In man, a deficiency of OPRT and ODC has 
been described, associated with orotic aciduria (Smith et al., 1961), while 
deficiency of APRT (Cartier and Hamet, 1974) and of HGPRT (Seegmiller et 
al., 1967) has been reported as well. HGPRT and APRT are enzymes of the 
purine salvage pathway. Some tissues have both salvage and de noJo pathways 
for synthesis of purine nucleotides, but others have an absolute requirement 
for externally supplied purines. Erythrocytes may transport purines from the 
tissues where they are synthesized to their sites of utilization (Murray, 
1971). HGPRT activity may play a role in purine transport across cell 
membranes (Benke et al., 1973). Because in most mammalian species little is 
known about the activity of these enzymes in erythrocytes, we decided to 
21 
determine the activities of HGPRT, APRT, OPHT and ODC in heraolysates from 
man and nine other mammals. 
2.3. MATERIALS AND METHODS 
Animals 
Blood samples were taken from adult human volunteers or adult animals. 
Swiss mice (Mus musculus), Wistar rats (Rattus norvegicus), White New-
Zealand rabbits (Oryctolagus cumculus), Beagle dogs (Cams familiaris), 
Texel sheep (Ovis arles) and Rhesus monkeys (Macaca mulatta) were taken 
for blood samples. Blood samples from horse (Equus caballus), pig (Sus 
scrofa) and cattle (Bos taurus) were obtained from the local slaughterhouse. 
Materials 
Phosphorylribose-l-pyrophosphate (PRPP) tetrasodium salt was obtained from 
Boehnnger, Mannheim. Orotic acid monosodium salt and orotidine S'-mono-
phosphonc acid trisodium salt were purchased from Sigma Chemical Co., St. 
Louis, U.S.A. 
14 14 
[Carboxyl- C]-orotic acid hydrate (42.4 mCi/mmole) and [carboxyl- C]-
orotidine 5'-monophosphate tnammonium salt (36.9 mCi/mmole) were obtained 
from New England Nuclear Corporation, as well as omnifluor and aquasol. 
14 14 
[8- C]-Hypoxanthine (58 mCi/mmole) and[8- C]-adenine (54 mCi/mmole) were 
from the Radiochemical Centre, Amersham, England. 
Aluminum sheets (20x20 cm) precoated with 0.1 mm of PEI-cellulose were 
obtained from Merck, Darmstadt, West Germany. 
Preparation of heraolysates 
Heparinized blood samples were centrifugea and erythrocytes were washed 
twice with 50 mM Tris-buffered saline (pH 7.4). Cells were lysed by addition 
of a 3-fold vol of 10 mM Tris buffer (pH 7.4). Some heraolysates, especially 
those from human volunteers and cattle, were prepared by freezing and thaw-
ing the cells twice in an aceton/dry ice bath. 
Enzyme assays 
14 Enzyme activities were estimated with radiochemical methods using C-
22 
labeled compounds. Determination of radioactivity was performed in a Packard 
3380 liquid scintillation spectrophotometer with external standardization. 
Protein was determined according to Lowry et al. (1951). Specific enzyme 
activities are expressed in nmoles of product formed m 1 hr/mg of protein, 
о 
at 37 С and the assay conditions described below. 
OPRT assay 
14 
The reaction mixture contained 0.3 mil [carboxyl- C]-orotic acid (0.15 mCi/ 
mmole), 0.7 mM PRPP, 5 mM MgCl and varying amounts of hemolysate protein 
(2-100 mg, depending on species studied) m 50 mM Tris buffer (pH 7.4). The 
final vol was 0.6 ml. Reactions were carried out in 30 ml-flasks sealed 
14 
with rubber caps. Liberated CO was trapped in 0.2 ml ethylene-glycol/ 
ethanolamine (2:1, by vol), present in a small polypropylene tube fitted in 
a slightly larger tube. After incubation for 60 m m with shaking OPRT activ­
ity was stopped by injection of 0.2 ml 0.25 M neutralized ethylene-diamine-
2 + 
tetraacetic acid. Because 0DC does not require Mg -ions decarboxylation 
can be allowed to proceed for another hour. Injection of 0.2 ml 5 M perch-
14 lone acid stops ODC activity and removes all CO from the reaction mix-
14 
ture within one hour. The small tube containing trapped CO is trans­
ferred to a scintillation vial with 10 ml of toluene-methanol (2.1, by vol) 
containing 4 g omnifluor per liter. 
ODC assay 
Hemolysate, appropriately diluted with 50 mM Tris buffer (pH 7.4) was in-
14 
cubated with 0.1 mM [carboxyl- C] orotidine 5'-monophosphate (0.2 mCi/ 
mmole) for 60 min in a final vol of 0.55 ml. Reaction was terminated by 
14 injection of 0.2 ml 5 M perchloric acid. Production of CO was measured 
as described above. 
HGPRT assay 
The activity of this enzyme was only measured with hypoxanthine as a sub­
strate. Incubation mixture contained 125 mM Tris buffer (pH 7.4), 10 mM 
14 
MgCl , 1 mM PRPP, 0.15 mM [8- C]-hypoxanthine (58 mCi/mmole) and 10-800 
V.g hemolysate protein in a final vol of 40 -1. In some experiments inosine 
was added to a final concentration of 1 mM. After incubation for 30 min 
reaction was terminated by immersing the tubes for 2 min in boiling water 
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and addition of excess carrier hypoxanthine and inosine. After centrifu-
gation separation of nucleotides from nucleosides and purine bases was 
achieved by chromatography on PEI-cellulose plates according to Reyes 
(1972). Spots corresponding to IMP, inosine and hypoxanthine »ere localized 
under u.v. light, cut out from the thin-layer and eluted with 1 ml of 0.1 
N HC1/0.2 M KCl in scintillation vials. After addition of 10 ml of aquasol 
radioactivity was determined. 
APRT assay 
The assay conditions were the same as for HGPRT, except that the reaction 
14 
mixture contained 0.1 mM [8- C]-adenine (54 mCi/mmole) and 15-250 yg 
protein. After termination of the reaction carrier adenine and adenosine 
were added. 
2.4. RESULTS AND DISCUSSION 
Assays of enzyme activities were always performed with two different pro-
tein concentrations and established to be linear with time during incubation. 
Doubling the concentration of the substrates or the cosubstrate PRPP did 
not result in an increase of the enzyme activity. Values measured for 
enzyme activities of most mammals were not significantly affected by the 
choice of lysis procedure, whether the hypotonic shock or the freeze/thaw-
ing procedure was employed. Bovine and human erythrocytes, however, showed 
a relatively strong resistance against osmotic lysis and were lysed by 
freeze/thawing. 
OPRT, ODC, HGPRT and APRT are present in hemolysates from all species 
studied with exception of horse erythrocytes, having OPRT and ODC activities 
below detection limit (Table 2.1). 
OPRT and ODC activities were very low in sheep erythrocytes and showed 
considerable variation between individual animals. In all other species 
studied more precise measurements of OPRT and ODC activities could be made. 
These enzymes showed a coordinate relationship. ODC activity was about 
twice as high as OPRT activity in mammalian erythrocytes. Only pig and 
rabbit erythrocytes showed a different ODC/OPRT ratio. A coordinate relation-
ship between OPRT and ODC was previously reported by Fox et al. (1971) for 
human erythrocytes and by Pausch et al. (1972) for various rat tissues. 
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TABLE 2 . 1 . 
М.ТПІТ\ Ol· HCPrf'. APRT, OPRT AM) ül С VNU OIX/OPRI Н,\ IO 'Ч ЧЛ.Ч>.Л I\N '•R^THHÜC YThS 
bnzyire α ς Ε ι ν ι ! ! » " ! a r e g iven in п п с К ч h r p t r Tif r r o l e i " П е r f s u l L s r e p r e s e n t the 
irean + S Numoers in p a r t n m.^ s r t f e r ι l e nLn^er f i n d i v i d u a l a 
*an 9 з 5 * Ч З Ι 7 ϋ ± - . 0 0 - ± 0 0ё ) 5 * 0 0 - ± П
Ч 
(¿) ( - ) ( (J) ( . 6 ) ( f. 
Honkey 3 1 3 * 8 1 і О ч і В І О э ( і * 0 І 7 І ^ з і О ч О ^ Э ± С 7 
(10) (•>) (6) ( Μ (η) 
Dog 2 61 « I 06 3 8 1 1 I 0 ' 0 3-. » Τ 19 0 6β · О 18 С ί 0 > 
(¿) (9) (9) (9) (91 
Mouse 9 59 1 0 9С 1 3 3 ± 3 1 0 5 0 t 0 0¿ с д ^ г О П 1 9 ± 0 2 
(5) (5) (5) (5) (5) 
Rat 3 24 * 0 36 3 - I ± 0 50 О Ί 1 i 0 06 0 -t7 i 0 06 2 3 ± 0 4 
(4) (5 6) (6) (<>) 
C a t t U 27 0 < 4 ч 3 ' б і І Р 1 1 6 ± 1 2 2 j í ] 7 9 í ) 3 
Ы ( s ) (5) (5) (5) 
Rihhic 82 7 ί "> Ο Ι ι ι Ί Ι З О в і ^ м 5 8 6 t > t i I ± 0 2 
(-) (4) (6) (6) 6) 
Pvg S9 9 * - 7 3 OÍ ± O 81 0 32 ± O 4 20 * С 60 13 Й ± 3 I 
(4) (..) (10) (1С) (10) 
Sheep ^З О * IO 1 j чЬ ± l 07 0 0^6 t 0 Ol- 0 Û35 t 0 015 
(IO) (IO) (5) (3) 
Horse 0 59 * С I I 13 S t 3 l <0 "05 <C 005 
(4) 7) (-) (4) 
OPRT and ODC activities measured in human erythrocytes are intermediate 
between the values reported by Fox et al. (1971) and those of Beardmore et 
al. (1972). Hatfield 81 Wyngaarden (1964) measured OPRT activity in sonified 
beef erythrocytes, freed from stroma by centnfugation. They reported a 
value of 11 nmoles/hr per mg protein. 
The assay of purine phosphoribosyltransferase activities may be dis­
turbed by 5'-nucleotidase (E.C.3.1.3.5), which converts the nucleotides 
formed to nucleosides. We found that no adenosine was formed during the 
APRT assay. However, small but significant amounts of inosine were formed 
from IMP under the conditions of HGPRT assay by lysates from human, rat 
and dog erythrocytes. Phosphorolytic cleavage of inosine by purine nucleo-
25 
side Phosphorylase (E .С.2.4.2.1) can occur in mammalian hemolysates (Duhm, 
1974). When this occurs hypoxanthine is formed, the starting compound for 
HGPRT assay. Because of the existence of this cyclic pathway the measured 
activity of HGPRT under these conditions is a minimum value. Therefore we 
studied the effect of excess non-radioactive inosine on the value of HGPRT 
measured. Excess inosine will inhibit the cleavage of radioactive inosine 
14 
formed via IMP from [8- C]-hypoxanthine. On the other hand, if the activ­
ity of purine nucleoside Phosphorylase is very high, a significant amount 
of nonradioactive hypoxanthine is formed resulting in dilution of the radio­
active substrate for HGPRT. Under reaction conditions employed, the sum of 
products (IMP plus inosine) was not significantly affected by the presence 
of excess inosine. This finding indicates that the cyclic pathway described 
above probably does not play a significant role. This may be caused by the 
low activity of S'-nucleotidase in erythrocytes (Adams et al., 1971). One 
should be aware, however, of the possibility that in other tissues, espe­
cially when 5'-nucleotidase activity is high, the cyclic pathway described 
can interfere with HGPRT assay. 
Xanthine oxidase (E.C.1.2.3.2) could also interfere with the HGPRT 
assay. This enzyme, however, is not found in mammalian blood cells (Al-
Khalidi fc Chaglassian, 1965). Chicken erythrocytes do contain xanthine 
oxydase which might be responsible for the low HGPRT activity found in 
these cells (Partsch & Altmann, 1973). 
There seems to be no direct correlation between HGPRT and APRT activ­
ities in mammalian erythrocytes. No such correlation is found when com­
paring enzyme activities in different tissues of man (Rosenbloom et al., 
1967) or Rhesus monkey (Kremtsky, 1969). In erythrocytes, however, HGPRT 
consumes a great deal of the available PRPP and deficiency of HGPRT is 
associated with increased PRPP concentration (Greene & Seegmiller, 1969). 
There is evidence that PRPP stabilizes the activity of the APRT enzyme 
(Greene et al., 1970). So HGPRT activity might have an indirect relation­
ship to APRT activity in erythrocytes (Gordon et al., 1974). The PRPP con­
centration in mammalian erythrocytes and its possible correlation with 
activities of HGPRT and APRT is currently under investigation. 
Purine phosphoribosyltransferase activities are also present in ery­
throcytes from mouse and rat. Murray (1966) reported absence of HGPRT from 
mouse and rat erythrocytes, while only traces of APRT activity were found. 
Adenine and hypoxanthine of low specific activities were used while incu-
26 
bâtions were carried out for 4 m m at 25 C. In our experiments purine 
bases of high specific activity were used and up to 400 \ig of hemolysate 
protein (for rat) had to be added in order to measure accurately HGPRT 
activity. Activities measured under these conditions are about an order of 
magnitude lower than those found by Murray in extracts from rat tissues. 
HGPRT values are extremely low for horse erythrocytes. This low activ-
ity seems to be a genuine property of horse erythrocytes since intracellular 
IMP production was also very low when intact horse erythrocytes were in-
14 
cubated with [θ- С]-hypoxanthine in phosphate buffer (pH 7.4), containing 
2+ glucose and Mg ions. HGPRT activity in horse leukocytes was about 30 
nmoles/hr per mg protein, so the low HGPRT activity appears to be restricted 
to the erythrocytes. Horse erythrocytes may provide an animal model for 
studying some aspects of HGPRT deficiency. A complete deficiency of HGPRT 
is associated with the Lesch-Nyhan syndrome (Seegmiller et al., 1967), while 
a partial deficiency is seen in a subgroup of gouty patients (Kelley et al., 
1969). There is, however, no clear-cut correlation between the severity of 
clinical manifestations and the severity of HGPRT deficiency measured in 
erythrocytes (Emmerson & Thompson, 1973). Dancis et al. (1973) have stressed 
the superiority of the leukocyte over the enucleate erythrocyte in providing 
an index of the enzymatic performance of other tissues. 
Values for HGPRT in human erythrocytes (measured with hypoxanthine as 
a substrate) range from 71 +_ 9 nmoles/hr per mg protein (Fox et al., 1971) 
to 128 jf 9 nmoles/hr per mg protein (Sorensen, 1970). For APRT in human 
erythrocytes, mean values from 14 to 35 nmoles/hr per mg protein (Watts et 
al., 1974, Bashkin et al., 1973) have been reported. Simmonds et al. (1973) 
reported a HGPRT activity of 54.8 nmoles/hr per mg protein in pig erythro­
cytes while for APRT a mean value of 4.3 nmoles/hr per rag protein was found. 
Krenitsky (1969) reported activities of 88 nmoles/hr per mg protein for 
HGPRT and 97 nmoles/hr per mg protein for APRT in extracts from blood cells 
of Rhesus monkey. These last values are much higher than the ones we have 
measured, which may be caused by the difference in preparation. 
It was suggested that erythrocytes function as purine carriers (Murray, 
1971). HGPRT and APRT may also have a role in the transport of purines 
across the cell membrane (Benke et al., 1973; De Bruyn & Oei, 1974). The 
low activities of APRT or HGPRT (or both) in some mammalian species do not 
support an involvement of these enzymes in purine transport in these animals. 
It is possible, however, that transport mechanisms for purines are different 
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between mammalian species. 
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C H A P T E R 3 
A SIMPLE AND SENSITIVE METHOD FOR ESTIMATING THE CONCENTRATION AND SYNTHE-
SIS OF 5-PHOSPHORIBOSYL 1-PYROPHOSPHATE IN RED BLOOD CELLS. 
W.J.M.Tax and J.H.Veerkamp 
(Clin.Chim.Acta (1977) 78, 209-216) 
3.1. SUMMARY 
A method is presented for the determination of 5-phosphoribosyl 1-pyro-
14 phosphate (PRPP), which is based on the release of CO from [carboxyl-
14 
C]orotic acid by the consecutive action of orotate phosphoribosyltrans-
ferase and orotidine 5'-monophosphate decarboxylase. The assay is simpler 
and less tiraeconsuming than most methods currently employed and is equally 
sensitive. The method proved to be suitable for measuring low concentra-
tions of PRPP such as found in human erythrocytes and fibroblasts. 
An increased PRPP concentration was observed in erythrocytes from 
patients with partial or complete deficiency of hypoxanthine-guanine phos-
phoribosyltransferase, from some (but not all) gouty patients and from a 
patient with deficiency of purine nucleoside Phosphorylase. PRPP synthetase 
activity was measured with a method similar to the assay for PRPP. In ery-
throcytes with an increased PRPP concentration, PRPP synthetase activity 
was found to be normal at both optimal and suboptimal substrate concentra-
tions . 
3.2. INTRODUCTION 
5-Phosphoribosyl 1-pyrophosphate (PRPP) is a substrate common to several 
metabolic pathways including the biosynthesis of purine and pyrimidine 
nucleotides and the salvage pathway for purines. A number of studies (1,2) 
have stressed the importance of PRPP concentration with regard to the reg-
ulation of purine nucleotide synthesis de novo. An increased intracellular 
concentration of PRPP may be caused by increased synthesis (3,4) or decreas-
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ed utilization (3,5) and can be involved in the pathogenesis of hyper-
uricemia. 
In the present communication we describe a simple and rapid procedure 
for measuring low concentrations of PRPP such as found in human erythrocytes 
14 
and fibroblasts. The assay is based on the release of CO from [carboxyl-
14 
Cjorotic acid in the presence of a mixture of orotate phosphoribosyl-
transferase (EC 2.4.2.10, OPRT) and orotidine 5'-monophosphate decarboxylase 
(EC 4.1.1.23, ODC). The OPRT-0DC reaction has been used before (6,7) to 
measure PRPP concentration in erythrocytes with a spectrophotometric tech-
nique but this method has not found much application. One reason for this 
might be that some investigators found no linear response at low PRPP con-
centrations (8). We have studied the validity of the radiochemical assay 
based on the OPRT-ODC reaction and found it to be reliable and linear with 
respect to PRPP concentration even at concentrations as low as 0.2 nmol 
per ml reaction mixture. In addition, in our hands this method was less 
time-consuming and more sensitive than techniques involving the chromato-
graphy of nucleotides formed in the presence of adenine phosphonbosyl-
transferase (EC 2.4.2.7) or hypoxanthine-guanme phosphoribosyltransferase 
(EC 2.4.2.8, HGPRT). 
The OPRT-ODC catalyzed reaction was also used to measure PRPP synthet-
ase (EC 2.7,6.1) activity. With this method we investigated whether the in-
crease in erythrocyte PRPP concentration found in some patients was due to 
an increased PRPP synthesis. This investigation included a search for 
kinetic variants of PRPP synthetase. Becker (3) has reported the occurrence 
of kinetic variants of this enzyme in erythrocytes from some patients with 
hyperuricemia. This enzyme abnormality is not detected by standard screen-
ing techniques. 
3.3. MATERIALS AND METHODS 
Materials 
Ribose 5-phosphate monobanum salt, PRPP tetrasodium salt and a preparation 
from brewers' yeast containing OPRT and ODC were obtained from Boehringer, 
14 
Mannheim, [carboxyl- C]Orotic acid, omnifluor and aquasol were purchased 
14 from New England Nuclear Corp., Dreieichenhain, G.F.R. [8- C]Hypoxanthine 
was from the Radiochemical Centre, Amersham. 
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Preparation_of hemolysate 
Venous blood samples were obtained from six children with deficiency of 
hypoxanthine-guanine phosphonbosyltransferase exhibiting the Lesch-Nyhan 
syndrome (9), from a gouty adult (E.F.) having partial deficiency of HGPRT, 
from two gouty adults with normal activity of HGPRT, and from a patient 
with deficiency of purine nucleoside Phosphorylase (EC 2.4.2.1) (10). 
Healthy adult volunteers served as control group. Blood was collected in 
hepannized tubes. Erythrocytes were isolated by centrifugation and washed 
twice with 50 mM Tris/HCl (pH 7.4) containing 100 mM NaCl. Lysates were ob­
tained by freezing and thawing the red blood cells twice. Both PRPP and PRPP 
synthetase from human erythrocytes are stable during this treatment. How­
ever, PRPP synthetase from erythrocytes of several mammalian species is 
unstable and must be assayed in freshly prepared hemolysates obtained by 
hypotonic shock (details will be published elsewhere). 
PRPP: assay I 
The assay was performed in scintillation vials sealed with rubber caps. 
Hemolysate was diluted 25-fold with 10 mM Tris/HCl (pH 7.4) containing 1 mM 
EDTA. 1-ml samples of diluted hemolysate were kept in boiling water for 45 
sec and immediately chilled on ice. During this procedure all interfering 
enzyme activities were destroyed while most of the PRPP remained intact. 
A correction was made for destruction of PRPP by measuring the recovery of 
PRPP (3.5 nmol), added to the hemolysates prior to the heating step. After 
thorough mixing, 100 μΐ of a suspension containing 0.4 mg (3 mU) of the 
0PRT-0DC preparation in 100 mM MgClQ was added. Reaction was started by 
ad 
14 
14 dition of 30 nmoles of [carboxyl- C]orotic acid (10 mCi/mmol). Liberated 
CO was trapped in 0.2 ml ethyleneglycol/ethanolamine (2 . 1, by vol.), 
present in a small polypropylene tube fitted in a slightly larger tube. 
After shaking for 15 m m at 37 C, 0.2 ml of 1 M HCl was injected and shak-
14 ing was continued for 1 h to remove all CO from the reaction mixture. 
14 
The small tube containing trapped CO was transferred to a scintillation 
vial and 10 ml of toluene/methanol (2 : 1, by vol.) containing 4 g omnifluor 
per liter was added. Blanks contained Tris buffer (10 mM, pH 7.4) instead 
of hemolysate. 
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PRPP. assay II 
14 
This assay is based on the HGPRT-catalyzed production of [ C]IMP (inosine 
14 
5'-monophosphate) from [ Cjhypoxanthine. HGPRT was partially purified 
from human erythrocytes by using its heat stability. 2 ml packed cells were 
diluted 10-fold with distilled water and heated for 1 m m at 100 C. Pre­
cipitate was removed by centrifugation. Heating and centrifugation were 
repeated once and the resulting colorless supernatant was lyophilized. The 
residue was taken up in 1 ml of 10 mM Tris/HCl (pH 7.4). The assay mixture 
contained in a final volume of 40 μΐ: 5 μπιοί Tris/HCl (pH 7.4), 0.4 pmol 
14 
MgCl , 8 nraol [8- C] hypoxanthine (58 mCi/nunol), 10 μΐ of the crude HGPRT 
suspension and 1-3 nmol of PRPP. After 15 m m at 37 С reaction was stopped 
by immersing the tubes in boiling water for 5 min. Carrier hypoxanthine and 
inosine (50 nmol of each) were added and reaction mixtures centrifuged. 
Hypoxanthine, inosine and IMP were separated on polyethyleneimine-cellulose, 
localized with ultraviolet light and eluted with 0.1 M HCl/0.2 M KCl accord­
ing to Reyes (11). After addition of 10 ml of aquasol radioactivity was 
determined. Results of PRPP measurements are expressed in nmol per ml packed 
cells. 
PRPP synthetase 
Reaction was carried out in scintillation vials sealed with rubber caps. 
Reaction mixture contained 25 mM phosphate buffer (pH 7.4), 1 mM ATP, 1 mM 
14 
ribose 5-phosphate, 10 mM MgCl , 0.3 mM [carboxyl- C]orotic acid (3 mCi/ 
mmol), 0.4 mg of the OPRT-ODC preparation and 0,5-1 mg of hemolysate protein. 
When enzyme activity was measured at suboptimal substrate concentration, 
the concentration of ATP or ribose 5-phosphate was decreased to 20 μΜ while 
14 
the concentration of the other substrate was maintained at 1 mM. C0„ 2 
produced was trapped in ethanolamine as described above. Incubation was 
о 
stopped after 30 m m at 37 С with injection of 0.2 ml 1 M HCl. Shaking 
14 
was continued for 1 h and CO measured as described above. Enzyme activity 
is expressed as nmol per h per mg protein. Protein was determined according 
to Lowry et al. (12). 
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3.4. RESULTS 
The validity of the OPRT-ODC based assay of PRPP was ascertained by measur­
ing various concentrations of PRPP using both the method based on the OPRT-
ODC reaction and the technique involving the HGPRT-catalyzed conversion of 
14 14 
[ C]hypoxanthine to [ C]IMP. Fig.3.1 shows that the results from both 
methods closely agree. Furthermore, a linear relationship was found between 
14 the concentration of PRPP present and the amount of CO released, even at 
concentrations as low as 0.2 nmol per ml of reaction mixture. During the 
heating step some PRPP is destroyed but the percentage of loss is repro­
ducible and does not depend upon PRPP concentration (Fig.3.2). The mean 
recovery with 13 hemolysates was 82 +_ 4%. So a correction can be made for 
the percentage lost during heating. 
1 4
 CO« rel«eid (nmol 
2 3 ,1 
[1 4C] IMP formed I n m o U 
Fig. 3.1. 
Relationship betwecr. the amount of 
PRPP present and the amount of 
14 
C09 released from [oarbox^l-
14 
C]orotta аага. The amount of 
ífípp Jas assayed h\¡ treasuring the 
14 14 
•prodj.at~on of [ C]T,WP from [ C]-
hypoxanthine by partially purified 
14 kGPRT, or the release of CO^ 
as described in Materials and 
Methods except that the heating 
step 'Jas omitted. 
When EDTA was absent during the heating step, a low recovery of PRPP 
was observed (Table 3.1). This phenomenon was not due to inhibition of the 
OPRT-ODC reaction but was the result of excessive destruction of PRPP. This 
destruction is not caused by an enzymatic process since it is not prevented 
by denaturation of the hemolysate protein. As a matter of fact, denaturation 
2+ 
results in an even lower recovery of PRPP. Addition of Mg ions apparently 
stimulates an enzymatic breakdown of PRPP. Evidence will be presented else-
where that acid phosphatase may be the enzyme responsible. 
PRPP concentration was measured in erythrocytes of normal adults and 
of a group of patients having a metabolic disorder related to purine 
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Fig. 3.2. 
Recovery of various amounts of 
PRPP added to hernclysates. Tne 
amount of PRPP add&d was measured 
with the liGPRT-based assay. After 
heatiiTj in boiling water for 45 
sec PRPP recovery was assayed by 
14 
measuring the release of CC^. 
14 ó 
from [carooxyl- C]orotic acid. 
A correction was made for PRPP 
present in the hemolysate. 
TABLE 3 . 1 . 
STABILITY OF PRPP DURING HEATING 
Э 5 nmol of PRPP was added to 1 ml hemolyule (15 ms pft>t£in) end heated In boding water for 4Б aec 
in the presence or absence ni 1 mM LDTA and 10 mM MeClj as Indicated Denatured hemolysate protein 
was obtained by heating the hemolysate in badine water for 5 mm pnor to the addition of PRPP Resilla 
are eapressed as the percrntaite of the amount of PRPP added Data are the теапч of three expenmenta 
Condilion&of heating 
Hemolysate protein 
Native 
Native 
Denatured 
Native 
Denatured 
EDTA 
+ 
-
— + 
+ 
M B 
-
-
— + 
+ 
PRPPrecoverv 
8 2 
2 3 
β 
3 9 
7G 
TABLE 3 . 2 . 
ERYTHROCYTE PRPP CONCENTRATION IN SOMF PATIENTS WITH A DISORDER IN PURINE 
METABOLISM 
Subject 
Re W . 
Ru W 
P v d A 
Ph v d A 
Ρ d R 
L.K ' 
Kt 
R V 
UN W 
E vd W 
Η V 
Controls (π B) 
Pathology 
HGPRT deficiency 
Partial HGPRT deficiency 
Purine nucleoside 
Phosphorylase deficiency 
Gout 
Gout 
Gout 
_ 
PRPP (nmol/ 
26 0 
33 3 
44 0 
26 0 
21 β 
38 2 
6 5 
5 9 
3 6 
4 0 
1 2 
1 5 * 0 2 
metabolism (Table 3.2). Partial deficiency of HGPRT was associated with an 
increased concentration of PRPP. A marked increase of PRPP concentration 
was observed in erythrocytes from six patients with complete deficiency of 
HGPRT showing the clinical features of the Lesch-Nyhan syndrome. A signif­
icant increase of erythrocyte PRPP concentration was also observed in a 
patient with deficiency of purine nucleoside Phosphorylase. PRPP concen­
tration was normal in erythrocytes from some patients with gout but increas­
ed in erythrocytes from two of these patients (L.N.W. and E.v.d.W.). 
The possible involvement of increased synthesis of PRPP in the observed 
increase of PRPP concentration was investigated by measuring PRPP synthetase 
activities. The enzyme preparation from erythrocytes requires phosphate for 
its activity. A concentration of 20 mM was found to be saturating. Micha-
elis-Menten kinetics were observed with respect to ATP and ribose 5-phos-
phate. K„ values were 59 and 60 μΜ, respectively (each value is the mean of 
three experiments). At high concentrations of ribose 5-phosphate (> 0.5 mM) 
the Lineweaver-Burk plot deviates from linearity, suggesting substrate in­
hibition. The kinetic data were used to select optimal and suboptimal sub­
strate conditions. Measurements were then made in hemolysates from controls 
and from some patients with increased erythrocyte PRPP concentration (Table 
3.3). PRPP synthetase was not significantly increased in erythrocytes of 
any of the patients studied, either at optimal or at suboptimal conditions. 
TABLE 3.3. 
PRPP SYNTHETASF ACTIVITY IN HUMAN HEMOLYSATE AT OPTIMAL AND SUBOPTIMAL SUB­
STRATE CONCENTRATIONS 
Subject 
Controls (n = 5) 
HGPRT déficient 
Ru W 
Re W 
Purine nucle-uside Phosphorylase deficient 
R V 
Coulv 
U N W 
E. v d W 
A T P 
Hi b ose 5-/' 
Activity (nmol/h perms 
1 mM 
1 mM 
450 ' 2 7 
37 0 
40 4 
38 6 
46 0 
38 8 
1 mM 
20 μΜ 
11 9 ί 0 7 
11 8 
12 Ъ 
8 6 
11.9 
10 7 
protein) 
20 μΜ 
1 mM 
12 9 < 2 0 
15 7 
13 9 
11 6 
10 1 
11 s 
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3.5. DISCUSSION 
The OPRT-based assay of PRPP described above includes a heating step which 
prevents interference of the assay by enzyme activities present in the hemo-
lysates tested (e.g. PRPP synthetase and PRPP-degrading enzymes). The assay 
is simpler and less time-consuming than procedures involving chromatographic 
or electrophoretic analysis of small samples from the incubation mixture. 
Furthermore, since one of the reaction products is measured completely and 
the blank value does not depend on the amount of incubation mixture which 
is analysed, but remains low, a high signal to noise ratio can be obtained 
by increasing the amount of hemolysate in the incubation mixture. 
The assay responds linearly over the concentration range tested, from 
0.2 to 3.5 nmol of PRPP per ml of reaction mixture (Fig.3.1). Johnson et al. 
(8) have stated that no such linearity was found at PRPP concentration lower 
than 10 nmol per ml. The discrepancy might be related to a difference m 
technique since we used a radiochemical procedure Instead of a spectro-
photoraetrical one. The importance of the presence of EDTA during extraction 
of PRPP from the cells is stressed by the results given in Table 3.1. Heavy 
metals apparently stimulate the destruction of PRPP. Denaturation of hemo-
lysate protein may increase the concentration of heavy metals by releasing 
them from metallo-protems. 
Normal values for erythrocyte PRPP concentration obtained with this 
technique are similar to values reported by most other investigators (3, 13, 
14). Methods that do not involve destruction of PRPP synthetase activity by 
heating seem to result in higher values for normal erythrocyte PRPP con-
centration (4, 15, 16). Other investigators previously observed also an in-
crease of PRPP concentration in erythrocytes from patients with partial (17) 
or complete (3, 5, 17) deficiency of HGPRT. 
The rate of synthesis of PRPP is normal m erythrocytes from patients 
with deficiency of HGPRT. An increased PRPP synthetase activity in cultured 
lymphocytes (18) and fibroblasts (19) from patients with deficiency of HGPRT 
has been associated with the increased PRPP concentration. However, other 
investigators have found normal activities of PRPP synthetase in HGPRT-
deficlent lymphoblasts (20) and fibroblasts (21). Anyway, in HGPRT-deficient 
erythrocytes the increase of PRPP concentration is not caused by an increased 
activity of PRPP synthetase and results from a decreased utilization of 
PRPP. The increased PRPP concentration observed in the patient with 
38 
deficiency of purine nucleoside Phosphorylase is not the result of increased 
PRPP synthetase activity, as is evident from Table 3.3. Since deficiency of 
purine nucleoside Phosphorylase blocks the synthesis of hypoxanthine from 
inosihe, the activity of HGPRT might be markedly decreased due to lack of 
substrate and the increased PRPP concentration may be ascribed to a de­
creased utilization of PRPP. 
No increase of PRPP synthetase was found m erythrocytes from two gouty 
patients despite an increased PRPP concentration in their erythrocytes. 
Enzyme activity was also normal at suboptimal ATP or ribose 5-phosphate 
concentration indicating normal kinetics. The increase of PRPP may be asso­
ciated with a decreased utilization instead of an increased production. 
This possibility is currently under investigation. 
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C H A P T E R 4 
CONCENTRATION AND SYNTHESIS OF PHOSPHORIBOSYLPYROPHOSPHATE IN ERYTHROCYTES 
OF GOUTY PATIENTS AND ADOLESCENTS WITH A HIGH SERUM URATE CONCENTRATION 
4.1. SUMMARY 
Hyperuricemia may result from overproduction of phosphoribosylpyrophosphate 
(PRPP), a key substrate of purine biosynthesis. The occurrence of inborn 
abnormalities of the enzyme PRPP synthetase was investigated in erythrocytes 
of a group of 50 adolescents with a high concentration of urate in serum 
and in a group of 12 adults with primary gout. The concentration of PRPP in 
erythrocytes was normal in all subjects. No striking increase of PRPP syn-
thetase activity was found in any subject, but the group of adolescents with 
a high serum urate concentration had a significantly higher activity of 
PRPP synthetase than the control group. No kinetic variants were detected 
when enzyme activity was measured at non-saturating concentrations of the 
substrates ATP or nbose 5-phosphate. The results are discussed in relation 
to the late onset generally observed in gout. 
4.2. INTRODUCTION 
Uric acid is the end product of purine metabolism in man. Gout is a disease 
associated with hyperuricemia and results from the deposition of urate crys-
tals and tissue reactions to the crystals. It is manifested clinically as 
arthritis, tophi and/or urate nephropathy. In primary gout there is a here-
ditary disorder leading to increased production of uric acid (primary me-
tabolic gout) or decreased excretion of this compound (1,2). 
The availability of phosphoribosylpyrophosphate (PRPP) plays an im-
portant role in the regulation of purine biosynthesis de novo (3-5), and 
an excess of PRPP leads to purine overproduction and hyperuricemia (2,3). 
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Deficiency of hypoxanthine - guanine phosphonbosyltransferase (HGPRT, EC 
2.4.2.8) results in a decreased utilization of PRPP and an increased con-
centration of this compound (2,3). A larger availability of PRPP may also 
be caused by an increased synthesis. Becker et al. (6) and Sperling et al. 
(7,8) found abnormal forms of the enzyme PRPP synthetase in some gouty 
patients, which were associated with an increased catalytic activity per 
enzyme protein molecule (6) or a decreased sensitivity to feedback inhi-
bition (7,8). The enzyme mutations were unique among the inborn errors of 
metabolism in causing hyperactivity rather than deficiency of the enzyme. 
Meyskens and Williams (9) found a normal PRPP concentration and PRPP syn-
thetase activity in erythrocytes from 7 patients with primary gout and from 
10 adult patients (mean age 49 years) with primary hyperuricemia. Feedback 
inhibition of the enzyme by ADP, GDP and 2,3-DPG was also normal. We now 
measured the concentration and synthesis of PRPP in erythrocytes of 12 
gouty patients and of 50 adolescents having a high concentration of serum 
urate. This investigation included a search for kinetic variants of the 
enzyme since Becker (10) reported that some gouty patients have an increased 
affinity of PRPP synthetase for one of the substrates. This enzyme abnormal-
ity is not detected under standard assay conditions. Earlier (11) we re-
ported an increased PRPP concentration in erythrocytes of 2 gouty patients. 
PRPP synthetase activity was normal, however, also at suboptimal conditions. 
PRPP concentration was normal in erythrocytes from one other gouty patient. 
4.3. MATERIALS AND METHODS 
Venous blood samples were obtained from 13 healthy male controls (22-30 
years), from 12 adult male gouty patients (29-74 years) and from 50 adoles-
cents (6 girls and 44 boys, mean age 18 years, range 10-23 years) with 
serum urate concentration higher than the 95th percentile point. Uric acid 
in serum of adolescents was determined by Dr. F.Klein (Faculty of Medicine, 
Erasmus University, Rotterdam) by a uricase-peroxidase procedure (12). Blood 
samples were transported in the presence of ice. Preliminary experiments 
had shown that both PRPP concentration and PRPP synthetase activity are 
stable for several hours under these conditions. Assays for PRPP and PRPP 
14 14 
synthetase were based on the release of CO from [carboxyl- C]orotic 
acid and were performed as previously described (11). When PRPP synthetase 
42 
activity was measured at suboptimal substrate concentrations, the con­
centration of ATP or ribose 5-phosphate was decreased to 50 μΜ while the 
concentration of the other substrate was maintained at 1 mM. These con­
ditions yielded enzyme activities which were about half-maximal for hemo-
lysates of controls. Protein was determined according to Lowry et al. (13), 
Statistical analysis was performed using the paired one-tailed Student's 
t-test. 
4.4. RESULTS 
The serum urate concentration of the group of adolescents included in the 
present investigation ranged from 399 to 553 ymol/l. Mean +_ S.D. was 424 +_ 
31 pmol/l. The upper limit of normal is usually defined as 7 mg per 100 ml 
or 416 iimol/l (1). Since the various therapeutic treatments of the gouty 
TABLE 4.1. 
PRPP CONCENTRATION AND PRPP SYNTHETASE ACTIVITY IN ERYTHROCYTES OF CONTROLS, 
GOUTY PATIENTS AND ADOLESCENTS WITH A HIGH SERUM URATE CONCENTRATION 
PRPP PRPP synthetase 
ATP 1 mM 1 ИМ 50 μΜ 
Ribose-5-P 1 mM 50 uM 1 mM 
Controls i.28 t 0.41 49.7 ±7.6 58 t 4 51 t 5 
(n=10) (0.58 - 1.77) (40.4 - 64.5) (53 - 63) (44 - 58) 
Gouty patientsl.25 t 0.41 53.7 t 10.2 52 ± 7 52 t 3 
(n=12) (0.62 - 2.06) (38.9 - 69.4) (43 - 62) (48 - 57) 
Adolescents 0.91 t 0.27 55.9 ±5.9 55 t 5 52 t 5 
(n=50) (0.45 - 1.49) (44.2 - 68.7) (40 - 64) (45 - 61) 
The results represent the mean t S.D. The range is given in parentheses. 
Concentration of PRPP is given in nmol/ml packed cells. Its concentration 
was measured in 13 control subjects. PRPP synthetase activity at optimal 
substrate concentrations is expressed as nmol/nr per mg protein. Enzyme 
activity at suboptimal substrate concentrations is expressed as a percentage 
of the activity measured at optimi substrate concentrations. 
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patients may markedly influence the serum urate concentrations, these con-
centrations are not given here. 
The concentration of PRPP in erythrocytes of all subjects was within 
2 S.D. of the mean value for the control group. The mean value for PRPP 
concentration was in the group of adolescents with a high serum urate con-
centration slightly below the mean of the controls (Table 4.1). 
The mean activity of PRPP synthetase in the group of gouty patients 
was higher than in the control group but the difference did not achieve 
statistical significance. The activity of PRPP synthetase was significantly 
higher (p < 0.01) in the group of adolescents with a high serum urate con-
centration. Four subjects of the latter group and 2 gouty patients had PRPP 
synthetase activities which were more than 2 S.D. above the normal mean, 
although the enzyme activity never exceeded the normal mean + 3 S.D. 
The activity of PRPP synthetase in the group of adolescents did not corre-
late with the serum urate concentration. The affinity of the enzyme for the 
substrates ATP and nbose 5-phosphate was normal in all subjects studied. 
An increased substrate affinity would be reflected by an increased per-
centage of the maximal enzyme activity when the assay is performed with 
suboptimal substrate concentration. 
5.4. DISCUSSION 
The results presented here suggest that large disturbances in PRPP metabolism 
are not a major cause of hyperuricemia and gout. PRPP concentration was 
normal m erythrocytes of all subjects, in contrast to the increased con-
centration previously found (11) in 2 gouty patients. Meyskens and Williams 
(9) also found no increased PRPP concentration in erythrocytes from gouty 
patients or hyperuncemic subjects. Becker (10) found normal erythrocyte 
PRPP concentrations in several gouty patients with an increased PRPP con-
centration in fibroblasts. Furthermore, erythrocyte PRPP concentration may 
be affected by drug therapy (3), Measurement of erythrocyte PRPP concentra-
tion is therefore of limited value in the study of abnormalities in PRPP 
metabolism. 
Hyperactivity of PRPP synthetase as reported by Becker et al. (6) and 
Sperling et al. (7) was not found in erythrocytes of any of the subjects 
studied. Fox (14) and Sperling et al. (15) reached a similar conclusion 
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after studying large numbers of hyperuricemic subjects. Meyskens and 
Williams (9) found a normal enzyme activity and normal feedback inhibition 
of PRPP synthetase in hyperuricemic and gouty patients. The results ob­
tained by Becker (10), however, suggested that in a significant number of 
gouty patients PRPP synthetase has an abnormally high substrate affinity, 
but a normal activity at high substrate concentration. No such kinetic 
variants were detected in the present investigation. Abnormal kinetics of 
HGPRT may also be associated with hyperuricemia and gout (10). Although we 
did not investigate the kinetics of HGPRT, the activity of this enzyme is 
probably normal since we found a normal PRPP concentration in erythrocytes 
of all subjects studied. Partial (11,16) or complete (3,10, 11,16) de­
ficiency of HGPRT leads to an increased PRPP concentration in erythrocytes. 
The activity of PRPP synthetase in the group of adolescents with high 
urate concentration was significantly higher than in controls. When the 
one-tailed t-test is applied to the figures given by Sperling et al. (15) 
for gouty patients and controls, PRPP synthetase activity is also signif­
icantly higher in his group of 34 gouty patients (p < 0.05) although the 
authors state that there is no significant difference. Our small group of 
12 gouty patients and the group of 7 gouty patients of Meyskens and Williams 
(Θ) did not show a significant increase. Primary gout usually manifests 
between the third and fourth decade of life, although it is regarded as a 
hereditary disorder (1). The late onset of the disease may be due to a slow 
accumulation of uric acid. A small but significant increase of the PRPP 
synthetase activity might therefore be of physiological significance. It 
seems worthwhile to investigate whether a similar increase in PRPP synthe­
tase activity can be demonstrated in other cell types of patients with 
hyperuricemia. If available, liver cells would be more appropriate than 
erythrocytes to study the enzymatic basis of uric acid overproduction, since 
in man purine synthesis de novo takes place mainly in the liver. Cultured 
fibroblasts appeared already more useful than erythrocytes for classifying 
patients with uric acid overproduction and aberrations in PRPP metabolism 
(10). 
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C H A P T E R 5 
PHOSPHORIBOSYLPYROPHOSPHATE IN ERYTHROCYTES OF TEN MAMMALIAN SPECIES: CON-
CENTRATION, SYNTHESIS AND DEGRADATION 
W.J.M.Tax and J.H.Veerkamp 
(Comp.Biochem.Physiol.(1978) 59 B, 219-222) 
5.1. SUMMARY 
1. The concentration of PRPP and the activity of PRPP synthetase have been 
measured in hemolysates from man and nine other mammalian species. PRPP 
synthetase activity was very low in dog hemolysate. 
2. High concentrations of PRPP appeared to be associated with low levels of 
HGPRT activity, suggesting that HGPRT is the major pathway for utiliza-
tion of PRPP in mammalian erythrocytes. 
3. An alternative catabolic route for PRPP was observed in mammalian hemo-
lysates, which seemed to be associated with acid phosphatase activity. 
The activity of acid phosphatase in mammalian hemolysates was measured. 
5.2. INTRODUCTION 
Previously we reported the activities of three phosphoribosyltransferases 
(HGPRT, APRT and OPRT) in erythrocytes of ten mammalian species (Tax et al., 
1976) . Enzyme activities showed large variations between species and it was 
speculated that the activities of HGPRT and/or APRT might be correlated 
with the concentration of PRPP. PRPP is a substrate common to several metab-
olic pathways including de novo synthesis of purine and pyrimidine nucleo-
tides and the salvage pathways for purines. The intracellular concentration 
of PRPP regulates the rate of purine nucleotide synthesis de novo in nu-
cleated cells (Kelley et al., 1970; Bagnare et al., 1974). The present 
communication deals with the results of our studies on PRPP in mammalian 
erythrocytes. The actual PRPP concentrations were measured as well as the 
activity of PRPP synthetase, the enzyme responsible for the synthesis of 
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PRPP. During these investigations we found evidence for a catabolic path­
way for PRPP, which was not related to phosphoribosyltransferase activity. 
2+ 
The enzymatic hydrolysis was stimulated by Mg and my be due to acid phos­
phatase activity. Therefore, acid phosphatase activity was also determined 
in hemolysates of all mammals studied. 
5.3. MATERIALS AND METHODS 
Materials 
14 
Carboxyl-[ C]orotic acid hydrate (42.4 mCl/mmole) and aquasol were obtained 
14 
from New England Nuclear Corporation, 8-[ C]inosine (60 mCi/mmole) from 
the Radiochemical Centre, Amersham, England. Ribose 5-phosphate, PRPP, acid 
phosphatase and a preparation from brewer's yeast containing OPRT and ODC 
were purchased from Boehringer, Mannheim. Ouabain and p-nitrophenyl-phos-
phate, disodium salt, were from Merck, Darmstadt, West Germany, 
Hemolysates 
Heparinized blood samples were obtained from the same mammalian species as 
were used in our previous investigations (Tax et al., 1976). Erythrocytes 
were obtained by centrifugation and washed twice with 50 mM Tris-HCl (pH 
7.4) containing 100 mM NaCl. Cells were lysed by hypotonic shock with a 3-
fold vol of 10 mM Tris-HCl (pH 7.4) or by freezing and thawing the cells 
twice in an aceton/dry-ice bath. 
PRPP concentration, synthesis and hydrolysis 
14 
The assay of PRPP concentration is based on the release of CO from 
14 
carboxyl-[ C]orotic acid by the consecutive action of purified OPRT and 
ODC. Synthesis of PRPP from ATP (1 mM) and ribose 5-phosphate (1 mM) in 
о 
the presence of 20 mM Ρ (pH 7.4) and 10 mM MgCl2 was measured at 37 С 
14 ^ 14 
by trapping the CO released from carboxyl-[ C]orotic acid in the pres­
ence of OPRT and ODC. The details of both assays have been reported else­
where (Tax & Veerkamp, 1977). 
Hydrolysis of PRPP was measured by incubating PRPP (10 nmoles) at 37 
С for 0-120 min in a solution containing 45 mM Tris-HCl (pH 7.4), 1 mM 
EDTA, 10 mM MgCl and dialysed hemolysate (15 mg protein) in a final volume 
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oí 1.1 ml. Residual PRPP was measured after incubation for various time 
14 intervals by addition of [carboxyl- C]orotic acid and purified OPRT and 
14 ODC, and trapping the CO released. 
Acid phosphatase assay 
Hydrolysis of p-mtrophenylphosphate at pH 7.4 and pH 5.0 was estimated by 
measuring the concentration of p-nitrophenol formed. Incubation mixtures 
contained 6 mM p-nitrophenylphosphate, 4 mil MgCl , 1.2 mM ouabain, hemo-
lysate protein (4 rag) and 40 mM Tris-HCl (pH 7.4) or 40 mM sodium citrate 
(pH 5.0) in a final volume of 1.25 ml. After 10 m m at 37 C, 250 yl of 
ice-cold 30% trichloroacetic acid was added. Precipitated material was 
removed by centrifugation and 2 ml of 1 N NaOH was added. Absorption was 
measured at 410 nm using a Zeiss PM QII spectrophotometer. The extinction 
3 -1 
coefficient for p-nitrophenol was 17.6 χ 10 M . Correction was made for 
spontaneous hydrolysis of p-nitrophenylphosphate. 
Purine nucleoside Phosphorylase assay 
The assay mixture contained 25 mM potassium phosphate (pH 7.4). 1 mM ethyl-
14 
ene-diaminetetraacetic acid, 200 μΜ 8-[ C]inosine and hemolysate protein 
(2-70 yg) in a total volume of 40 μΐ. After incubation for 20 min at 37 C, 
the assay mixture was boiled for 2 m m and centrifugea after addition of 
carrier hypoxanthine and inosine. Separation of product from substrate on 
PEI-cellulose plates and elution of radioactive compounds was achieved 
according to Reyes (1972). Aquasol was used as scintillation solution. 
Protein 
All enzyme activities are expressed in nmoles of product formed in 1 hr per 
mg of protein. Protein was determined according to Lowry et al. (1951). 
Animals 
The following species were used: Man - Forno sapiens^ Swiss mouse - Mus 
musculus , Wistar rat - Pattus norvegious, White New Zealand rabbit -
Oryatolagus auniaulus, Beagle dog - Canis familiaris, Texel sheep - Ovis 
ames, Rhesus monkey - Macaca mulatta, Horse - Equus cdballus, Pig - Sus 
scrofa, Cow - Sos taurus. 
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5.4. RESULTS AND DISCUSSION 
All enzyme activities were checked for linearity with regard to time and 
protein concentration. The linearity and validity of the PRPP assay has been 
described elsewhere (Tax & Veerkamp, 1977). Doubling the concentration of 
the substrates of PRPP synthetase did not result in an increase of enzyme 
activity with any of the hemolysates. PRPP synthetase activity from ery­
throcytes of several mammalian species was unstable to a freeze-thaw treat­
ment. Therefore, this enzyme activity was always assayed in freshly pre­
pared hemolysates obtained by hypotonic shock. 
The results of our measurements of concentration and synthesis of PRPP 
in mammalian erythrocytes are given in Table 5.1. The PRPP concentration and 
TABLE 5.1. 
CONCENTRATION OF PRPP AND ACTIVITY OF PRPP SYNTHETASE, HGPRT, AND ACID 
PHOSPHATASE IN MAWALIAN ERYTHROCYTES 
Concentration of PRPP is given in nmoles/ml packed cells and enzyme activities 
in nmoles/hp per mg protein. The results represent the mean ^  S D 
Numbers in parentheses refer to the number of Individuals. 
Species 
Han 
Monkey 
Dog 
House 
Rat 
Cattle 
Rabbit 
Pig 
Sheep 
Horse 
PRPP 
1.52«0.21 
(6) 
2.13t0.49 
(4) 
1.33i0.42 
(•) 
11.7«0 9 
(«) 
10.312.4 
(5) 
61.8418.1 
(7) 
1.31*0.46 
(5) 
0.16.0.05 
И) 
0.87t0.13 
(4) 
62.4±7 a 
(4) 
PRPP 
synthetase 
45.0±2.7 
(S) 
6.95il.82 
(4) 
0.21i0.05 
(4) 
го.ui.г 
(4) 
25.3i5.4 
(4) 
1β.1ι4.5 
(4) 
24.013.4 
(4) 
2.99i0.60 
(4) 
11.U4.1 
(6) 
5.B81O.40 
(4) 
HGPRT 
95 6*8.3 
(4) 
ЭІ.З18.І 
(10) 
2.6311.06 
(4) 
9.59i0.90 
(5) 
3.24i0.36 
(4) 
27.0i4.4 
(5) 
β2.7ι2.0 
(4) 
59.9i4.7 
(4) 
53.OilO.2 
(10) 
O.591O.II 
(4) 
Acid phospha­
tase (pH 7 4) 
15.7i4 5 
(3) 
121 ііг 
(3) 
74.lil? 5 
(4) 
274 i44 
(3) 
198 135 
(3) 
21.8i2.7 
(Э) 
136 ±20 
Pi 
62.5il7.6 
(4) 
33.5i5.8 
(3) 
40.5il6.5 
(3) 
Acid phospha­
tase (pH 5.0) 
49.2i2.8 
(3) 
339 i28 
(3) 
206 i49 
(4) 
496 i27 
(3) 
383 iSO 
(3) 
72.βι16.2 
(4) 
327 «62 
(Э) 
138 1І 
(4) 
ββ.5.14.6 
(3) 
121 i34 
(3) 
PRPP synthetase activity in erythrocytes show large variations between the 
mammalian species, as was previously observed for the activities of purine 
phosphoribosyltransferases and orotate phosphoribosyltransferase (Tax et al., 
1976). There seems to be no direct correlation between the PRPP concentra­
tion and the PRPP synthetase activity in the different species. The values 
for the PRPP concentration in human and pig erythrocytes are similar to 
those reported by Dean et al. (1973), but Micheli et al. (1975) reported 
concentrations of PRPP in erythrocytes of man, pig, cow and rat which were 
higher and showed a quite different mutual ratio. 
PRPP stabilizes the activity of the APRT enzyme (Greene et al., 1970) 
and therefore a correlation might exist between PRPP concentration and 
APRT activity (Tax et al., 1976). No such correlation was found. 
The data on HGPRT activity were also reported in our previous article 
(Tax et al., 1976) but are presented here in order to compare the synthetic 
capacity for PRPP with the capacity of a major PRPP utilizing enzyme. It 
has been generally believed that PRPP in erythrocytes is utilized entirely 
by phosphoribosyltransferase activities. HGPRT seems to be the most im­
portant consumer of PRPP in erythrocytes. OPRT activity is much lower than 
HGPRT activity in mammalian erythrocytes (Tax et al., 1976) while the sub­
strate of APRT, adenine, is virtually absent in mammalian cells (Murray et 
al., 1971). Deficiency of HGPRT in man is associated with an increased 
erythrocyte PRPP concentration while deficiency of OPRT or APRT is not (Fox 
8i Kelley, 1971). Steady state concentrations of PRPP cannot, of course, be 
deduced from capacities of synthesis and utilization measured at optimal 
conditions. Actual enzyme activities in г о are modulated by the avail­
ability of substrates and the concentration of regulatory compounds, and 
will generally be much lower than maximal capacities. However, some corre­
lations between HGPRT activity and PRPP concentration seem to hold. The 
increased concentration of PRPP in erythrocytes of patients with deficiency 
of HGPRT has already been mentioned. Partial deficiency of HGPRT in man is 
also associated with an increased concentration of PRPP in erythrocytes 
but the increase is less pronounced (Sperling et al., 1972; Tax & Veerkamp, 
1977). HGPRT activity is nearly absent in horse erythrocytes and PRPP 
concentration in these cells is markedly high. Low activity of HGPRT and a 
relatively high concentration of PRPP is also found in erythrocytes of rat 
and mouse. In erythrocytes of all mammals except horse, rat and mouse the 
optimal activity of HGPRT appears to be much higher than the PRPP synthetase 
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capacity. At first sight, PRPP concentration of bovine erythrocytes is sur­
prisingly high. In man, an increased PRPP concentration was observed in 
erythrocytes from patients with deficiency of purine nucleoside Phosphor­
ylase (Cohen et al., 1976, Tax & Veerkamp, 1977). This increase may be due 
to a decreased utilization of PRPP since the substrate of HGPRT, hypoxan-
thine, is not formed. Therefore we measured the activity of purine nucleo­
side Phosphorylase in bovine erythrocytes. Enzyme activity was found to be 
very low (39 nmoles/hr per mg protein, 5 determinations) when compared with 
the activity in human erythrocytes (1308 nmoles/hr per mg protein). Duhm 
(1974) also reported a very low activity of purine nucleoside Phosphorylase 
in bovine erythrocytes as well as an extremely low permeability for inosine. 
Fox & Marchant (1974) described an alternative pathway for catabolism 
of PRPP which did not involve phosphoribosyltransferase activity. Alkaline 
phosphatase seemed to be the responsible enzyme. Hydrolysis of PRPP was 
found in extracts of all human tissues assayed except erythrocytes. We ob­
served a substantial degradation of PRPP when this compound was heated in 
2+ 
the presence of Mg and human hemolysate. This destruction seemed to be 
о 
an enzymatic process (Tax & Veerkamp, 1977). Incubation of PRPP at 37 С 
2+ 
and pH 7.4 with dialyzed hemolysate of man or rat in the presence of Mg 
leads to destruction of PRPP(Table 5.2).Non-enzymatic hydrolysis of PRPP m 
2+ 
the presence of Mg does occur but is much slower than hydrolysis in the 
presence of hemolysate. Recovery of PRPP is nearly complete after incubation 
2+ 
for 2 hr in the absence of Mg . Human erythrocytes contain two acid phos-
2+ phatases, one of which is strongly stimulated by Mg (Kornfeld & Gregory, 
1969). Therefore, acid phosphatase might be the enzyme responsible for 
destruction of PRPP. Commercial acid phosphatase from potato was found to 
hydrolyze PRPP at pH 7.4. Acid phosphatase activity was measured in hemoly-
sates of all ten mammalian species, at both pH 7.4 and pH 5.0 with p-nitro-
phenylphosphate as substrate. MgCl was included in the assay mixture. 
Ouabain was added to inhibit К -activated phosphatase activity associated 
with Na -K -ATPase (Heller & Hanahan, 1972). The results of these measure­
ments are included in Table 5.1. Enzyme activity at pH 5.0 was much higher 
than at pH 7.4, the ratio being 2-3 for all species studied. Large vari­
ations in enzyme activity were observed between species. Acid phosphatase 
activity in human hemolysate is much lower than in rat hemolysate. Hydro­
lysis of PRPP by human hemolysate proceeds at a slower rate than hydrolysis 
by rat hemolysate (Table 5.2). This finding is therefore consistent with the 
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TABLE 5.2. 
HYDROLYSIS OF PRPP BY DIALYZED HEHOLYSATE OF HAN AND RAT WITH 
AND WITHOUT Mg2* 
The amount of résiduel PRPP was measured after 0.60 and 120 mfln 
Incubation at pH 7 4 and 370C Values are the mean of two experiments 
Hemolysate Ид 2* PRPP (imoles) 
0 min 
9 8 
10 1 
9 7 
9 7 
10 4 
60 min 
8 2 
S 9 
β 9 
3 3 
9 3 
120 min 
6 9 
3 8 
β Э 
0 2 
8 9 
hypothesis that the observed hydrolysis of PRPP is due to acid phosphatase 
activity. A similar enzymatic breakdown of PRPP was found with dialyzed 
hemolysates of mouse and rabbit. 
The enzymatic hydrolysis of PRPP in mammalian hemolysates may inter-
2+ fere with m гіго investigations on PRPP metabolism when Mg is present 
in the incubation mixture. The possible physiological significance of this 
catabolic pathway in intact erythrocytes requires further investigations. 
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C H A P T E R 6 
THE URINARY EXCRETION OF OROTIC ACID AND OROTIDINE, MEASURED BY AN ISOTOPE 
DILUTION ASSAY 
W.J.M.Tax, J.H.Veerkamp and E.D.A.M.Schretlen 
(Accepted for publication in Clin.Chim.Acta) 
6.1. SUMMARY 
Unknown concentrations of orotic acid can be measured by competition with 
14 
a known amount of [carboxyl- C]orotic acid for reaction with a limiting 
amount of phosphoribosylpyrophosphate in the presence of orotate phosphor-
ibosyltransferase and orotidine monophosphate decarboxylase. The dilution 
14 
of the specific radioactivity in the product CO is a sensitive and ac-
curate measure of the amount of orotic acid present in the sample. Orotidine 
can also be determined after hydrolytic cleavage to orotic acid. 
The method was used to measure orotic acid and orotidine in urine 
samples from newborns, healthy controls and patients with gout or deficiency 
of hypoxanthine-guanine phosphoribosyltransferase receiving allopurinol. 
Urinary excretion of orotic acid and orotidine in newborns was similar 
whether the infants were breast-fed or received milk powder. The excretion 
of orotidine was increased in all patients receiving allopurinol. After 
allopurinol administration orotic acid excretion was increased in gouty 
patients but close to normal values in patients with deficiency of hypo-
xanthine-guanine phosphoribosyltransferase. The results are discussed in 
relation to the mechanism by which allopurinol inhibits pyrimidme metab-
olism. 
6.2. INTRODUCTION 
Excessive urinary excretion of orotic acid is observed in hereditary orotic 
aciduria (1), after administration of allopurinol (2-4) or 6-azauridine (5), 
55 
in inherited disorders of the urea cycle (6, 7) and in deficiency of purine 
nucleoside Phosphorylase (8). In some of these cases orotidine excretion is 
also increased. The colorimetrie test (9) which is frequently used to quan-
titate orotic acid does not distinguish between orotic acid and orotidine 
(2) and several compounds interfere with this assay (10). Christopherson 
and Finch (11) described an isotope dilution assay for orotic acid which 
was specific and sensitive but rather time-consuming. Furthermore, the 
procedure included a column adsorption step with a low and variable recov-
ery of orotic acid. In the present communication we describe a simple and 
rapid procedure for measuring orotic acid and orotidine. The assay is based 
14 
on the competition between unlabeled orotic acid and [carboxyl- C]orotic 
acid for reaction with a limiting amount of phosphoribosylpyrophosphate 
(PRPP) in the presence of excess orotate phosphoribosyltransferase (OPHT, 
EC 2.4.2.10) and orotidine monophosphate decarboxylase (ODC, EC 4.1.1.23). 
The amount of unlabeled orotic acid can be calculated from the dilution of 
14 
the specific activity of [carboxyl- C]orotic acid in the product CO by 
reference to a standard curve. 
The method was used to measure the urinary excretion of orotic acid 
and orotidine by healthy controls, by patients receiving allopurinol medi-
cation (patients with primary gout or deficiency of hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT, EC 2.4.2.8)) and by newborns. Some of 
these newborns received dietary milk powder which was reported to contain 
a high concentration of orotic acid (12). The milk powder itself was also 
assayed for orotic acid and orotidine. 
6.3. MATERIALS AND METHODS 
Materials 
PRPP was obtained from Boehringer, Mannheim. A preparation containing OPRT 
and ODC activities was obtained from either P-L Biochemicals or Sigma. 
[Carboxyl- C]orotic acid, [carboxyl- C]orotidine, omnifluor and aquasol 
were purchased from New England Nuclear Corp., Dreieichenhain, G.F.R., and 
[8- C]hypoxanthine from the Radiochemical Centre, Amersham. [8- C]-
Xanthine was from ICN (Irvine, Ca.). 
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Urine specimens 
Urine was collected for 24-h periods from 2 healthy children (age 10 and 
15 y), 4 healthy adults, 3 patients with complete deficiency of HGPRT on 
allopunnol medication (200 mg/day), 1 patient with partial deficiency of 
HGPRT (300 mg of allopunnol per day) and 3 patients with primary gout re­
ceiving allopunnol (300 mg/day). Urine specimens were also obtained from 
2 breast-fed newborns and 4 newborns receiving milk powder (full-term in­
fants, age 4-9 days). The milk powder was Almiron 42 (Nutricia, the Nether­
lands) . 
Hydrolysis of orotidine 
Orotidine was cleaved to orotic acid by heating 1-ml samples of urine with 
0.2 ml of 12 M HCl at 100 0C for 2 h in sealed glass tubes. 
Colorimetrie procedure for orotic acid 
Orotic acid was extracted from hydrolyzed or non-hydrolyzed samples with 
silicagel and measured colorimetrically according to Kesner et al. (10). 
Isotope dilution procedure for orotic acid 
3-ml samples of urine or 1-ml samples of hydrolyzed urine were applied to a 
Dowex-50 column (1 g dry weight, H -form). The column was eluted twice with 
3 ml of distilled water. The eluate was neutralised with 2 M NaOH and brought 
to a final volume of 10 ml. The assay mixture (final volume 0.5 ml) contain­
ed 25-250 μΐ of eluate, 25 mM Tris/HCl (pH 7.4), 5 mM MgCl , 2 UM PRPP, 3 
14 
UM [carboxyl- C]orotic acid (41 mCl/mmol) and 0.1 mg or 0.3 mg 0PRT/0DC 
mixture (enzyme preparations from P-L and Sigma, respectively). After in-
o 
cubation for 30 min at 37 C, 0.2 ml of 1 M HCl was injected and shaking 
14 
continued for 1 h. CO was trapped and measured as described before (13). 
14 
The radioactivity in CO (F) is related to the amount of orotic acid in 
the sample (X) according to F = A.B/(B+X), where A is the radioactivity in 
14 
CO measured in the absence of the unknown sample of orotic acid and В 
14 is the amount of [carboxyl- C]orotic acid. In calculating the concentration 
of orotidine, the results obtained with hydrolyzed samples were corrected 
for the amount of orotic acid present, as measured with non-hydrolyzed 
samples. Hydrolysis, purification procedure on Dowex and isotope dilution 
assay were all performed in duplicate. 
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6.4. RESULTS 
14 
Experiments with [ C]labeled orotidine revealed that this compound was 
14 hydrolyzed completely to [ C]orotic acid within 2 h in the presence of HCl 
о 
at 100 С. The orotic acid formed was stable under these conditions. Using 
the colorimetrie procedure we then measured the sum of orotic acid and the 
orotic acid released from orotidine in hydrolyzed urine samples. When non-
hydrolyzed urine was applied to the silicagel column, orotidine and orotic 
acid could not be separated completely. Above pH 1.0 orotidine was retained 
on the column, but the elution of orotic acid was not complete. At lower pH 
all of the orotic acid was eluted but also part of the orotidine. Since 
orotidine is also reactive with respect to the colorimetrie test (2) we 
investigated whether the interference by orotidine was serious. Color yield 
per mol was found to be only 3.5 times higher with orotic acid than with 
orotidine. Since orotidine excretion is usually much higher than excretion 
of orotic acid, the colorimetrie procedure apparently is not suitable to 
obtain separate values for orotic acid and orotidine. 
To eliminate substances interfering with the isotope dilution assay, 
the urine samples had to be purified by running through a Dowex-50 H col­
umn. These substances could be hypoxanthine and xanthine, since these com-
14 
pounds interfered when added to the assay mixture. Using [ C] labeled com­
pounds it could be shown that these latter compounds are retained completely 
(> 98%) on the Dowex column, while all orotic acid is eluted (> 96%). The 
isotope dilution assay was not interfered by orotidine, uracil, uric acid 
or oxipurinol when these compounds were present in a concentration which 
was 20-fold higher than the concentration of orotic acid. 
The radioactivity (F) present in trapped CO was measured after addi­
tion of various known amounts of unlabeled orotic acid (Fig. 6.1). The 
values of F can also be calculated from the formula F = A.B/(B+X) when A 
and В are known (see Materials and Methods). The close agreement between 
the calculated and the experimental values of F (Fig.6.1) illustrates the 
accuracy of the method. It is of course essential for this method that 
other effects than isotope dilution do not contribute to the decrease of 
radioactivity m CO . This condition was tested in two ways. In one series 
14 
of experiments a higher concentration of [carboxyl- C]orotic acid (B) was 
present in the assay mixture. The second test involved the addition of a 
known amount of unlabeled orotic acid to the column eluates. In both cases 
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0 5 Ю 
nmol 01 orotic acid added ( Χ) 
14, Fig. 6.1. Experimental and calculated values of radioactivity in COg (F) 
as a function of the amount of orotic acid added (X), F was measured (open 
circles) by liquid scintillation counting of trapped ^COg and calculated 
(drawn curve) according to F = A.B/(B+X) аз d^sarzbed in Materials and 
Methods, /alues for A and В averaged 82,000 dpm and 1.6 nmol, respectively. 
consistent values of X were obtained for a given sample. This indicates that 
only isotope dilution is responsible for the decrease in radioactivity in 
C 02· 
The colorimetrie test was used as a reference method for the isotope 
dilution assay. Two different samples of urine were hydrolyzed and applied 
to a Dowex column. The column eluates were assayed for orotic acid by both 
methods. Values obtained with the colorimetrie test were 9.2 and 4.7 \¡g 
orotic acid per ml eluate. The corresponding values measured with the iso-
tope dilution assay were 8.6 and 4.7 respectively. At low concentrations of 
orotic acid (< 1 pg per ml eluate) the colorimetrie method is less precise 
due to its low sensitivity and agreement with the isotope dilution assay 
is worse. 
The sensitivity of the isotope dilution assay is about 0.1 nmol (20 ng) 
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TABLE 6 . 1 . 
URINAR» IXCRPIUN OF OROTIC ACID AND OROIIOINE [Ν NEWBORNS, CONIROlb AID 
PATIEN1S RECEIVING ALLOPURINOL 
Creatiti ι ne Orotic dcid Proti dine 
mq/1 mg/1 mg/24 h mg/1 mg/24 h 
Newborns (n-6) 166 i 56 0 / i 0 3 - 3 ' ι 1 3 
Contra's (n-6) 1204 t248 1 3 t 0 2 1 5 t 0 5 4 5 i l 5 b 0 i U 9 
Al lopurinol-treated 
- fiout 
II ν S. 910 7 6 
J M. 862 25 Ζ 
J ï 66/ 13 O 
11 2 
33 3 
26 1 
39 7 
107 
39 1 
5B 6 
142 
7a S 
- Deficiency 
Ru h 
Ri' И 
Ρ К 
of HGPRT 
379 
424 
340 
4 4 
2 6 
6 3 
J 7 
2 2 
3 5 
8« 8 
123 
113 
и ι, 
1-14 
62 6 
P a r t i a l defic ency of Hf.PRT 
E f 809 1 4 2 1 73 5 112 
Concentrations of orotic acid and orot idine in urine were measured by the 
iso'oiie d i l u t i o n procedure described in "Materials and Methods' For newborns 
and controls the means » S O are given LompleLe sampling of 24-h urine could 
not be i>e'tu'iiied with newborns and therefore no values per 24 h are given for 
this gtoup 
of orotic acid. This procedure therefore allows the measurement of orotic 
acid and orotidine in urine samples without concentrating the urine. Values 
obtained for newborns, healthy controls and patients on allopurinol medi­
cation are given in Table 6.1. No difference in orotic acid and orotidine 
excretion was observed between children (10 and 15 y) and adults and there­
fore both groups were combined under the heading "controls". Orotidine 
excretion was increased in all patients receiving allopurinol, both in con­
centration and in amount per 24 h. Excretion of orotic acid after allo­
purinol administration was increased in gouty patients but was close to 
normal values in patients with partial or complete deficiency of HGPRT. 
Urinary concentrations of orotidine and orotic acid were similar in breast­
fed newborns and in newborns receiving commercial milk powder. The newborns 
are therefore presented as one group in Table 6.1. The concentration of 
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orotic acid and orotidine in urine from newborns is slightly lower than in 
urine from adults, but when the excretion is calculated per mg creatinine 
the values are higher in urine from newborns (Table 6.1). The milk powder 
fed to some newborns contained no detectable orotidine and 15.8 + 1.1 mg 
of orotic acid per 100 g powder (mean +_ S.D. of six determinations). 
6.5. DISCUSSION 
The procedure described provides a specific, sensitive and relatively simple 
method for the measurement of orotic acid and orotidine in biological sam-
ples. The colorimetrie assay described by Kesner et al. (10) does not dis-
tinguish between orotic acid and orotidine, and is less sensitive. The iso-
tope dilution method published by Christopherson and Finch (11) involved 
an extraction procedure which yielded a low and variable recovery of orotic 
acid. Furthermore, the assay required thin-layer chromatography to separate 
the products from the substrate. No significant loss of orotic acid occurs 
14 in our method. The use of [carboxyl- C]orotic acid for the isotope dilution 
assay permits the isolation of the product (CO ) during the assay. The inter-
ference of the assay by hypoxanthine indicates that some HGPRT activity may 
be present in the OPRT/ODC preparation (11). Urinary hypoxanthine, however, 
could be retained completely on the Dowex column. Orotidine could be mea-
sured after hydrolytic conversion to orotic acid. It appears to be difficult 
to separate orotidine from orotic acid. We obtained no complete separation 
with a silicagel column and even with high-pressure liquid chromatography 
the separation is poor (14). 
Normal values for orotic acid and orotidine excretion obtained with 
this method are similar to values reported by other investigators (2-4, 15). 
Increased urinary excretion of orotidine after allopurinol administration 
was previously observed in normal subjects (2) and in patients with gout (3) 
or deficiency of HGPRT (4, 16). Normal subjects (4) and gouty patients (3) 
showed an increased orotic acid excretion after allopurinol administration. 
Both normal (4) and increased (16) excretion of orotic acid was reported 
for patients with deficiency of HGPRT receiving allopurinol. We found val-
ues close to normal for this group (Table 6.1). The orotidine excretion 
after allopurinol administration can be ascribed to inhibition of ODC by 
ribonucleotides of allopurinol and its oxidation product oxipunnol (16-18). 
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The increased excretion of orotic acid after administration of allopurinol 
may be due to inhibition of OPRT by accumulated orotidme monophosphate (18). 
A similar mechanism may be responsible for the increased excretion of oro-
tidine and orotic acid following administration of 6-azauridine (5), 5-
azacytidine (19)and 5-azaorotic acid (20). The absence of orotic aciduria 
after allopurinol administration in patients with deficiency of HGPRT is 
still consistent with this hypothesis, since the inhibition by orotidme 
monophosphate is competitive with PRPP (18) and PRPP concentration is in­
creased in erythrocytes (13, 21) and fibroblasts (21) of these patients. 
Urinary concentrations of orotic acid and orotidine were similar in 
newborns receiving milk powder and in breast-fed children. A high content 
of orotic acid (100-130 mg per 100 g of powder) was reported for commercial 
milk powder (12). We found a lower value (16 mg per 100 g powder). The 
difference may be caused by the use of milk powder from different manufac­
turers or may reflect the use of a more specific method (isotope dilution 
assay versus colorimetrie determination). The dietary intake of orotic acid 
by newborns receiving milk powder (estimated to be about 10 mg per day) 
does not affect the urinary excretion of this compound. Diet apparently does 
not affect the urinary excretion of orotidine and orotic acid (15). 
The isotope dilution method described is specific and very sensitive. 
Urinary concentrations of orotic acid as low as 1 μΜ can be quantitated 
without concentrating the sample. This method seems therefore also appro­
priate to investigate small disturbances of orotic acid metabolism due to 
drug-induced enzyme inhibition or secondary to deficiencies of purine 
nucleoside Phosphorylase (8), of adenosine deaminase (22) or of enzymes of 
the urea cycle (6, 7). 
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C H A P T E R 7 
MECHANISM OF ALLOPURINOL-MEDIATED INHIBITION AND STABILIZATION OF HUMAN 
OROTATE PHOSPHORIBOSYLTRANSFERASE AND OROTIDINE PHOSPHATE DECARBOXYLASE 
W.J.M.Tax, J.H.Veerkamp, J.M.F .Trijbels and E.D.A.M.Schretlen 
(Biochem.Pharmacol. (1976) 25^ , 2025-2032) 
7.1. SUMMARY 
Allopurinol ribonucleotide and oxipunnol 7-ribonucleotide appeared to be 
strong inhibitors of orotidine phosphate decarboxylase in human hemolysates. 
The enzyme exhibited bimodal kinetics. The ribonucleotides of allopurinol 
and oxipunnol caused an inhibition of orotate phosphonbosyltransferase, 
which appeared to be due to accumulation of OMP. Inhibition of OMP was com­
petitive with respect to phosphonbosylpyrophosphate with a К value of 11 
μΜ. The inhibition of ODC and OPRT activity may cause the increased urinary 
excretion of orotidine and orotic acid, respectively, observed after allo­
purinol therapy. Values measured for OPRT activity in intact erythrocytes 
and in hemolysates agreed very well. Therefore OPRT activity does not de­
crease during cell lysis and extraction. Hypoxanthine-guanine phosphoribo-
syltransferase deficiency as well as allopurinol therapy led to a marked 
increase in OPRT and ODC activities in human hemolysates. In lysates from 
leukocytes only a slight increase of ODC activity was observed, while OPRT 
activity did not differ significantly from the controls. In vitro incubations 
of hemolysates demonstrated a considerable increase of the stability of OPRT 
by addition of OMP or PRPP and of ODC by addition of OMP, PRPP, UMP and the 
ribonucleotides of allopurinol and oxipunnol. These findings suggest that 
the apparent increase of OPRT and ODC activity after allopurinol therapy is 
due to stabilization of the enzymes during the life span of the erythrocytes. 
7.2. INTRODUCTION 
Allopurinol inhibits the final enzyme of purine metabolism in man, xanthine 
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oxidase (EC 1.2.3.2.) and is an effective agent for treatment of hyper­
uricemia (1). Allopurinol therapy also interferes with pyrimidine metabolism 
as indicated by an increased excretion of orotidine and orotic acid in 
urine (2, 3). Subsequent investigations have established that allopurinol 
and its major metabolite oxipurinol inhibit pyrimidine biosynthesis in 
cultured human cells by interfering with the conversion of orotic acid to 
UMP (4, 5). The increased excretion of orotidine has been ascribed to in­
hibition of orotidine 5'-monophosphate decarboxylase (EC 4.1.1.23) by 
ribonucleotides of allopurinol and oxipurinol. The increase in excretion of 
orotic acid suggests that inhibition of orotate phosphoribosyltransferase 
(EC 2.4.2.10) may also occur but the exact mechanism has not yet been 
elucidated. 
In addition it was observed that activities of OPRT and ODC in ery­
throcytes from patients receiving allopurinol were markedly elevated. This 
phenomenon has been attributed to enzyme stabilization in VIVO (7) or enzyme 
activation (8). The apparent increase in activity might also be due to 
stabilization of the enzymes during cell lysis and extraction rather than 
stabilization гп vito (5, 9). 
In the present study we have examined the mechanisms responsible for 
enzyme inhibition on the one hand and apparently increased enzyme activities 
on the other hand. In these studies we used both normal blood cells and 
cells obtained from patients deficient in hypoxanthme-guanine phosphonbo-
syltransferase (EC 2.4.2.8) activity. Our results suggest that allopurinol-
induced inhibition of ODC activity is associated with inhibition of OPRT 
activity by accumulated OMP. In addition, evidence is presented that the 
apparent increase in OPRT and ODC activities is probably due to stabiliza­
tion of the enzymes during the life span of the erythrocyte. 
7.3. MATERIALS AND METHODS 
Materials 
Phosphoribosylpyrophosphate tetrasodium salt was purchased from Boehringer, 
Mannheim. Orotic acid monosodium salt and orotidine 5'-monophosphoric acid 
tnsodium salt were obtained from Sigma Chemical Co., St.Louis, Mo. (U.S.A.). 
Allopurinol, oxipurinol and allopurinol ribonucleotide were gifts from Dr. 
G.B.Elion, Burroughs-Wellcome Co., Research Triangle Park, N.C. (U.S.A.). 
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Oxipurinol 7-ribonucleotide was generously provided by Henning Chemie Si 
Pharmawerk, Berlin, West Germany. Dextran Τ 500 and Sephadex G-25 (coarse) 
14 
were obtained from Pharmacia, Uppsala, Sweden. [Carboxyl- CJorotic acid 
14 (42.4 mCi/m-mole), [carboxyl- C] orotidine 5'-monophosphate (36.9 mCi/m-
14 
mole) and [6- CJorotic acid (49.1 mCi/m-mole) were obtained from New Eng­
land Nuclear Corp., Dreieichenhain, West Germany, as well as omnifluor and 
aquasol. Aluminum sheets (20 χ 20 cm) precoated with 0.1 mm of polyethyl-
eneimine-cellulose were purchased from Merck, Darmstadt, West Germany. The 
other chemicals were of the highest quality commercially available. 
Blood samples 
Venous blood samples were obtained from three gouty patients receiving 
allopurinol (300 mg/day) for at least 6 months, from three children with 
HGPRT-deficiency who have been on allopurinol medication (200 mg/day) for 
several years and from a gouty adult (E.F.) with partial deficiency of 
HGPHT (1 per cent of normal value) who also has received the drug (300 mg 
per day) for several years. Two children with HGPRT-deficiency exhibited 
all symptoms of the Lesch-Nyhan syndrome including automutilation (10) 
while the third one (P.K.) had no severe neurological lesions. Adult volun­
teers served as control group. 
Preparation of cells and cell extracts 
In order to separate leukocytes from erythrocytes by differential sedimenta­
tion, dextran was added to the blood samples (11). After the erythrocytes 
had settled, they were washed twice with Tris-buffered saline (pH 7.4). 
The cells were used intact or lysed by rapidly freezing and thawing twice. 
Leukocytes were centrifuged at 1500 rpm and remaining erythrocytes were 
removed by a hypotonic shock for 60 sec after which isotonicity was restored. 
Leukocytes were washed with phosphate-buffered saline and lysed either by 
prolonged hypotonic shock or by sonication. Lysates of leukocytes were 
immediately assayed for enzyme activities while hemolysates could be stored 
at -20 for several weeks without detectable loss of OPRT and ODC activity. 
Analytical procedures 
The actual PRPP content of stock solutions was determined enzymatically 
14 
using [8- C]adenine and adenine phosphoribosyltransferase partially purified 
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from human erythrocytes (12) The reaction was stopped by boiling for 2 
min and AMP was separated from adenine by thin-layer chromatography on PEI-
cellulose (13). Enzyme activities were estimated with radiochemical methods 
14 
using C-labeled compounds. Determination of radioactivity was performed 
m a Packard 3380 liquid-scintillation spectrophotometer with external 
standardization. Protein was determined according to Lowry et al. (14). 
Specific enzyme activities are expressed in nmoles of product formed in 
о 
1 hr per mg of protein at 37 under the assay conditions specified below. 
All enzyme assays were checked on linearity with respect to enzyme con­
centration and time. 
Assay of orotate phosphoribosyltransferase^_Assay I 
Incubation mixtures contained 0.05 M Tris-HCl buffer (pH 7.4), 5 mM MgCl , 
14 0.7 mM PRPP, 0.3 mM [carboxyl- CJorotic acid (0.15 mCi/m-mole) and enzyme 
protein in a total volume of 0.6 ml. Reactions were carried out in scin-
14 
tillation vials sealed with rubber caps. The CO evolved was trapped in 
0.2 ml of a mixture of ethyleneglycol-ethanolamine (2 1, v/v) present in a 
small polypropylene tube fitted in a slightly larger tube. After incubation 
for 10-60 m m with shaking, 0PRT activity was stopped by injection of 0.2 
2+ 
ml 0.25 M neutralized EDTA. Because ODC does not require Mg -ions, de­
carboxylation can be allowed to proceed for another hour. Injection of 0.2 
14 
ml 5 M perchloric acid removed all CO from the reaction mixture within 
14 
1 hr. The small tube containing trapped CO was transferred to a scintil­
lation vial with 10 ml of toluene-methanol (2 1, v/v) containing 4 g omni-
fluor per litre. Blanks contained no enzyme protein. 
This assay was also employed when 0PRT activity was determined in 
intact erythrocytes. A 25% suspension of erythrocytes in phosphate-buffered 
saline containing 0.1% glucose and 0.1% MgCl was preincubated for 1 hr 
14 
resulting in intracellular PRPP synthesis. [Carboxyl- C]orotic acid was 
added to 500 ul of this suspension to reach a final concentration of 0.3 
14 
mM (sp. act. 0.15 mCi/m-mole). During a 30-min incubation CO production 
was trapped as described above. Reaction was terminated by injection of 
perchloric acid. Preliminary experiments had shown that intracellular orotic 
acid concentration almost instantaneously equals the medium concentration. 
Assay II 
In this assay unreacted orotate is separated from the products which are 
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synthesized from orotate by OPRT and any consecutive enzyme which may be 
present (15). The reaction mixture contained 40 mM Tns-HCl (pH 7.4), 0.1 
14 
mM [6- C]orotic acid (49.1 mCi/m-mole), 5 mM MgCl , 1.1 mM PRPP and enzyme 
protein in a final volume of 50 yl. The mixture was Incubated for 30 min 
in small polypropylene tubes. Reaction was terminated by immersing the tubes 
in boiling water for 2 min. Carrier orotic acid and uridine were added and 
precipitated protein removed by centrifugation for 10 min at 4500 g in a 
Misco centrifuge (Microchemical Specialities Co., Berkeley, California, 
U.S.A.). Ten-jl samples of the supernatant were spotted on PEI-cellulose 
thin-layer plates. Development was accomplished with 0.2 M LiCl (saturated 
with boric acid and adjusted to pH 4.5)-ethanol (1:1, v/v). Chromatograms 
were dried at room temperature. The spots were visualized under u.V. light 
and cut out. In order to circumvent any self absorption of radioactivity, 
compounds were eluted prior to counting by shaking with 1.0 ml of 0.1 M 
HC1-0.2 M KCl for 40 min in scintillation vials. Ten ml of aquasol was 
added and radioactivity measured. Blanks were obtained by immersing the 
tubes in boiling water for 2 min prior to incubation. The conversion of 
substrate into products was calculated by comparing net radioactivity in 
products derived from orotate with the total amount of radioactivity pre­
sent. A higher PRPP concentration than in assay I was necessary since the 
higher protein concentration employed seemed to be associated with an in­
crease of enzymatic breakdown of PRPP. 
Assay of orotidine-51-phosphate decarboxylase 
Cell lysates, appropriately diluted with 50 mM Tns-HCl buffer (pH 7.4) 
14 
were incubated with 0.1 mM [carboxyl- C] orotidine 5'-monophosphate 
(0.2 mCi/m-mole) for 10-60 min in a final volume of 0.55 ml. Reaction was 
14 
terminated by injection of 0.2 ml 5 M perchloric acid. Production of CO 
was measured as described for OPRT, assay I. 
Stabilization studies 
Hemolyzed red cells were diluted with 9 vol of Tns-HCl buffer (50 mM, pH 
о 
7.4) and incubated for 16 hr at 37 . To avoid bacterial contamination 
penicillin-G (100 U/ml) and streptomycin (100 yg/ml) were present in the 
incubation vessels. When it was necessary to remove inhibitors of OPRT or 
ODC before enzyme assay lysates were passed through Sephadex G-25 columns 
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after incubation. 10 mM Tris-HCl (pH 7.4) was used for suspending the 
Sephadex powder as well as for eluting the protein from the column. The 
enzymes were eluted in the void volume together with hemoglobin. 
7.4. RESULTS 
Activities of orotate_phosphoribosyltransferase and orotidine S'-phosphate 
decarboxylase in circulating blood cells 
OPRT and ODC activities were elevated in hemolysates from the allopurinol-
treated group when compared with the control group (Table 7.1).This increase 
in enzyme activity was seen with both the HGPRT-deficient patients and the 
gouty patients. Enzyme activities were also measured in HGPRT-deficient 
subject P.K. before allopurinol therapy was started. Values averaged 1.0 
nmole/hr per mg protein for OPRT, and 1.7 nmole/hr per mg protein for ODC 
activity. 
In lysed leukocytes OPRT activity of the allopurinol-treated patients 
was not higher than m controls. ODC activity was slightly higher than in 
6 control subjects. 
OPRT activity was also measured in intact erythrocytes after prein-
cubation in a PRPP-generating system. For control subjects, OPRT activities 
in intact erythrocytes and in lysed erythrocytes agreed very well (Table 7.2). 
However, OPRT assay in intact erythrocytes from allopurinol-treated patients 
resulted always in lower values when compared with corresponding hemolysates. 
Effect of allopurinol_and its_metabolites on activity of orotidine S'-
phosphate decarboxylase 
Allopurinol and oxipurinol were found to have no effect on ODC activity in 
hemolysates. However, when a hemolysate was preincubated with allopurinol 
or oxipurinol (1 mM) in the presence of 1 mM PRPP compounds were synthe-
sized which strongly inhibited ODC activity. Longer periods of preincubation 
resulted in stronger inhibition of ODC. The inhibitors formed during the 
preincubation period were shown to be competitive with respect to orotidine 
5'-monophosphate (Fig.7.1).The inhibitory agents are presumably allopurinol 
ribonucleotide and oxipurinol 7-ribonucleotide. These compounds appeared to 
be competitive inhibitors of ODC (Fig.7.2).Oxipurinol 7-ribonucleotide 
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TABLE 7 . 1 . 
ORLTATE PKOSPHCRIBOSV.-TRA^SFERASE АЧТ OKfT· I4L MONUPhObPHA-E CECJRSCKVlASE 
ACTIVITIES IN HUMAN LEI KCKÏTLS AS[Ì fcRYTIIRL4.ÏTES 
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TABLE 7 . 2 . 
OROTATE PH0SPH0HIB05YLTRANSfERAS£ ACTIVITY IN INTACT AND LYSED HUMAN ERYTHROCYTES 
Intact cells 
0.22* 0.19 
0.22 0.22 
0.14 0.12 
0.59 1.09 
0.17 1.23 
Ο.βΙ 1.49 
0.84 1.87 
Enzyme activity vas measured by assay I and is given in maoles/hr per mg protein. 
Controls: 
C.H. 
h.T. 
W.G. 
Allopurinol treated 
H. v.S. 
P.K. 
Re. U. 
Hu. V. 
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Fig. 7.1. Inhibition of ODC in 
hemolysate after incubation with 
allopurinol or oxipurinol in the 
presence of 1 mM PRPP. 
Control (êiy allopurinol during 
30 min (0), oxipurinol during 
30 min (Α.), oxipurinol during 
60 min (к). 
Fig. 7.2. Inhibition of ODC in 
hemolysate by ribonucleotides 
of allopurinol and oxipurinol. 
Control (в), 1.1 χ 10~S M oxi­
purinol 7-ribonucleotide (k), 
-4 
5 χ 10 M allopurinol ribo­
nucleotide (0). 
(К value 0.06 μΜ) was a much stronger inhibitor of ODC than the former 
compound (K value 5 μΜ). 
The synthesis of allopurinol l-nbonucleotide is catalyzed by HGPRT, 
since no inhibition of ODC was observed when allopurinol and PRPP were in­
cubated with HGPRT-deficient lysate. HGPRT activity did not appear neces­
sary for an inhibitory oxipunnol ribonucleotide to be formed (Table 7.3). 
Xanthosine monophosphate was reported to be a competitive inhibitor of ODC 
activity (3, 6). It was also inhibitory in our assay system. However, pre­
incubation of xanthine and PRPP with hemolysate did not result in a detect­
able inhibition of the ODC activity. 
We found bimodal kinetics for the ODC activity in hemolysates.At (un-
physiologically) high concentrations of substrate the ODC enzyme shows 
higher apparent values for both К and V (Fig. 7.3). At OMP concentra-
m max 
tions lower than about 30 μΜ а К value of 1.7 + 0.4 μΜ (mean + S.D., 4 
m — — 
determinations) was found. Values for high К averaged 33 μΜ. Similar 
m 
kinetics were observed when the enzyme concentration was 4-fold higher. 
This finding of bimodal kinetics does not affect the К values reported 
above for oxipurinol 7-ribonucleotide and allopurinol ribonucleotide. These 
values were determined at the low concentration range of OMP. 
Effect of allopurinol and its metabolites on activity of orotate phospho-
ribosyltransferase 
Unless otherwise indicated all results described in this section have been 
obtained using assay II for OPRT assay. Allopurinol has no inhibitory effect 
on OPRT activity at saturating concentrations of orotic acid and PRPP. Even 
at concentrations of PRPP which are suboptimal for OPRT we found no in­
hibition of OPRT activity by allopurinol. Under these conditions hypoxan-
thine strongly inhibits OPRT activity (Table 7.4). This inhibition is 
probably due to consumption of PRPP in a HGPRT-catalyzed reaction since no 
inhibition was found with HGPRT-deficient lysate. Inhibition is nearly ab­
sent when PRPP concentration is high. 
A small but significant inhibition of OPRT activity was found when 
allopurinol 1-ribonucleotide or oxipurinol 7-ribonucleotide was present m 
the assay mixture. Inhibition was stronger at lower PRPP concentrations 
and also increased with longer incubation periods. This type of inhibition 
could be explained by assuming that the presence of ribonucleotides of allo-
73 
TABLE 7.3. 
RELATIVE OROTIDINE MONOPHOSPHATE DECARBOXYLASE ACTIVITY IN HEMOLYSATES AFTER 
PREINCUBATION UITH ALLOPbRINOL AND OXIPURINOL 
PreincubatLon conditions HGPRT-deficient 
PRPP 
Allopurinol • PRPP 
Ояіригіпоі + PRÍP 
100· 
42 
42 
ico* 
loo 
12 
* 100Z - value was 0.7 nmoles/hr per mg protein 
* IO0Z - value was 2.θ nmoles/hr per mg protein 
Time of preincubation waa 60 min. compounds were added in a concentration of 1 mM 
0НР concentration during aasay was 0. ] mM. 
[nmoles/mg protein per hr j 1/ODC 
10-
/[OMP] (mM) 
Fig. 7.3. 
Biphasia kinetics of 0DC in human hemolysate. 
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TABLE 7.4. 
RELATIVE OROTATE PHOSPHORIBOSYLTRANSFERASE ACTIVITY IN HEMOLYSATES IN THE PRESENCE 
OF ALLOPURINOL AND HYPOXANTHINE 
\ 
Addxtion\ PRPP (mM) 
Hypoxanthine (1 mM) 
Allopurinol (1 mM) 
0.5 
39 
107 
Normal 
2.0 
82 
94 
HGPRT-deílxienc 
0.5 2.0 
103 104 
112 102 
Control values (set at 100%) vere С.19, 0.20, 1.1 and 1.2 nraoles/hr per mg protein, 
respectively. Resuite are the mean of two experiments. 
Hg. 7.4. 
Inhibition of OPRT in hemolysate 
by OMP. Control Ό), 2 χ 10~4 
M OMP (к). 
1/[PI?PP] 
lOlmMI"' 
purinol and oxipurinol causes an accumulation of an inhibitor. Because ODC 
activity is inhibited by ribonucleotides of allopurinol and oxipurinol (see 
above) OMP might accumulate during their presence. This compound was there­
fore studied with regard to possible inhibition of OPRT activity. 
When studying the effect of OMP on OPRT, care must be taken to prevent 
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utilization of this compound. Some dephosphorylation of OMP was found to 
occur in hemolysates but this reaction was of minor importance at the low 
concentrations of OMP used in these studies. Decarboxylation of OMP is much 
more of a problem since ODC activity in hemolysates is twice as high as 
OPRT activity. In order to prevent a decrease in the OMP concentration 
during the OPRT assay due to ODC activity, allopurinol ribonucleotide (1 mM) 
was added to all reaction mixtures (including controls) when studying the 
effect of OMP. Under these conditions OMP appeared to be a potent inhibitor 
of OPRT activity. Inhibition is competitive with respect to PRPP (Fig.7.4). 
When the К value is calculated from the Lineweaver-Burk plots, a value of 
ι 
13 μΜ is obtained. However, this value depends on the PRPP concentration. 
Because of the known instability of PRPP (16) the values of the PRPP con­
centrations may be to some extent inaccurate, which affects the calculated 
value of К . Therefore the К value for OMP was also determined according 
to the Dixon method (17), using various concentrations of inhibitor and two 
different concentrations of PRPP. This method yielded а К value of 11 μΜ 
(Fig.7.5). 
Several nucleotides appeared to be inhibitors of OPRT (Table 7.5). 
Assay I for OPRT was used in these experiments. Prior to testing the effect 
of these nucleotides on OPRT activity, their non-interference with the ODC 
reaction was ascertained. Inhibition was competitive with respect to PRPP 
for all inhibitors tested, except TTP. This compound strongly inhibits 
OPRT activity even at a high concentration of PRPP. 
Stabilization studies 
When hemolysates were diluted with Tris-HCl buffer (pH 7.4) and incubated 
for 16 hr at 37 , both OPRT and ODC activity decreased strongly. The extent 
of this decrease was very different for various hemolysates (Table 7.6). 
This great variability is reflected in the variability of the values found 
after incubation in the presence of stabilizing compounds, since these 
values were calculated by comparison with their respective control values. 
The presence of 0.1 mM allopurinol ribonucleotide or oxipurinol 7-ribonu-
cleotide appeared to stabilize ODC activity, but no effect on OPRT activity 
was observed. Allopurinol ribonucleotide had similar effects at 1 mM, but 
no stabilization could be measured with 1 mM oxipurinol 7-ribonucleotide. 
As a matter of fact, OPRT and ODC activities were under these conditions 
even lower than in controls without any addition. Stabilization of ODC 
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200 MOO 
[PNP], juM 600 aoo 
Fig. 7.5. 
Determination of K¿ value of OMP for OPRT from hemolysate according to Dixon 
(17). OPRT activity was measured with assay II (see Methods). Allopurinol 
ribonucleotide (1 mM) was present to prevent decarboxylation of OMP. Con-
centration of PRPP was 1 mM (Ф) or 0.5 mM (Ш). 
TABLE 7.5. 
EFFECT OF NUCLEOTIDES ON QUOTATE PH0SFH0RIB05YLTRANSFERASE ACTIVITY IK HEMOLYSATE 
Relativa OPRT activity 
hon· 
TTP 
ΑΗΡ 
OtP 
ATF 
IMF 
IMF 
ADF 
CMF 
c-AMP 
100 
14 È 1 
4B t 2 
54 ± ) 
62 1 1 
71 ± 2 
75 ± 2 
76 i 1 
89 ± 4 
100 ± 5 
Haan and deviation ίτοα th« nean of two experimenta arc given ев percenta of the 
tontiol. Concentration of nucleotides was 3 вМ, and concentration of PRPP yae 0.2 ι 
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TABLE 7.6. 
REIATIVF ACTIVITY OF OPRT АЧТ) ÛDC AFTEH OVERNIGHT INCUftATION AT 370(, IN THE 
PRFSF-irE ÜF NÎClEOTIDtS 
Addition ^ *[ ÜPRT ODC 
None 
UHF (I mM) 
OHP (0 1 пЛ) 
ОЧГ (1 ι*) 
Окіриппэ. nbc-uclcotide (0 1 
Allopurinol ribo-ucleocide (0 
Allopurinol ribonucleotide (1 
1 mM) 
1 4.4) 
oHi 
115 
119 
IS2 
92 
9І 
91 
100 
(112-ΙΙβ) 
(113-124) 
(157-2S9) 
(SO-IOC) 
(82-100) 
(72-107) 
236 
201 
508 
258 
305 
318 
100 
(219-253) 
(181-226) 
(208-10)3) 
(179-348) 
(187-528) 
(273-404) 
Values bett-een bracketb indicate the range observed with different hemolysates. 
Before incubano- relative OPRT activity tas 1233 (672-2667, n-101 and relative 
ODC activity was 623 (396-1255» n-10) 
occurred also when UMP was present at a concentration of 1 mM, but was not 
detectable at 0.1 mM. Again, no stabilizing effect on OPRT was observed. 
OPRT activity, as well as ODC activity was stabilized by OMP at 1 mM. 
Stability of both enzymes was not significantly influenced by any of the 
following compounds at 1 mM concentration: orotic acid, allopurinol, oxi-
purinol, TMP or TTP. OPRT and ODC activities in hemolysates incubated for 
5 hr in Tris-HCl buffer were only 6 and 30 per cent, respectively (mean of 
2 experiments) of the enzyme activities before incubation. When the incu­
bation was performed in phosphate buffer (50 mM, pH 7.4) instead of Tris-
HCl buffer, both OPRT and ODC activity appeared much more stable. Activities 
were 95 and 81 per cent of the starting value, respectively (mean of 2 
experiments). Complete stabilization of OPRT and ODC activities (110 and 96 
per cent respectively of the starting value, 2 experiments) was observed in 
Tris-HCl buffer during the 5-hr period when at 30 min intervals PRPP was 
added to a final concentration of 0.4 mM. 
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7.5. DISCUSSION 
The effects of allopunnol on OPRT and ODC activities include enzyme in­
hibition on one hand leading to increased excretion of orotic acid and oroti-
dine (2, 3) and an apparent increase of enzyme activities in erythrocytes on 
the other hand (7,8)(Table 7.1). The observed increase in orotidine excretion 
was ascribed to inhibition of the ODC enzyme (3, 7). Our experiments sustain 
this explanation. Allopunnol ribonucleotide and xanthosine 5'-monophosphate 
are potent inhibitors of ODC activity (3, 4). We found no inhibition of ODC 
after preincubation of hemolysates with xanthine and PRPP, despite the fact 
that XMP inhibited ODC activity. However, xanthine is a much poorer substrate 
for HGPRT than is allopunnol (18). Allopunnol ribonucleotide is readily 
formed from allopunnol and PRPP, and strongly inhibits ODC activity (Fig. 
7.1, 7.2). Since HGPRT activity is necessary for the formation of this in­
hibitor (Table 7.3) allopunnol-mediated inhibition of ODC activity cannot 
be ascribed to allopunnol ribonucleotide in HGPRT-deficient patients. 
Several studies (5-7) have stressed the importance of oxipurinol metabolites 
as inhibitors of ODC. Oxipurinol is converted to an inhibitor of ODC activity 
by HGPRT-deficient hemolysate in the presence of PRPP (Table 7.3). Oxipurinol 
7-ribonucleotide may be responsible for inhibition of ODC in HGPRT-deficient 
patients treated with allopunnol (6). Oxipurinol ribonucleotides may be 
more important in οίνο with regard to ODC inhibition than is allopunnol 
ribonucleotide. This is suggested by comparison of their concentrations in 
rat liver after allopunnol administration (19) and of their К values. The 
К value of oxipurinol 7-ribonucleotide for the ODC enzyme of human hemolysate 
(0.06 yM) is similar to the values reported for yeast and rat liver (6). 
For allopunnol ribonucleotide the observed К value was slightly higher 
than the values for the enzyme from erythrocytes (3), yeast and rat liver (6). 
Several nucleotides inhibit OPRT activity (Table 7.5) but have no 
effect on ODC activity of human hemolysates. CMP, GMP and AMP were reported 
to inhibit cow brain ODC activity (20) while GMP, AMP and IMP did not affect 
ODC activity in human hemolysates (3). К values for GMP, AMP and IMP were 
all determined to be greater than 100 viM with the enzyme from yeast (6). 
UMP inhibition of rat liver ODC has been reported (21) but this was not con­
firmed by other investigators (22). 
The ODC enzyme from rat liver (6), yeast (6) and human fibroblasts (23) 
exhibits bimodal kinetics, as in human hemolysate (Fig. 7.3). The К value 
m 
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at low OMP concentrations (1.7 μΜ) is close to the values reported for 
erythrocytes (3), rat liver (6), fibroblasts (23) and yeast (6). The К 
m 
value at high concentrations of OMP (33 μΜ) was much higher than in rat 
liver (6) and yeast (6). Very recently a triphasic Lineweaver-Burk plot was 
found with partially purified ODC from human erythrocytes (24). 
Competitive inhibition of OPRT by allopurinol has been suggested (2) 
as an explanation for the observed increase in excretion of orotic acid 
during allopurinol therapy, but our results do not support this hypothesis. 
Since OMP might accumulate during allopurinol therapy by inhibition of ODC 
activity, the competitive inhibition of OPRT activity by OMP may be a 
probable cause for the excretion of orotic acid. Inhibition by OMP of OPRT 
activity in baker's yeast was previously reported (25, 26) but the mechanism 
of inhibition was not clarified. Recently a similar competitive inhibition 
was also demonstrated in rat liver (27). Because tissue concentrations of 
PRPP are probably much below the К value of PRPP for the OPRT enzyme (28, 
29), competitive inhibition of OPRT by OMP may be of physiological signif­
icance. 
Several other nucleotides inhibit OPRT activity in hemolysates (Table 
7.5) and in other systems. UMP inhibition of OPRT was found with rat liver 
(27) but not with the enzyme from rat hepatoma cells (30) and baker's yeast 
(26). The enzyme from yeast was inhibited by CMP and GMP, but not by adenine 
nucleotides or uridine nucleotides (26). IMP, XMP and GMP inhibited only 
slightly the activity of a pyrimidine phosphoribosyltransferase from murine 
leukemia cells while CMP, TMP and AMP were ineffective (31). 
OPRT activity may also be inhibited by depletion of PRPP. A decrease 
of PRPP concentration has been reported in human red cells following a single 
dose of allopurinol (32). No such decrease was found in human fibroblasts 
(4) when allopurinol concentration was 0.1 mM which is much higher than the 
plasma levels in man (33). Allopurinol had no detectable effect under con­
ditions at which hypoxanthine caused a marked inhibition of OPRT by PRPP 
depletion (Table 7.4). This is consistent with the high К value of allo­
purinol (1 mM) for HGPRT when compared with the natural substrate hypoxan­
thine (2.4 μΜ) (18). Since allopurinol has also a short halflive (34) de­
pletion of PRPP does not appear to be the mechanism responsible for allo-
purinol-induced orotic aciduria. 
The apparent increase of erythrocyte OPRT and ODC activities after 
allopurinol therapy (Table 7.1) has been attributed to stabilization in vivo 
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(7), to enzyme activation (8), and most recently to stabilization of these 
enzymes during cell lysis and extraction (5, 9). Our results do not support 
this last suggestion. Measurement of OPRT activity in intact and lysed 
erythrocytes of controls reveals that these activities agree very well 
(Table 7.2). In intact erythrocytes from allopurinol-treated patients the 
14 14 
production of CO from [carboxyl- C]orotic acid is consistently lower 
than in lysates. This can be attributed to inhibition of ODC activity by 
ribonucleotides of allopurinol and/or oxipurinol. Assay II was not appro­
priate for measuring OPRT activity in intact erythrocytes, because of 
technical complications. Besides, this assay is also sensitive to indirect 
inhibition by OMP due to the presence of inhibitors of ODC. 
о 
Decrease of ODC activity during incubation at 37 is partially prevented 
by OMP and also by allopurinol ribonucleotide, UMP and oxipurinol 7-ribo-
nucleotide (Table 7.6). Because these latter compounds compete with OMP 
at the ODC enzyme, the stabilizing effect might be called pseudosubstrate 
stabilization. A similar in vitro stabilization of ODC has been found with 
the enzyme purified from yeast (6). An increased thermal stability of ODC 
activity was present in lymphoblasts after incubation with oxipurinol (5) 
and in rat liver after administration of allopurinol (35). An increased 
heat stability of ODC from cow brain was found in the presence of competi­
tive inhibitors of the enzyme (20) . The occurrence of biphasic kinetics 
for the ODC enzyme from hemolysate (Fig. 7.3) might be associated with a 
change in quaternary structure brought about by OMP (31). All findings sug­
gest that both OMP and inhibitors of ODC which are competitive with OMP may 
change the quaternary structure of the ODC enzyme and thereby affect the 
stability and activity of the enzyme. The inhibition of the enzyme activities 
observed after incubation with 1 mM oxipurinol ribonucleotide can be attrib­
uted to the tight binding of this compound to the enzyme protein during the 
gel filtration. The same phenomenon was found with lymphoblast extracts (5). 
Stabilization of OPRT was observed in the presence of OMP which appeared 
to be a competitive inhibitor of OPRT with respect to PRPP. TTP, an inhibitor 
of OPRT which is not competitive with regard to PRPP, has no stabilizing 
effect. PRPP itself gives complete protection of both OPRT and ODC activities 
when loss of this instable compound is compensated for by addition of fresh 
PRPP at regular intervals. The stabilizing effect of phosphate on OPRT and 
ODC activities is probably mediated by PRPP since phosphate is an activator 
of PRPP synthesis in hemolysates (36). Stabilization by PRPP could account 
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for the apparent increase of both OPRT and ODC activities measured in the 
HGPRT-deficient subject P.K. before allopurinol therapy was started. Ery­
throcyte PRPP concentrations are elevated m HGPRT-deficient patients (37). 
A similar increase of OPRT and ODC activities was reported previously (38) 
in HGPRT-deficient patients without allopurinol therapy. It was suggested 
from thermal inactivation studies that the increase was not due to stabili­
zation by PRPP. Because of the instability of PRPP these studies do not 
seem very suitable to investigate a possible stabilization by PRPP. 
The ODC activity in leukocytes (Table 7.1) is slightly higher than 
that reported earlier (8). Values for OPRT activity in human leukocytes 
have not been reported previously. The absence of a striking increase of 
OPRT and ODC activities in leukocytes after allopurinol administration is 
consistent with the theory of enzyme stabilization because of the short 
life-span of these cells. 
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C H A P T E R 8 
PYRIMIDINE METABOLISM IN ERYTHROCYTES OF THE NEWBORN 
W.J.M.Tax, J.H.Veerkamp and E.D.A.M.Schretlen 
(Accepted for publication in Biol. Neonate) 
8.1. SUMMARY 
Activities of orotate phosphoribosyltransferase and orotidine 5'-phosphate 
decarboxylase were found to be significantly higher in erythrocytes from 
newborn infants than in erythrocytes from adults, and approximated those 
observed in patients with deficiency of hypoxanthine-guanine phosphoribosyl-
transferase. Enzyme activities were increased to a varying extent in patients 
with reticulocytosis. The results are discussed in relation to red cell age 
and stabilization of the enzymes by phosphoribosylpyrophosphate. 
Pyrimidine 5'-nucleotidase was assayed by a new radiochemical method 
involving thin-layer chromatography for separation of product from sub­
strate. Enzyme activity was higher with orotidine monophosphate than with 
uridine monophosphate. The activity of this enzyme was similar in erythro­
cytes of newborns and adults. 
8.2. INTRODUCTION 
Orotate phosphoribosyltransferase (OPRT, EC 2.4.2.10) and orotidine 5'-
phosphate decarboxylase (ODC, EC 4.1.1.23) catalyze the final steps of pyri­
midine biosynthesis de novo. Both enzymes are deficient in all but one cases 
of hereditary orotic aciduria, an inborn error of metabolism which is 
associated with megaloblastic anemia and macrocytosis (2,8). Deficiencies 
of folic acid or vitamin В are other well-known causes of megaloblastic 
anemia and macrocytosis due to defects in nucleic acid synthesis. Macro­
cytosis is also observed in the neonatal period. The mean corpuscular volume 
3 
is 115 ν during the first weeks of life of the full term child (4). It 
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seemed interesting to investigate whether the neonatal macrocytosis could 
be associated with a disturbance of pyrimidine metabolism during this period, 
other than those caused by folic acid or vitamin В deficiency. 
In a previous investigation (16) we observed that both OPRT and ODC 
activities in human hemolysate are very labile in vitro but can be stabiliz­
ed by phosphoribosylpyrophosphate (PRPP). PRPP concentration is higher in 
erythrocytes of neonates than in those of adults (3) which may increase the 
stability of OPRT and ODC. Furthermore, the mean cell age of circulating 
erythrocytes is considerably lower in neonates than in adults (4). Since 
several enzymes have an increased activity in young erythrocytes (4,6,9) a 
study of OPRT and ODC activity in erythrocytes of newborn children appeared 
to be an interesting approach. 
Uridine monophosphate (UMP) which is the product of the consecutive 
action of OPRT and ODC but also a degradation product of ribonucleic acid, 
may be degraded by pyrimidine 5'-nucleotidase in erythrocytes (20). Hered­
itary deficiency (20) and lead-induced inhibition (13) of this cytoplasmic 
enzyme are associated with hemolytic anemia. It is known that the mean half 
life of neonatal erythrocytes is only 20 to 30 days compared with 55 days 
for erythrocytes from the adult (4). The activity of pyrimidine 5'-nucleotid­
ase in neonatal erythrocytes has not yet been determined. Comparative 
measurements of pyrimidine 5'-nucleotidase were therefore included in the 
present study, using UMP and orotidine monophosphate (OMP) as substrates. 
8.3. MATERIALS AND METHODS 
Venous blood samples were obtained from healthy adults, newborns (four to 
nine days old, born at term) and seven children with various diseases. 
Children I, II and III had megaloblastic anemia while child IV had auto­
immune hemolytic anemia. Patient V had congenital hemolytic anemia, baso­
philic stippling of red cells, enlarged spleen and reticulocytosis (reticulo­
cyte count ranged from 4 to 11%). These finding were suggestive of deficiency 
of pyrimidine 5'-nucleotidase (20). Patients VI and VII were deficient in 
hypoxanthine-guanine phosphonbosyltransferase (HGPRT, EC 2.4.2.8) and did 
not receive allopurinol medication. 
Erythrocytes were isolated by centrifugation, washed twice with 50 mmol/ 
1 Tris-HCl (pH 7.4) containing 100 mmol/1 NaCl and lysed by freezing and 
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thawini; twice. 
14 
OPRT and ODC were assayed by measuring CO released from [carboxyl-
14 14 
Cjorotic acid and [carboxyl- C] orotidine monophosphate, respectively. 
Details have been described elsewhere (15). 
Pyrimidine 5'-nucleotidase was assayed by incubating hemolysate (0.4 
14 
- 1.0 mg of protein), Tris-HCl (28 mmol/l, pH.7.4) and either UMP- С (2.2 14 
mmol/l, 1.1 mCi/mmol) or OMP- С (2.2 mmol/l, 0.5 mCi/mmol) in a final 
о 
volume of 45 μΐ for 90 m m at 37 C. Reaction was terminated by heating for 
о 5 min at 95 С. Carrier undine or orotidine was added and 10 Ul samples 
were analysed by thin-layer chromatography using polyethyleneimme-cellulose 
(14). Distilled water was used in the separation of uridine and UMP while 
0.2 mol/1 LiCl was suitable to separate orotidine from OMP. Compounds were 
localised under ultraviolet light and eluted with 1 ml of 0.1 mol/1 HCl 
/ 0.2 mol/1 KCl. Radioactivity was determined with 10 ml of Aquasol. 
Spectral analysis of erythrocytes was performed according to Valentine 
et al. (20). Protein was determined according to Lowry et al. (11). Enzyme 
activities are expressed as nmoles per hr per mg protein. Statistical anal­
ysis was performed using the paired one-tailed Student's t-test. 
8.4. RESULTS 
Activities of both OPRT and ODC were found to be higher in erythrocytes 
from neonates than in erythrocytes from adults (Table 8.1). The difference 
is highly significant (p < 0.001). The ratio of ODC to OPRT activity is 
similar in erythrocytes from both groups. At about 3 months of age enzyme 
activities are within the range for erythrocytes from adults (Table 8.1). 
OPRT and ODC activities were higher in erythrocytes from children with 
deficiency of HGPRT than in erythrocytes from controls. Increased enzyme 
activities were also measured in erythrocytes from anemic patients (I to V) 
with a large variation in reticulocyte counts (normal reticulocyte count at 
this age is below 2%). The increase of enzyme activities seems to correlate 
with the percentage of reticulocytes (Table 8.1). 
Spectral analysis at 240-300 nm of erythrocyte extracts from patient 
V revealed no abnormality in erythrocyte nucleotide pool. Maximal absorption 
was measured at 258 nm, as is observed with extracts of control erythrocytes. 
Measurement of pyrimidine 5'-nucleotidase in erythrocytes from patient 
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TABLE 8.1. 
ACTIVITIES OF OROTATE PHOSPHORIBOSYLTRANSFERASE AND OROTIDINE -5 -PHOSPHATE 
DECARBOXYLASE IN HUMAN HEMOLYSATE. 
Adults (n-26) 
Children 2-5 months (n-3) 
Newborns (n· •9) 
RetLculocytosis 
Patient 
Patient 
Patient 
Patient 
Patient 
I (2.1) 
11 (2.7) 
III (7.0) 
IV (12.4) 
V (3.B) 
HGPRT deficiency 
Patient 
Patient 
VI 
VII 
OPRT 
0.22 
0.14 
0.77 
0.49 
1 .40 
1 .70 
3.84 
0.59 
0.73 
1 .00 
+ 
+ 
+ 
0 
0 
0 
.08 
.05 
.32 
ODC 
0.52 + 0. 
0.36 + 0. 
1 .66 + 0, 
1 .01 
1 .32 
2.63 
5.25 
1.52 
2.17 
1.70 
,20 
,10 
28 
Enzyme activities + S.D in ninoles/hr per mg protein were determined as 
described in "Materials and Methods". The figures for erythrocytes from 
adults were taken from reference 15 Percentage of reticulocytes is given 
in parentheses for Che patients 1-V. 
V yielded enzyme activities of 10.54 and 15.45 nmoles/hr per mg protein 
with UMP and OMP as substrates, respectively. These values are higher than 
the values found in erythrocytes from healthy adults (Table 8.2). No differ­
ence was found in pyrimidine 5'-nucleotidase activity of erythrocytes from 
newborns and adults (Table 8.2). Measurements of enzyme activity were per­
formed without addition of Mg since this did not influence enzyme activ­
ity. Kinetic studies with respect to OMP as a substrate yielded a К value 
m 
of 0.52 +_ 0.15 mraol/1 (mean jf S.D. of 5 experiments). OMP appeared to be a 
better substrate for pyrimidine 5'-nucleotidase assay than UMP, since 
enzyme activity was about 50% higher. 
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TABLE 8 . 2 . 
ACTIVITY OF PYRIMIDINE -5'-NUCLFOTIDASE IK ERYTHROCYTES FROM NEUBOR.NS 
ΑΧΟ ADULTS. 
Substrace 
UMP OMP 
Adults (п-б) 5.9 *_ 2.4 θ.9 + 3.2 
Newborns (n-5) 6.2 + 2.8 10.4 • 3.5 
Enzyroe acCLVity *_ S.D. in nmoles/hr per rag protein was measured as 
described in "Materials and Methods". 
8.5. DISCUSSION 
The OPRT and ODC activities in the erythrocytes of newborn infants are sig­
nificantly higher than those of the adult and comparable to those of patients 
with reticulocytosis (Table 8.1) When human erythrocytes were separated 
according to cell age, OPRT and ODC activities were higher in young cells 
than in older ones (7). After induction of reticulocytosis in the rabbit by 
acetophenylhydrazine, OPRT and ODC activities decreased rapidly after ini­
tial high enzyme activities (10). The mean cell age of neonatal erythrocytes 
is younger than that of adult erythrocytes (4). These findings suggest that 
the increased activities of OPRT and ODC in erythrocytes of the newborn 
reflect a young population of cells. A similar association of young cell 
age and high enzyme activity in erythrocytes has previously been reported 
for several enzymes of glucose metabolism (9) and purine metabolism (3,6). 
The specific activity of adenine phosphoribosyltransferase was positively 
correlated with the reticulocyte percentage (6). 
Another factor which may contribute to the increased OPRT and ODC 
activities in neonatal erythrocytes is stabilization of the enzymes by 
PRPP, The concentration of PRPP is significantly higher in erythrocytes of 
neonates than in those of adults (3). OPRT and ODC in human hemolysate are 
89 
stabilized in vitro by PRPP (16). The increased activities of OPRT and ODC 
in erythrocytes from patients with deficiency of HGPRT (1, 16, Table 8.1) 
may be ascribed to stabilization by PRPP. PRPP concentration is increased 
in erythrocytes of these patients (5, 17). It has been argued that the in­
creased activity of OPRT and ODC in these erythrocytes is not due to 
stabilization by PRPP. The evidence against stabilization by PRPP was main­
ly based on thermal inactivation experiments (1). Since PRPP is very un­
stable at elevated temperatures especially in the presence of hemolysate 
and Mg -ions (17), such experiments do not seem appropiate to investigate 
stabilization by this compound. Stabilization of enzyme activity by PRPP 
has also been postulated to explain the increased activity of adenine 
phosphonbosyltransferase in erythrocytes from neonates and from patients 
with deficiency of HGPRT (3). 
Pyrimidine 5'-nucleotidase is usually assayed by measuring the release 
of inorganic phosphate from UMP, CMP or TMP (12, 20). A radiochemical assay 
has been described which was based on precipitation of CMP (18). We employ­
ed a simple chromatographic procedure to separate product from substrate. 
OMP proved to be the substrate that gave the highest enzyme activity, but 
the К value measured for OMP is higher than that observed for CMP and UMP 
m 
(12, 19). OMP can also be decarboxylated by ODC present in the hemolysate, 
but it can be calculated from the figures given in Tables 8.1 and 8.2 that 
the decrease of substrate concentration caused by ODC activity is negligible. 
No significant difference in pyrimidine 5'-nucleotidase activity (with 
either OMP or UMP as substrate) was observed between neonatal erythrocytes 
and erythrocytes from adults (Table 8.2). Since it was reported that this 
enzyme activity decreased with the age of the red cell (19) one might ex­
pect an increased enzyme activity in neonatal erythrocytes which have a 
young mean cell age. Apparently there is no rapid decrease of enzyme activ­
ity with increasing cell age. Consistent with this is the observation that 
pyrimidine 5'-nucleotidase in erythrocytes from patients with marked 
reticulocytosis is only two-fold increased when compared with normal erythro­
cytes (12, 20). We also measured a slight increase of the activity of this 
enzyme in patient V with reticulocytosis. 
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C H A P T E R 9 
INHIBITION OF OROTATE PHOSPHORIBOSYLTRANSFERASE AND OROTIDINE 5'-PHOSPHATE 
DECARBOXYLASE OF HUMAN ERYTHROCYTES BY PURINE AND PYRIMIDINE NUCLEOTIDES 
W.J.M.Tax and J.H.Veerkamp 
(Accepted for publication in Biochem.Pharmacol.) 
9.1. SUMMARY 
Orotidine 5'-phosphate decarboxylase of human hemolysates exhibits triphasic 
kinetics with К values of 33, 1.7 and 0.082 μΜ. Inhibition of this enzyme 
m 
at low OMP concentrations (< 3 μΜ) by several naturally occurring purine and 
pyrimidine nucleotides was investigated. No significant inhibition was ob­
served with IMP, GMP, TMP, ADP, ATP and TTP at 5 mM. Inhibition constants 
for CMP, AMP and dAMP were 31 μΜ, 0.11 mM and 0.21 mM, respectively. The 
results are discussed in relation to inhibition by nucleotides of orotate 
phosphoribosyltransferase, previously measured with a method which depends 
on orotidine 5'-phosphate decarboxylase activity. 
9.2. INTRODUCTION 
Orotate phosphoribosyltransferase (EC 2.4.2.10) and orotidine 5'-phosphate 
decarboxylase (EC 4.1.1,23) catalyze the conversion of orotic acid to UMP 
in de novo pyrimidine biosynthesis: 
2+ 
orotate + PRPP ^ — ^ 7 OMP + PP 
OMP > UMP + co 2 
0DC activity is inhibited by its product UMP (1-3) and by ribonucleotides of 
several purine and pyrimidine analogues, e.g. azauridine (4,5), allopurinol 
(3, 6-7) and oxipurinol (5-7). Conflicting evidence has been presented with 
respect to inhibition of 0DC by naturally occurring nucleotides (see Dis­
cussion). We demonstrated that 0PRT activity in human hemolysates is also 
inhibited by its product, OMP. The inhibition was competitive with respect 
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to PRPP (7). Furthermore, several purine and pyriraidine nucleotides appeared 
to be inhibitors of OPRT activity without affecting ODC activity (7). Traut 
and Jones (8) have criticized this latter conclusion. Since OPRT activity 
14 14 
was assayed by measuring the release of CO from [carboxyl- C]orotic acid, 
the assay was dependent on the ODC activity and inhibition of ODC activity 
would be mistakenly interpreted as inhibition of OPRT activity. Prior to 
testing the effects of nucleotides on OPRT activity their non-interference 
with the ODC reaction was ascertained at 0.1 mM OMP (7). During the OPRT 
assay OMP concentration is, however, much lower and inhibition of ODC by 
nucleotides might be significant (8). We therefore decided to investigate 
in detail the inhibition of ODC activity in human hemolysates by purine and 
pyrimidine nucleotides at low concentrations of OMP (< 3 μΜ). Special atten­
tion was given to the possibility that derivatives of adenosine (AMP, ADP, 
ATP, dAMP) inhibit the conversion of orotic acid to UMP. Inhibition of OPRT 
(9) or ODC (8) by AMP has been suggested as the mechanism responsible for 
inhibition of cell growth by adenosine. Deficiencies of enzymes of adenosine 
catabolism (adenosine deaminase deficiency (10) and purine nucleoside Phos­
phorylase deficiency (11)) are associated with immunodeficiencies. 
9.3. MATERIALS AND METHODS 
The procedures for measuring the activities of OPRT and ODC in human hemo-
14 lysates using [carboxyl- C]labeled substrates were described before (7). 
Freshly prepared hemolysates were used for all experiments. ODC was assayed 
14 
at 0.2 - 3 УМ substrate concentration with [carboxyl- C]orotidine 5'-
monophosphate of high specific activity (37 mCi/mmol). All inhibitors tested 
were present at a final concentration of 5 mM except for CMP which was 
present at 2.5 mM. Care was taken to maintain the pH at 7.4 when nucleotides 
14 
were present. Radioactivity in samples of [carboxyl- C]orotic acid and 
14 [carboxyl- C]orotidine 5'-monophosphate was measured in the presence of 
14 
0.2 ml of hydroxide of Hyamine (Packard) to trap any CO released into 
the scintillation fluid. 
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9 . 4 . RESULTS 
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Fig. 9.1. Inhibition of ODC in human hemolysate by C^íP. Control (Φ), 
2.5 χ 10~ZM CW (o). 
At OMP concentrations below 3 μΜ а К value of 0.082 + 0.024 μΜ (mean + 
m — — 
S.D., 8 determinations) was found. All compounds previously reported as 
inhibitors of OPRT in hemolysates (7), and in addition dAMP, were tested 
for inhibition of ODC at 2 μΜ 0MP(Table 9.1).Only CMP, AMP and dAMP caused 
a significant inhibition, which was competitive with respect to OMP. Fig.l 
illustrates the inhibition by CMP. The К value for CMP was lower than for 
ι 
AMP or dAMP(Table 9.1).PRPP at 1 mM did not affect the activity of ODC or 
the inhibition of ODC by CMP, AMP and dAMP. 
At a high concentration of PRPP (0.8 mM) OPRT activity was inhibited 
by TTP but not by AMP, ADP, IMP or TMP and only slightly (< 15%) by ATP or 
GMP. At a non-saturating concentration of PRPP (0.2 mM) AMP, ADP, ATP, IMP, 
GMP, TMP and TTP inhibited OPRT activity as earlier reported (7). The 
14 14 
amount of CO measured in the assay of OPRT activity with [ C-carboxyl]-
orotic acid could not be increased under these inhibitory conditions by a 
prolongation of the second incubation period after injection of EDTA. Since 
2+ EDTA injection only stops the OPRT reaction by complexing the Mg ions, 95 
TABLE 9 . 1 
INHIBITION OF ERTHROCVTE OROTIDINE-S'-PHOSPHATE DECARBOXVLASE AT 
LOU CONCENTRATION OF OMP 
Competitive I n h i b i t o r к^ value 
CMP 3 1 t 4 uM 
AMP 0 11 ι 0.03 m4 
dAMP 0 21 ι 0 04 ілМ 
The OMP concentration ranged from 0 2 - 3 μΜ The It value f o r OMP 
was 0 082 » 0 024 uM (mean ι S 0 of 8 determinations) К values 
are the mean ± S D of 3-6 determinations The f o l l o w i n g compounds 
were not I n h i b i t o r y when t e s t e d a t a f i n a l concentration of 5 ι * and 
an OMP concentration of 2 wM GMP, IMP, TMP, AOP, ATP, TTP 
but does not affect ODC activity, a prolongation of this second incubation 
period would relieve inhibition of ODC activity, which could decrease 
14 
CO production. This was not the case, which indicates that the inhi­
bition is on the level of OPRT, not on that of ODC. 
9.5. DISCUSSION 
Previously we found bimodal kinetics for the ODC enzyme in human hemolysates 
with К values of 33 and 1.7 μΜ (7). At low concentrations of OMP (< 3 μΜ) 
m 
we now found a third К value of 0.082 PM. Brown et al. (12) demonstrated 
m 
that purified ODC from human erythrocytes exists in three forms, corres­
ponding to monomer, dimer and tetramer, with К values of 25, 3 and 0.6 VM, 
respectively. It appears therefore that the К values of 33, 1.7 and 0.082 
UM measured in crude hemolysates correspond to monomer, dimer and tetramer 
forms of the enzyme. The difference in К values between purified enzyme 
m 
and crude hemolysate may be related to the purification procedure. The 
enzyme from human liver was also found to exist in monomer, dimer and tetra­
mer forms (13). The kinetic properties of the individual forms appeared 
identical, possibly as a result of interconversion during the assay. The K^ 
96 
value was 0.12 мМ (13). Fyfe et al. (6) found blphaslc kinetics for the ODC 
enzyme from rat liver with К values of 4 and 1 UM. Two К values (4.5 and 
m m 
0.33 MM) were also reported for the ODC enzyme from human fibroblasts (14). 
Inhibition of ODC activity by CMP was also observed for the enzyme 
from cow brain (2) and human liver (13) with K. values of 0.14 mM and 40 UM, 
respectively. AMP and GMP were also effective inhibitors of cow brain ODC 
when present at 5 mM (2). ODC from human hemolysate was not inhibited by 
IMP or GMP and only slightly by AMP at 5 UM OMP (3). The tetramer form of 
ODC, purified from human hemolysate by Brown and 0'Sullivan (5) was inhib­
ited for less than 10 per cent by 5 μΜ AMP, ADP, ATP, GMP, TMP or CMP at 
0.5 μΜ OMP. The results of inhibition studies on the OPRT/ODC enzyme com­
plex from Ehrlich ascites cells (8) seem to be completely opposite to our 
data. AMP, ADP, IMP, TMP and TTP were found to have little effect on the 
0PRT activity while being inhibitors of the ODC activity. The conditions 
used in these experiments, however, were markedly different from the ones 
we applied. ODC activity was measured at 0.1 μΜ OMP which is much lower 
than the К value (0.8 μΜ) of the enzyme preparation used (15) while 0PRT 
ш 
activity was assayed at a saturating concentration of PRPP. Inhibition of 
0PRT from human hemolysate is, however, competitive with PRPP for all in­
hibitors except TTP as was stated before (7) and confirmed in the present 
investigation. Inhibition of ODC activity cannot be the cause of the mea-
14 14 
sured decrease in CO production from [carboxyl- C]orotic acid in the 
presence of purine and pyrimidine nucleotides, as suggested by Traut and 
Jones (8). 
The К values with respect to ODC activity, measured for the naturally 
occurring nucleotides CMP, AMP and dAMP are high both in comparison to their 
physiological concentration and in comparison to the К value for OMP. Thus, 
the inhibition of ODC by these nucleotides does not seem to be of physiol­
ogical significance. The intracellular concentration of PRPP is well below 
the К value of 0PRT for this compound (16). Inhibition of OPRT which is 
m 
competitive with respect to PRPP may be important for the in vivo regulation 
of pyrimidine biosynthesis and deserves further investigation. 
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C H A P T E R 10 
ACTIVITY OF ADENOSINE DEAMINASE AND PURINE NUCLEOSIDE PHOSPHORYLASE IN 
ERYTHROCYTES AND LYMPHOCYTES OF MAN, HORSE AND CATTLE 
W.J.M.Tax and J.H.Veerkamp 
(Accepted for publication m Comp. Blechern. Phys.) 
10.1. SUMMARY 
1. Activities of ADA and PNP were measured in erythrocytes and lymphocytes 
of man, horse and cattle. 
2. In bovine heraolysates both enzyme activities are low when compared with 
activities in human heraolysates. In horse hemolysates both enzyme activ-
ities are virtually absent. 
3. Enzyme activities are consistently lower (about 50%) in intact lympho-
cytes than in sonicated lymphocytes. This finding suggests that the 
uptake of nucleosides is rate-limiting for both enzymes in intact lympho-
cytes . 
4. The activity of ADA in horse lymphocytes is comparable to that in lympho-
cytes of patients with severe combined immunodeficiency associated with 
ADA deficiency. 
10.2. INTRODUCTION 
Deficiency of adenosine deaminase (ADA) or purine nucleoside Phosphorylase 
(PNP) in man is associated with defects of cell-mediated immunity (Giblett 
et al., 1972, Giblett et al., 1975; Parkman et al., 1975). In horse and 
cattle erythrocytes ADA activity is virtually absent (McGuire et al., 1976; 
Van Belle, 1969). A low activity of PNP was reported for bovine erythrocytes 
(Duhm, 1974). When ADA and PNP activities in lymphocytes from horse and 
cattle would also be low, these cells might provide a suitable system for 
studying the metabolic disturbances caused by deficiency of ADA or PNP. 
Previously we reported large differences in activities of several other 
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enzymes of purine and pyrimidine metabolism between erythrocytes of ten 
mammalian species (Tax et al., 1976; Tax and Veerkamp, 1978). Now we found 
large variations in ADA and PNP activity of erythrocytes and lymphocytes 
between man, horse and cattle. 
10.3 MATERIALS AND METHODS 
Enzyme preparations 
Hepannized blood samples were obtained from adult human volunteers, from 
horses (healthy adults) and from cattle (local slaughterhouse). Erythro-
cytes were isolated by centrifugation, washed twice with Tris-buffered 
saline (pH 7.4) and lysed by adding 3 vol 10 mM Tris (pH 7.4). Lymphocytes 
were isolated from peripheral blood using Ficoll-Isopaque according to 
Böyum (1968). Cells were counted with a hemocytometer and lysed by soni-
cation (Branson sonifier, 8 periods of 5 sec at maximal output). Intact or 
sonified lymphocytes as indicated were used for all enzyme assays immedi-
ately upon preparation. Freshly prepared hemolysates were used for assays 
of ADA. 
Enzyme assays 
о 
All enzymes were assayed at 37 С by radiochemical methods. Enzyme activ-
6 
ities are expressed as nmol/h per 10 lymphocytes or for erythrocytes as 
rmol/h per mg protein. Protein was measured according to Lowry et al. (1951). 
Isotonic conditions were maintained during incubations with intact lympho­
cytes. 
Adenosine deaminase assay 
The reaction mixture (60 μΐ) of lymphocytes contained 40 mM phosphate buffer 
14 (pH 7.4), 110 mM NaCl, 0.16 mM [8- Cjadenosine (49 mCi/mmol) and the 
g 
equivalent of 0.025-0.25 χ 10 cells. Hemolysates were assayed by incubating 
hemolysate protein (60-3000 Ug) with 50 mM Tris-HCl buffer (pH 7.4), 1 mM 
14 
EDTA and 0.16 mM [8- C]adenosine in a final volume of 60 μΐ. After 30 min 
reaction was terminated by boiling for 2 min and addition of excess carrier 
adenosine, inosine and hypoxanthine. Separation was achieved by high volt­
age paper electrophoresis with 40 mM sodium borate (pH 8.65) containing 
100 
1 mM EDTA (1 h at 70 V/cm). Spots were localized under ultraviolet light 
and eluted with 5 ml of 0.1 M NaOH. Radioactivity was determined in 10 ml 
of Aquasol (New England Nuclear, Dreieichenhain, W.Germany). 
Purine nucleoside Phosphorylase assay 
Assay conditions in lymphocytes were the same as for ADA except that 0.35 
14 
mM [8- C]inosine (9 mCi/nmol) replaced adenosine and total volume was 50 
μΐ. Incubation mixture for measuring purine nucleoside Phosphorylase in 
hemolysates contained 30 mM Tris-HCl (pH 7.4), 1 mM EDTA, 100 mM phosphate 
14 (pH 7.4) and 0.35 mM [8- C]inosine in a volume of 50 μΐ. Incubations were 
terminated after 10 rain by boiling for 2 min and addition of carrier inosine 
and hypoxanthine. Substrate and product were separated by thin-layer chro­
matography on polyethyleneimine-cellulose using distilled water as developer 
and eluted with 1 ml 0.1 M HCl/0.2 M KCl. Radioactivity was determined after 
addition of 10 ml of Aquasol. 
Intact lymphocytes were preincubated in the phosphate-containing medium for 
15 min before addition of inosine. 
Animals 
The following species were used: Man - Чото sapiens. Horse - Equus oaballus, 
Cattle - Bos taurus. 
10.4. RESULTS 
With all enzyme assays, product formation was linear with time and protein 
concentration. In ADA assays, both inosine and hypoxanthine were formed due 
to the presence of PNP activity. No AMP was formed from adenosine by lymph­
ocytes, and the addition of EDTA prevented the production of AMP in hemo­
lysates. Hypoxanthine was the only product formed from inosine in PNP assays. 
ADA activity in cattle hemolysate was low when compared with the activ­
ity in human hemolysate and was below detection limit in horse hemolysate 
(Table 10.1). Cattle hemolysate also showed a low PNP activity. PNP activ­
ity was still lower in hemolysate of horse. Species differences in PNP 
activity were much smaller m lymphocytes (Table 10.2). PNP and ADA activ­
ities were consistently lower (about 50%) in intact lymphocytes than in 
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TABLE 10.1 
ADA AND PNP ACTIVITIES IN HEMOLYSATES OF MAN, CATTLE AND HORSE. 
Species ADA PNP 
Man 
Cattle 
Horse 
Enzyme activities in nmol/h per mg protein. Values are the means 
± S.D. of 3-5 determinations. 
59 + 18 
0.7 ì 0.7 
< 0.2 
1249 + 222 
39 ± 17 
1.0 ± 0.5 
TABLE 10.2 
ADA AND PNP ACTIVITIES IN LYMPHOCYTES OF MAN, CATTLE AND HORSE. 
Species ADA PNP 
Intact cells Lysate Intact cells Lysate 
Man 44 ί 15 102 ± 30 177 ± 4Θ 385 ± 154 
Cattle 21 ± 7 50 ± 18 48 ± 18 96 ± 12 
Horse 4 ± 2 7 ± 2 42 ± 3 74 ±22 
Enzyme activities in nmol/h per 10 cells. 
Values are the means ± S.D. of 4 determinations. 
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sonicated lymphocytes. ADA activity in horse lymphocytes was only a few 
percent of the value found in human lymphocytes, while cattle lymphocytes 
had an intermediate value. 
10.5 DISCUSSION 
Activities of ADA and PNP in human hemolysate (Table 10.1) are comparable 
to those reported by other investigators (Cartier and Hamet, 1976, Parkman 
et al., 1975, Scholar and Calabresi, 1973, Snyder et al., 1976). The low 
value of PNP activity in horse hemolysate has not been reported before. 
Castles et al. (1977) reported rather high values of both PNP and ADA 
activities in horse hemolysate. No significant ADA activity could be detect-
ed in horse hemolysate by McGuire et al. (1976). These authors also measured 
ADA activity in lymphocytes from normal horses and horses with combined 
immunodeficiency. In both groups ADA activity was similar to our values. 
They did not, however, compare ADA activity in horse lymphocytes with that 
in other mammalian lymphocytes. ADA activity in lysed human lymphocytes 
(Table 10.2) is similar to values measured by others in total lysate from 
lymphocytes (Cartier and Hamet, 1976) or in 20,000 g supernatant of sonic 
extracts (Snyder et al., 1976). However, PNP activity in totallysate (Table 
10.2) seems to be much higher than the values reported for 20,000 g super-
natants (Scholar and Calabresi, 1973, Snyder et al., 1976). This finding 
suggests that part of the lymphocyte PNP activity is membrane-associated, 
as is proposed for fibroblasts (Cohen and Martin, 1977). Both ADA and PNP 
activities are lower in intact lymphocytes than in sonicated lymphocytes 
(Table 10.2) probably because the uptake of nucleosides is rate-limiting 
(Snyder et al., 1976). 
Deficiency of ADA in man is associated with immunodeficiency. A low 
ADA activity was found in lymphocytes of both normal horses and foals 
with combined immunodeficiency (McGuire, 1976). ADA activity is apparently 
not necessary for normal lymphocyte function in horses. Comparison of 
lymphocyte metabolism in man and horse may provide valuable information 
about the role of ADA in lymphocytes. 
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C H A P T E R 11 
URIDINE METABOLISM IN LYMPHOCYTES AND ERYTHROCYTES OF MAN, HORSE AND CATTLE 
11.1. SUMMARY 
1. No conversion of uridine to uracil or uridine nucleotides was found in 
intact erythrocytes and in hemolysates of man, horse and monkey. 
2. Uridine Phosphorylase activity was high in lymphocyte extracts of man 
and cattle, but low in those of horse. Conversion of uridine to uracil 
was also found with intact lymphocytes from man but not with those from 
horse. 
3. Both uridine kinase activity and incorporation of uridine into nucleo-
tides and RNA were of the same order of magnitude when human lymphocytes 
were compared with those of horse. 
4. Rates of phosphorylation and phosphorolysis of uridine in intact lympho-
cytes were only a few percent of the corresponding enzyme activities 
measured in lymphocyte extracts. 
5. The results are discussed in relation to adenosine-induced pyrimidine 
starvation and the phenomenon that horses have a normal imraunoresponse 
despite a low activity of adenosine deaminase in their lymphocytes. 
11.2. INTRODUCTION 
Pyrimidine nucleotides can be formed by de novo biosynthesis or by re-
utilization of nucleosides, the salvage pathway. The relative contribution 
of both pathways to the total production of pyrimidine mucleotides is dif-
ferent in various types of cells. Uridine kinase (EC 2.7.1.48) plays a key 
role in the salvage pathway. The enzyme phosphorylates uridine and cytidine 
as well as a number of pyrimidine nucleoside analogues (1). Drug resistance 
may be associated with deficiency of uridine kinase (2). The enzyme is 
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induced in lymphocytes stimulated by phytohemagglutinm (3). Undine can 
also be catabolized to uracil by uridine Phosphorylase (EC 2.4.2.3). 
Catabolism of uridine may be significant as evidenced by the rapid con-
version to uracil in the blood of rat (4), mouse (5) and dog (6). 
In a previous investigation (7) we found that the activity of adenosine 
deaminase (ADA, EC 3.5.4.4) in horse lymphocytes is comparable to that in 
lymphocytes of patients with severe combined immunodeficiency associated 
with ADA deficiency (8). The mechanism by which the enzyme deficiency leads 
to immunodeficiency is still unknown, but there is ample evidence for inter-
ference of pyrimidine synthesis de novo (9-11) . When ADA deficiency leads 
to interference of pyrimidine synthesis de novo, such an interference could 
be bypassed in horse lymphocytes when pyrimidine nucleotides are formed 
preferentially by the salvage pathway. Horse lymphocytes have a low activ-
ity of orotidine 5'-phosphate decarboxylase (ODC, EC 4.1.1.23), the final 
enzyme of the de novo pathway (12). We now studied the metabolism of uridine 
in lymphocyte extracts of man, horse and cattle as well as in intact lympho-
cytes of man and horse. 
Horse and human erythrocytes were also investigated with respect to 
their uridine metabolism since we found previously (13) marked differences 
between both species in the activities of orotate phosphoribosyltransferase 
(OPRT, EC 2.4.2.10) and ODC. 
11.3. MATERIALS AND METHODS 
Materials 
Ficoll (MW 400,000) was obtained from Pharmacia and Isopaque from Nyegaard 
& Co., Oslo, Norway. A Ficoll-Isopaque solution was prepared by dissolving 
9.56 g Ficoll in 130 ml distilled water and adding 20 ml Isopaque; dis-
tilled water was added until a final specific gravity of 1.077 was obtained. 
Minimum essential medium for suspension cultures (MEMS), human serum and 
14 
horse serum were obtained from Flow Lab. [2- C]uridine was purchased from 
the Radiochemical Centre, Amersham and hydroxide of Hyamine 10-X from 
Packard. Thin-layer plates containing polyethyleneimine-cellulose (PEI-
cellulose) were obtained from Merck. Omnifluor was purchased from New Eng-
land Nuclear Corp. 
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Preparation of cell suspensions and cell extracts 
Blood samples from human adults, healthy adult horses and cattle were col­
lected in heparinized tubes. Erythrocytes were isolated by centrifugation, 
washed twice with 50 mM Tris/HCl (pH 7.4) containing 100 mM NaCl, and 
resuspended in a solution containing 40 mM potassium phosphate (pH 7.4), 
110 mM NaCl, 5.5 mM glucose and 1 mM MgCl . Lymphocytes were isolated at 
room temperature by Ficoll-Isopaque gradient centrifugation of diluted blood 
(14) and counted in a hemocytometer. For experiments with intact lymphocytes 
cells were suspended in a mixture of 10% homologous serum and 90% MEMS con­
taining 2 mM glutamin and penicillin (100 U/ml) and streptomycin (100 \ig/ 
ml). 
Hemolysates were prepared by freezing and thawing the erythrocytes 
twice. Extracts of lymphocytes were obtained by sonication (Branson sonifier, 
8 bursts of 5 sec at maximal output) in 50 mM Tris-HCl (pH 7.4) containing 
1 mM EDTA and centrifugation at 7,000 g (15 min, 4 С). 
Enzyme assays 
Uridine kinase and uridine Phosphorylase activities in hemolysates and 
о lymphocyte extracts were assayed at 37 С by radiochemical methods. Enzyme 
6 
activities are expressed in nmol/hr per 10 cells.Linearity of the reactions 
with respect to time and amount of cell extract was ascertained. The in­
cubation mixture (70μ1) for uridine kinase assay contained 40 mM Tris-HCl 
(pH 7.4), 1 mM EDTA, 10 mM MgCl , 5 mM ATP and 70 VJM [2-14C]uridine (55 
mCi/ramol). Reaction was terminated after 60 min by heating the incubation 
о 
mixture at 95 С for 5 min (Eppendorf heater). After centrifugation and 
addition of carriers, uracil and uridine nucleotides were separated from 
uridine by thin-layer chromatography (TLC) on PEI-cellulose (15). Assay 
conditions for uridine Phosphorylase were the same as for uridine kinase 
except that 40 mM orthophosphate (pH 7.4) was added. 
Metabolism of uridine by intact cells 
6 
Suspensions of erythrocytes (25%, by vol) or lymphocytes (30 χ 10 cells/ml) 
о 14 
were preincubated for 30 min at 37 С with gentle shaking. [2- C]uridine 
was then added to a final concentration of 70 μΜ. After appropriate times 
(up to 3 hr) 50 lil samples were taken and mixed with 10 μΐ 10 mM uridine/ 
10 mM uracil. Cells were separated from the medium by centrifugation at 
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3,500 g (5 min 4 С, Burkard Koolspin centrifuge) and the cells were washed 
with 50 Ul saline. Medium and wash fluid were combined, deproteinized, and 
analyzed by means of TLC on PEI-cellulose . Cells were extracted with 50 μΐ 
0.5 N HC10. and acid-insoluble material was washed once with 50 μΐ 0.5 N 
4 
HC10 . Centrifugation was at 9,500 g (5 min, 4 С). Extract together with 
4 
the wash fluid was neutralized with 5 N К0Н and after centrifugation of 
KC10 samples were analyzed on TLC sheets coated with PEI-cellulose. 0.2 ml 
of 1 N hydroxide of Hyamine was added to the acid-insoluble cell material 
and left overnight at room temperature. Radioactivity was then counted with 
10 ml of toluene containing 4 g of omnifluor per liter. 
11.4. RESULTS 
14 
After incubation of erythrocytes of man, horse or Rhesus monkey with [2- C]· 
uridine, no significant radioactivity was found in either uracil or uridine 
nucleotides. Virtually all radioactivity was recovered in uridine. Hemo-
lysates from these three species also showed no conversion of uridine. 
Uridine kinase activity is similar in lymphocyte extracts of man, 
cattle and horse (Table 11.1). Uridine Phosphorylase activity is higher than 
TABLE 11.1. 
ACTIVITIES OF URIDINE KINASE AND URIDINE PHOSPHORYLASE IN 
LYMPHOCYTE EXTRACTS OF MAN, CATTLE AND HORSE 
Species Uridine kinase Uridine Phosphorylase 
Man 0.51 i 0.15 (6) 2.13 ± 0.32 (4) 
Cattle 0.48 t 0.35 (8) 1.90 t 0.91 (4) 
Horse 0.57 ± 0.15 (6) 0.33 ι 0.19 (4) 
Enzyme activities are given in nmol/hr per 10 cells as 
the means i S.D Numbers in parentheses refer to the 
number of individuals. Extracts from lymphocytes were 
prepared as described in Materials and Methods. 
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TABLE 1 1 . 2 . 
URIDINE METABOLISM IN INTACT LYMPHOCYTES OF MAN AND HORSE 
Species Phosphorylat ion Phosphorolysis 
N u c l e o t i d e s RNA Uracil 
Man 1860 t 199 ( 4 ) 974 t 172 ( 4 ) 7661 ι 1539 ( 3 ) 
Horse 1970 ι 462 ( 4 ) 1123 ι 63 ( 4 ) < 1000 ( 4 ) 
Intact lymphocytes were incubated with 70 uM [2- C] undine 
(55 mCi/HiTOl) for periods up to 3 hr. Radioactivity in cells 
and medium was analyzed as described 1n Materials and Methods. 
The conversion of undine to nucleotides or uracil and the 
incorporation Into RNA are given 1n dpm/hr per 10 cells. Values 
are the means ι S.D. of 3-4 experiments 1n quadruplicate. 
uridine kinase activity In lymphocyte extracts from man and cattle, but 
lower In lymphocyte extracts from horse. 
When Intact lymphocytes from man and horse were Incubated with uridine, 
product formation was linear with time for at least 2 hr. No conversion of 
uridine could be detected after incubation with a mixture of 90% MEMS and 
10% human serum or horse serum. A significant amount of uracil was found 
in the medium after incubation of human lymphocytes with uridine but not 
after incubation of horse lymphocytes. Both with human and horse lymphocytes 
most of the intracellular acid-soluble radioactivity was associated with 
uridine nucleotides. Radioactivity was also present in the acid-insoluble 
material which is assumed to contain the cellular RNA. Table 11.2 shows that 
both the conversion of uridine to uridine nucleotides and its incorporation 
into RNA are of the same order of magnitude in human and horse lymphocytes. 
The amount of uridine which is metabolized by intact lymphocytes (Table 11.2) 
6 
can be calculated in nmol/hr per 10 cells from the specific activity of 
uridine (122,000 dpm/nmol) when the original intracellular uridine pool is 
6 
neglected. Both the rate of phosphorylation (about 24 pmol/hr per 10 cells) 
6 
and of phosphorolysis (about 62 pmol/hr per 10 cells in human lymphocytes 
and < 8 pmol/hr per 10 horse lymphocytes) are only a few percent of the 
enzymatic activities measured in lymphocyte extracts. 
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11.5. DISCUSSION 
Human erythrocytes apparently do not phosphorylate (or cleave) uridine, as 
was also reported by others (16). The presence of uridine kinase in ery-
throcytes from Rhesus monkey has been reported (17) but we could not con-
firm this report. Horse erythrocytes also lack uridine kinase which is 
remarkable since two enzymes of the de novo pathway, OPHT and ODC, are also 
absent in horse erythrocytes (13). Therefore UMP can also not be synthesized 
from exogenous orotic acid in horse erythrocytes and must be either con-
served during the life span of the erythrocytes or supplied by some unknown 
alternative pathway. 
The much slower rate of metabolism of uridine in intact lymphocytes in 
comparison to that in lymphocyte extracts may be related to cell permeabil-
ity, to availability of other substrates or to cellular regulation systems. 
The low intracellular concentration of orthophosphate may limit the activ-
ity of uridine Phosphorylase. The activity of intracellular uridine kinase 
2+ 
may be restricted by the concentration of ATP and Mg . A more important 
factor is probably the uridine uptake through the cell membrane of the 
lymphocyte (18). The activity of uridine kinase is subject to inhibition 
by pyrimidine nucleotides in cell extracts (1), but there is no evidence 
for this feedback control in intact cells. 
The activity of undine kinase found in human and bovine lymphocytes 
7 
is comparable to values reported (18-20). (The extract of 10 human lympho-
cytes was equivalent to about 1 mg of protein). 
The presence of uracil in the medium after incubation of intact human 
lymphocytes with uridine does not necessarily implicate that phosphorolysis 
takes place at the cell membrane, though a membrane-associated uridine 
Phosphorylase has been demonstrated in mouse fibroblasts (21) and rat liver 
(22). Usually only the radioactivity present m the cells is analyzed and 
the medium is discarded (18,23). 
In horse lymphocytes the rate of catabolism of uridine is less than in 
lymphocytes of man and cattle and lower than the rate of phosphorylation (Ta-
bles 11.1,11.2).Furthermore, the activity of ODC is markedly lower than in 
lymphocytes from man and cattle (12). Horse lymphocytes apparently have a 
preference for the utilization of uridine to synthesize pyrimidine nucleo-
tides. This may contribute to the fact that horses have a normal iramuno-
response despite a low ADA activity in their lymphocytes (7). In this respect 
110 
it should be mentioned that uridine can reverse adenosine toxicity in fibro­
blasts (9) and lymphoma cells (10,11), but not in cells which are deficient 
in uridine kinase (24). Myoblast cells having a decreased activity of uridine 
kinase were more sensitive to the growth inhibitory effects of adenosine 
than the parental line (25). 
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C H A P T E R 12 
SURVEY AND SUMMARY 
12.1. THE SIGNIFICANCE OF PHOSPHORIBOSYLPYROPHOSPHATE 
Phosphoribosylpyrophosphate plays a key role in pyrimidine and purine metab-
olism and their interrelationship. It is a substrate as well as an allos-
teric activator of both pyrimidine and purine synthesis de novo, and is also 
a substrate of the salvage pathway for the synthesis of purine nucleotides 
(see 1.3). PRPP is also involved in the conversion of allopurinol and oxi-
purinol to their ribonucleotide derivatives (see 1.4). The ribonucleotides 
of allopurinol and oxipunnol are the effectors of the allopurinol 
effects on pyrimidine metabolism (see below, 12.2). The synthesis of PRPP 
may be related to the catabolism of adenosine and inosine through the inter-
mediates ribose 1-phosphate and ribose 5-phosphate (Fig. 1.8). The inhibi-
tion of pyrimidine biosynthesis de novo secondary to deficiency of ADA or 
PNP is probably associated with a decrease of PRPP concentration (see 1.5). 
The first part of this thesis (chapter 2-5) is therefore devoted to a 
study of the concentration and metabolism of PRPP in mammalian erythrocytes. 
Special attention is given to the effects of inherited enzyme deficiencies. 
In chapter 2 we report on the activities of phosphoribosyltransferases 
(OPRT, APRT and HGPRT) in hemolysates of ten mammalian species. These en-
zymes are responsible for the utilization of PRPP in erythrocytes. Both 
HGPRT and OPRT activities were virtually absent in horse hemolysates. The 
deficiency of HGPRT was confirmed in studies with intact horse erythrocytes. 
In chapter 3 a simple and sensitive assay is described for estimating 
the concentration and rate of synthesis of PRPP. The procedure is based on 
14 14 
the release of CO from [carboxyl- C]orotic acid in the presence of a 
preparation of OPRT and ODC. In this way the total product of the PRPP-
dependent reaction can be measured, in contrast to procedures involving thin-
layer chromatography or electrophoresis of small samples from the assay mix-
ture. Using this assay an increased PRPP concentration was measured in ery-
throcytes from patients with partial or complete deficiency of HGPRT. The 
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increased PRPP concentration appears to result from a decreased utilization 
of PRPP, since the activity of PRPP synthetase was normal. A patient with a 
deficiency of PNP also had an increased erythrocyte PRPP concentration which 
may also be ascribed to a decreased utilization of PRPP since this enzyme 
deficiency blocks the formation of hypoxanthine, the substrate of HGPRT. 
PRPP synthetase activity was found to be normal in erythrocytes from all 
subjects studied. 
In chapter 4 the occurrence of inherited abnormalities of PRPP metab-
olism in hyperuricemia and gout was investigated. An increased availability 
of PRPP may cause an accelerated rate of purine biosynthesis de novo and 
overproduction of uric acid, as discussed in 1.3. This investigation in-
cluded measurements of PRPP synthetase activity at suboptimal concentra-
tions of the substrates ATP and ribose 5-phosphate in order to detect ab-
normalities in substrate affinity. No such kinetic variants were detected 
in erythrocytes of 12 adults with primary gout and of 50 adolescents with a 
high concentration of urate in serum. The concentration of PRPP in erythro-
cytes was normal in all subjects studied. No striking increases of PRPP 
synthetase activity were found in the erythrocytes of any subject, but the 
group of adolescents with a high serum urate concentration had a signifi-
cantly higher activity of PRPP synthetase than the control group. This find-
ing may be relevant to the pathogenesis of gout since the late onset of this 
disease may be due to a slow accumulation of uric acid. It seems worthwhile 
to investigate PRPP metabolism in other cell types from hyperuricemic and 
gouty patients. Lymphocytes or cultured fibroblasts seem to be more appro-
priate than the anucleate erythrocyte which lacks the de novo pathway for 
purine synthesis. 
In chapter 5 the concentration of PRPP in hemolysates of ten mammalian 
species is compared with the capacities of the enzymes responsible for the 
synthesis and utilization of this compound. Actual enzyme activities in vivo 
are modulated by the availability of substrates and the concentration of 
regulatory compounds, and will usually be much lower than maximal capacities. 
Some correlations, however, between enzyme activities and PRPP concentration 
seem to hold. Low activities of HGPRT were consistently associated with 
high concentrations of PRPP, e.g. in erythrocytes of patients with a de-
ficiency of HGPRT (chapter 3) and in horse erythrocytes (chapter 5). In 
cattle erythrocytes there was a high activity of HGPRT together with a high 
concentration of PRPP. The activity of PNP, however, was extremely low in 
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these erythrocytes and therefore the formation of the HGPRT substrate hypo-
xanthine was absent. The high concentration of PRPP in cattle erythrocytes 
therefore appears to result from a decreased utilization (cf. deficiency of 
PNP in man, chapter 3). In chapter 5 we also report on an alternative route 
for the catabolism of PRPP. The enzymatic degradation of PRPP observed in 
mammalian hemolysate seems to be associated with acid phosphatase activity. 
The activity of acid phosphatase was measured in hemolysates of ten mam-
malian species using p-nitrophenylphosphate as substrate. The activity of 
the enzyme appeared to correlate with the rate of enzymatic degradation of 
PRPP. 
12.2. ALLOPURINOL AND THE METABOLISM OF OROTIC ACID 
The enzyme complex formed by the two terminal enzymes of pyrimidine bio-
synthesis de novo, OPRT and ODC, catalyzes the conversion of orotic acid 
via OMP to UMP. The first enzyme of pyrimidine biosynthesis, carbamoylphos-
phate synthetase II, is usually regarded as the rate-limiting enzyme, but 
under certain conditions and m some cell types the conversion of orotic 
acid to OMP may be the limiting step of the de novo pathway (see 1.3). 
Deficiency of ADA or PNP may limit the availability of PRPP and in this way 
inhibit the further metabolism of orotic acid (see 1.5). The effects of 
allopurinol on OPRT and ODC will be discussed in detail below. 
OPRT and ODC activities were measured in hemolysates of ten mammalian 
14 
species (chapter 2). The enzyme assays are based on the release of CO 
14 14 
from [carboxyl- Cjorotic acid or [carboxyl- C]orotidine 5'-monophosphate, 
respectively. The activities of both enzymes appeared to be very low in 
sheep hemolysates and below detection limit in horse hemolysates. OPRT and 
ODC showed a coordinate relationship in mammalian hemolysates, ODC activity 
being about twice as high as OPRT activity. Only pig and rabbit hemolysates 
showed a deviating ODC/OPRT ratio. 
Sensitive and specific methods are needed in order to study the effects 
of allopurinol on the urinary excretion of orotic acid and orotidine. In 
chapter 6 an isotope dilution assay for orotic acid is described, which is 
14 based on the competition with a known amount of [carboxyl- C]orotic acid 
for reaction with a limiting amount of PRPP in the presence of purified 
14 OPRT and ODC. The dilution of the specific radioactivity of the CO re-
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leased is a measure of the amount of orotic acid present in the sample. 
Orotidine can be determined after hydrolytic cleavage to orotic acid. The 
excretion of orotidine was increased in all patients receiving allopurinol. 
After allopurinol administration orotic acid excretion was increased in gouty 
patients but close to normal values in patients with deficiency of HGPRT. 
The increase in the urinary excretion of orotic acid and/or orotidine 
after allopurinol administration indicates an inhibition of OPRT and/or ODC 
activities. The mechanism of this inhibition is studied in chapter 7. When 
allopurinol or oxipurinol was incubated with hemolysate in the presence of 
PRPP, compounds were formed which strongly inhibited ODC activity. The in­
hibitors which were competitive with respect to OMP were presumably allo­
purinol ribonucleotide and oxipurinol 7-ribonucleotide (see Fig.1.7 for 
formulae). The inhibition of ODC leads to an accumulation of OMP, which may 
be dephosphorylated and excreted as orotidine in the urine. Furthermore, 
14 
OMP proved to be an inhibitor of OPRT. It is obvious that the CO -method 
mentioned above could not be used to study the inhibition by OMP because 
14 
this method depends on the ODC activity. Instead, [6- C]orotic acid was 
used as substrate and products were separated from unreacted orotic acid 
by thin-layer chromatography. The inhibition by OMP was competitive with 
respect to PRPP with a К value of 11 yM. The inhibition of OPRT by accu­
mulated OMP might explain the increased urinary excretion of orotic acid 
after allopurinol administration. The absence of orotic aciduria after ad­
ministration of allopurinol in patients with a deficiency of HGPRT is still 
consistent with the proposed mechanism, since the inhibition by OMP is com­
petitive with PRPP and intracellular PRPP concentration is increased in 
these patients (see chapter 3). The same mechanism may also be responsible 
for the increased urinary excretion of orotic acid following administration 
of azauridine, azacytidine and azaorotic acid (see 6.5). 
OPRT and ODC activities in hemolysates of allopurinol-treated patients 
are consistently higher than in control hemolysates, as reported in chapter 
7. This phenomenon can not be ascribed to stabilization by allopurinol of 
these enzymes during cell lysis and extraction, since OPRT activity of 
controls is the same in hemolysates as in intact erythrocytes. During in­
cubation of hemolysates at 37 C, the activities of OPRT and/or ODC appeared 
to be stabilized by allopurinol ribonucleotide and oxipurinol 7-ribonucleo-
tide, and also by PRPP and OMP. These in vitro experiments suggest that the 
apparent increase of OPRT and ODC activities after allopurinol therapy is 
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due to stabilization of the enzymes during the life-span of the erythrocytes 
The absence of a striking increase of OPRT and ODC activities in leukocytes 
after allopurinol administration is consistent with the theory of enzyme 
stabilization because of the short life-span of these cells. 
Chapter 8 supplies evidence for the instability of OPRT and ODC in 
aging erythrocytes The activities of OPRT and ODC in erythrocytes from 
adults are much lower than in erythrocytes from newborns or from patients 
with reticulocytosis. In these latter two groups the mean red cell age is 
younger than in adults. Another factor which may contribute to the in-
creased OPRT and ODC activities m neonatal erythrocytes is stabilization 
of the enzymes by PRPP which is present at a higher concentration in ery-
throcytes of newborns than in those of adults 
Chapter 8 also deals with the activity of pyrimidine 5'-nucleotidase 
in erythrocytes of newborns and adults. This enzyme catalyzes the de-
phosphorylation of UMP, which is the product of the consecutive action of 
OPRT and ODC but also a degradation product of ribonucleic acid Pyrimidine 
5'-nucleotidase was assayed by a new radiochemical method involving thin-
layer chromatography. The activity of this enzyme was similar in erythro-
cytes of newborns and adults, and was higher with OMP as substrate than 
with UMP. Although OMP is a substrate for both ODC and pyrimidine 5'-
nucleotidase, there is no mutual interference in the assays of both enzymes 
at appropriate substrate concentrations. 
Several purine and pyrimidine nucleotides appeared to inhibit OPRT 
activity (chapter 7). The inhibition was competitive with respect to PRPP 
for all inhibitors tested, except TTP. Prior to testing the effects of 
nucleotides on OPRT activity their non-interference with the ODC reaction 
was ascertained (at 0.1 mM OMP) since the OPRT assay was dependent on ODC 
activity. During the OPRT assay, however, OMP concentration is very low 
and there might be a significant inhibition of ODC by nucleotides. There-
fore we investigated in detail the inhibition of ODC activity in human 
hemolysates by purine and pyrimidine nucleotides at low concentrations of 
OMP (chapter 9). ODC of human hemolysate exhibited triphasic kinetics 
(chapters 7 and 9). The inhibition constants of all purine and pyrimidine 
nucleotides - except for CMP - with respect to ODC were high and inhibition 
14 
of ODC could not be the cause of the decrease in CO production from 
14 [carboxyl- C]orotic acid, which is observed when OPRT is assayed in the 
presence of these nucleotides. Inhibition of OPRT which is competitive 
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with respect to PRPP may be important for the regulation of pyrimidine bio-
synthesis and deserves further investigation. 
12.3. ADENOSINE DEAMINASE DEFICIENCY AND PYRIMIDINE METABOLISM 
Deficiencies of ADA and PNP in man are associated with certain forms of 
severe immunodeficiency. Although the precise mechanism which relates the 
enzyme deficiency to the immunodeficiency is not known, there is ample 
evidence that ADA deficiency causes an interference with pyrimidine bio-
synthesis de novo (see 1.5). It is difficult to obtain ADA-deficient lympho-
cytes for investigation since the deficiency is rare and the few patients 
known have severe lymphopenia. Therefore, many studies in this field are 
performed with model systems containing an inhibitor of ADA activity, e.g. 
EHNA (see 1.5). One objection to such studies is that the enzyme inhibitors 
are usually not quite specific. It seemed worthwhile to search for lympho-
cytes which by nature have a low activity of ADA. Since the absence of ADA 
activity in horse erythrocytes had been reported in the literature, we 
decided to measure ADA and PNP activities in erythrocytes and lymphocytes 
of the horse. 
We could confirm the deficiency of ADA in horse erythrocytes (chapter 
10). PNP activity was also virtually absent in these cells. The deficiency 
of both enzymes prevents the irreversible loss of purine nucleosides which 
would otherwise occur since HGPRT activity is absent in these cells (see 
chapter 2). 
Both ADA and PNP activities were consistently lower (about 50%) in 
intact lymphocytes than in sonicated lymphocytes (chapter 10) suggesting 
that the uptake of nucleosides is rate-limiting. ADA activity in extracts 
of horse lymphocytes was much lower than in those of human lymphocytes and 
was comparable to the reported values for lymphocyte extracts of patients 
with severe combined immunodeficiency disease associated with ADA deficiency. 
Similar conclusions were reached in experiments with intact lymphocytes. 
ADA activity is apparently not necessary for normal lymphocyte function in 
horses. Comparison of lymphocyte metabolism in man and horse may provide 
valuable information about the role of ADA in lymphocytes. PNP activity in 
horse and cattle lymphocytes was about 20% of that in human lymphocytes. 
Chapter 11 deals with comparative measurements of uridine metabolism 
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in erythrocytes and lymphocytes of man and horse Undine was not metabolized 
in erythrocytes of both species The absence of uridine kinase in horse 
erythrocytes is remarkable since the enzymes OPRT and ODC are also absent 
(see chapter 2) and therefore Ш1Р can also not be synthesized from exogenous 
orotic acid. Uridine nucleotides must be either conserved during the life­
span of the erythrocyte or supplied by some yet unknown pathway. Preliminary 
experiments in our laboratory indicate that the activity of pyrimidine 5'-
nucleotidase is lower in horse erythrocytes than in human erythrocytes. 
In lymphocyte extracts of horse the conversion of uridine to UMP pro­
ceeded more rapidly than the conversion to uracil. In lymphocyte extracts 
of man and cattle the catabolism of uridine to uracil appeared to be the 
major reaction of undine metabolism. This conclusion was confirmed in ex­
periments with intact lymphocytes. The metabolism of uridine in intact cells 
occurred at a much slower rate than in lymphocyte extracts, probably be­
cause nucleoside uptake is rate-limiting (cf. adenosine and inosine metab­
olism, chapter 10). Furthermore, ODC activity was markedly lower in lympho­
cyte extracts of horse than in those of man and cattle Horse lymphocytes 
apparently have a preference for the utilization of uridine to synthesize 
pyrimidine nucleotides An inhibition of pyrimidine synthesis de novo, 
associated with deficiency of ADA, may be bypassed by means of the salvage 
pathway. 
It is interesting to compare the inhibition of pyrimidine synthesis de 
novo caused by deficiency of ADA with the hereditary deficiency of the 
enzymes OPRT and ODC. Accumulation of orotic acid was observed when cells 
were cultured in the presence of adenosine and ADA inhibitors, but there 
is no orotic aciduria in ADA- deficient patients. ADA deficiency apparently 
affects only some cell types, particularly the cells of the immune system. 
Most patients with hereditary orotic aciduria also have a disturbance of 
the immune system as evidenced by the occurrence of leukopenia. The mega­
loblastic anemia associated with the inherited deficiency of OPRT and ODC, 
however, is not found in patients with ADA deficiency. Uridine therapy is 
successful in hereditary orotic aciduria but seems to have little effect 
in patients with deficiency of ADA This discrepancy might be related to 
differences in the metabolism of uridine between various cell types. In 
human lymphocytes, which would be the target cells for uridine therapy in 
ADA deficiency, catabolism to uracil appears to be the major route of 
uridine metabolism. 
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S A M E N V A T T I N G 
Pyrimidine en purine nucleotxden spelen een belangrijke rol in de stofwisse-
ling van de cel, onder andere als bouwstenen voor de nucleïnezuren en als 
co-enzymen. Deze nucleotiden kunnen op een tweetal manieren worden gevormd 
in de cel. Bij synthese "de novo" wordt uitgegaan van eenvoudige verbindingen 
als CO , ATP, glutamine en ribose in de vorm van phosphonbosylpyrophosphaat 
(PRPP). Bij de zogenaamde "salvage pathway" worden de nucleotiden gevormd 
uit stikstofbasen of nucleosiden. De enzymen van de "salvage pathway" zijn 
ook chemotherapeutisch van belang omdat een groot aantal antimetabolieten 
door deze enzymen wordt omgezet tot de werkzame verbindingen. Er zijn een 
aantal erfelijke stofwisselingsziekten bekend op het gebied van de pyrimi-
dine- en purinestofwisseling. Deze vormden het uitgangspunt voor het hier 
beschreven onderzoek. 
Pyrimidinestofwisseling en purinestofwisseling staan niet op zichzelf 
maar zijn in voortdurende wisselwerking met elkaar en met de stofwisseling 
van koolhydraten en aminozuren. De nauwe samenhang tussen pyrimidine- en 
purinestofwisseling is het belangrijkste thema van dit proefschrift. Een 
drietal aspekten van deze samenhang werd bestudeerd, de rol van PRPP in de 
stofwisseling van pyrimidines en purines (hoofdstukken 2-5), de effekten van 
allopurinol op de purine- en pyrimidinestofwisseling (hoofdstukken 6-9) en 
de mogelijke stoornis in de synthese van pyrimidine nucleotiden als gevolg 
van bepaalde erfelijke enzymdefekten m de purinestofwisseling (hoofdstukken 
10-11). 
Bij het bestuderen van de stofwisseling en de regulering ervan wordt 
veelal gebruik gemaakt van celextrakten of gezuiverde enzymen. Grote voor-
zichtigheid is geboden bij het extrapoleren van de resultaten van dergelijke 
studies naar het metabolisme van de intakte cel, omdat de kondities bij in 
vitro experimenten meestal sterk afwijken van de fysiologische kondities. 
Bovendien moet men er rekening mee houden dat tussen verschillende celtypes 
aanmerkelijke verschillen kunnen bestaan wat betreft de relatieve betekenis 
van bepaalde metabole routes. Daarom zijn in dit proefschrift, waar mogelijk, 
de resultaten verkregen met celextrakten vergeleken met metingen aan intakte 
cellen en zijn veelal zowel erythrocyten als lymphocyten betrokken in het 
onderzoek. 
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In hoofdstuk 1 wordt een overzicht gegeven van de huidige kennis om-
trent de pyrimidine- en purinestofwisseling, de regulering ervan en de 
stoornissen die worden veroorzaakt door erfelijke enzymdeficiënties. 
In hoofdstuk 2 worden de aktiviteiten gerapporteerd van de phosphonbo-
syltransferasen (adenine phosphoribosyltransferase, hypoxanthine-guanine 
phosphoribosyltransferase en orootzuur phosphoribosyltransferase) m hemo-
lysaten van 10 zoogdierspecies. Beide laatstgenoemde enzymen waren afwezig 
in hemolysaat van het paard. De aktiviteit van orotidine-5'-monophosphaat 
decarboxylase bleek in hemolysaten van zoogdieren ongeveer tweemaal zo hoog 
als de aktiviteit van orootzuur phosphoribosyltransferase. 
In hoofdstuk 3 worden de methodes beschreven die zijn ontwikkeld om de 
concentratie van PRPP en de snelheid waarmee deze verbinding wordt gevormd 
te bepalen. Verhoogde concentraties van PRPP werden gemeten in de erythro-
cyten van patiënten met een deficiëntie van hypoxanthine-guanine phosphori-
bosyltransferase of van purine nucleoside Phosphorylase. Deze verhoogde con-
centraties lijken een gevolg te zijn van een verminderd verbruik van PRPP. 
Een verhoogde concentratie van PRPP kan ook worden veroorzaakt door een 
verhoogde synthesesnelheid. Een verhoogd aanbod van PRPP kan een versnelde 
purine biosynthese en een overproduktie van urinezuur teweegbrengen, In 
hoofdstuk 4 wordt het onderzoek beschreven naar de concentratie van PRPP en 
de aktiviteit van PRPP synthetase in erythrocyten van jichtpatienten en van 
een groep adolescenten met een hoge concentratie urinezuur in het serum. 
De aktiviteit van PRPP synthetase werd ook gemeten bij suboptimale concen-
traties van de substraten om afwijkingen in de substraataffiniteit van het 
enzym te kunnen ontdekken. Dergelijke kinetische varianten werden niet ge-
vonden. De concentratie van PRPP in de erythrocyten was eveneens normaal. 
De aktiviteit van PRPP synthetase in hemolysaat was in de groep van adoles-
centen met een hoge urinezuurconcentratie in het serum significant hoger 
dan in de controlegroep. Deze bevinding kan van belang zijn voor het begrip 
van de Pathogenese van primaire jicht. 
In hoofdstuk 5 wordt de concentratie van PRPP in hemolysaten van tien 
zoogdierspecies vergeleken met de capaciteiten van de enzymen die betrokken 
zijn bij de synthese en het verbruik van deze verbinding. Een lage aktivi-
teit van hypoxanthine-guanine phosphoribosyltransferase ging steeds gepaard 
met een hoge concentratie van PRPP. In hoofdstuk 5 wordt tevens gerappor-
teerd over de enzymatische afbraak van PRPP in hemolysaten die veroorzaakt 
lijkt te worden door zure fosfatase. 
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In hoofdstuk 6 is een isotopenverdunningsmethode beschreven voor de 
bepaling van orootzuur, een intermediair uit de pyrimidine synthese de novo. 
Ook orotidine (dat ontstaat door dephosphorylering van orotidine-S'-mono-
phosphaat) kan op deze manier worden bepaald na hydrolytische omzetting tot 
orootzuur. De uitscheiding van orotidine in de urine bleek verhoogd te zijn 
bij alle patiënten die allopurinol kregen toegediend. Allopurinol is een 
struktureel analogon van hypoxanthine en wordt therapeutisch gebruikt om de 
concentratie van urinezuur in het serum te verlagen (via remming van het 
enzym xanthine oxidase). De uitscheiding in de urine van orootzuur was bij 
de meeste patiënten eveneens verhoogd na toediening van allopurinol. 
Hoofdstuk 7 handelt over het mechanisme waarmee allopurinol een ver-
hoogde excretie van orootzuur en orotidine in de urine kan teweegbrengen. 
Metabolieten van allopurinol (allopurinol ribonucleotide, oxipurinol-7-
ribonucleotide) bleken competitieve remmers te zijn van orotidine-5'-mono-
phosphaat decarboxylase. Hierdoor treedt een ophoping van orotidine-5'-
monophosphaat op, dat in de vorm van orotidine kan worden uitgescheiden. 
Bovendien bleek orotidine-5'-monophosphaat een remmer te zijn van het enzym 
orootzuur phosphonbosyltransferase. De remming was competitief met PRPP. 
Deze remming kan een verklaring geven voor de verhoogde uitscheiding van 
orootzuur na toediening van allopurinol. 
In hoofdstuk 7 is eveneens beschreven dat bij patiënten met allopuri-
nol-therapie de aktiviteiten van orootzuur phosphoribosyltransferase en 
orotidine-5'-monophosphaat decarboxylase in de erythrocyten verhoogd zijn. 
De resultaten van in vitro experimenten suggereren dat deze verhoogde enzym-
aktiviteiten mogelijk het gevolg zijn van stabilisatie van deze enzymen door 
metabolieten van allopurinol gedurende de levensduur van de erythrocyt, 
Een dergelijke verhoging van enzymaktiviteiten werd niet gevonden in leuko-
cytenextracten. 
De stabiliteit van enzymen van de pyrimidmestofwisseling in de ouder-
wordende erythrocyt vormt het belangrijkste onderwerp van hoofdstuk 8. 
De aktiviteiten van orootzuur phosphonbosyltransf erase en orotidine-5'-
monophosphaat decarboxylase bleken lager te zijn in erythrocyten van vol-
wassenen dan m rode bloedcellen van pasgeborenen, welke gemiddeld een 
jongere celleeftijd hebben. De aktiviteit van pyrimidine-5'-nucleotidase 
bleek hetzelfde te zijn in erythrocyten van pasgeborenen en van volwassenen. 
Dit enzym werd gemeten met een nieuwe radiochemische methode en vertoonde 
een hogere aktiviteit met orotidine-S'-monophosphaat dan met uridine-S'-
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roonophosphaat als substraat. 
Hoofdstuk 9 handelt over de invloed van purine en pyrimidine nucleo-
tiden op de aktiviteiten van orootzuur phosphoribosyltransferase en oroti-
dine-5'-monophosphaat decarboxylase in hemolysaten van de mens. Het laatst-
genoemde enzym vertoonde trifasische kinetiek. Enige nucleotiden bleken 
remmers te zijn van orootzuur phosphoribosyltransferase (veelal competitief 
ten opzichte van PRPP) of van orotidine-5'-monophosphaat decarboxylase (com-
petitief met orotidine-5'-monophosphaat). 
In hoofdstuk 10 wordt gerapporteerd over de aktiviteiten van adenosine 
deaminase en purine nucleoside Phosphorylase in lymfocyten en hemolysaten 
van mens, paard en rund. Deficiënties van deze enzymen gaan bij de mens 
gepaard met stoornissen in de cellulaire en humorale immuniteit. De aktivi-
teiten van beide enzymen waren in intakte lymfocyten steeds lager dan in 
lymfосуtenextracten. De aktiviteit van adenosine deaminase bleek zeer laag 
te zijn in zowel hemolysaten als in lymfocyten van het paard. 
Aangezien deficiëntie van adenosine deaminase bij de mens gepaard 
schijnt te gaan met een remming van de pyrimidine synthese "de novo", werd 
een onderzoek gedaan naar het relatieve belang van de "salvage pathway" 
voor de synthese van pyrimidine nucleotiden in lymfocyten en erythrocyten 
van mens en paard. De resultaten van dit onderzoek zijn beschreven in hoofd-
stuk 11. Undine bleek niet te worden omgezet door erythrocyten. De omzet-
tingssnelheid van undine in intakte lymfocyten was veel geringer dan die 
in extracten van lymfocyten. De aktiviteit van undine kinase was vergelijk-
baar in lymfocyten van mens, rund en paard. Een hoge aktiviteit van uridine 
fosforylase werd gemeten in lymfocytenextracten van mens en rund maar niet 
in die van het paard. Intakte lymfocyten van de mens maar niet die van het 
paard bleken in staat om undine om te zetten tot uracil. Bovendien was de 
aktiviteit van orotidine-5'-monophosphaat decarboxylase (het laatste enzym 
van de "de novo" synthese) veel lager in lymfocytenextracten van het paard 
dan in die van de mens en het rund. Lymfocyten van het paard schijnen een 
voorkeur te hebben voor het gebruik van uridine om pyrimidine nucleotiden 
te synthetiseren. 
In hoofdstuk 12 tenslotte is getracht de belangrijkste resultaten van 
de voorafgaande hoofdstukken te kombineren en hun onderlinge samenhang te 
verduidelijken. 
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T O E L I C H T I N G 
Gewaardeerde leek, 
Wanneer U geheel onbekend bent met de biochemie, zal het U wellicht moeilijk 
vallen om te begrijpen waarover dit proefschrift handelt. Misschien begint 
U verwachtingsvol de Nederlandstalige samenvatting te lezen maar raakt U de 
draad kwijt bij termen als pyrimidines en purines, enzymen en metabolieten, 
stofwisselingsziekten. Daarom wil ik proberen in het kort toe te lichten wat 
de achtergronden zijn van het hier beschreven onderzoek. 
In de cellen van alle levende wezens vindt voortdurend een groot aantal 
scheikundige reakties plaats waarbij stoffen worden gevormd of afgebroken. 
Deze omzettingen worden teweeggebracht door bepaalde eiwitten, enzymen ge-
naamd. Voor elke reaktie is een apart enzym aanwezig in de cel. Het geheel 
van al deze omzettingen noemen we de stofwisseling of het metabolisme. De 
verbindingen die worden gevormd of afgebroken noemen we metabolieten. Omdat 
de stofwisseling erg veel verschillende reakties omvat is het ondoenlijk de 
gehele stofwisseling tegelijk te bestuderen. Veelal beperken onderzoekers 
zich dan ook tot een bepaald onderdeel, bv. de koolhydraatstofwisseling, de 
vetstofwisseling enz. 
In de zogenaamde nuclel'nezuren van de cel is de informatie vastgelegd 
die bepaalt welke eiwitten (waaronder de enzymen) door de cel zullen worden 
geproduceerd. Deze informatie wordt van geslacht tot geslacht overgeërfd. 
Een afwijking in dit erfelijke materiaal kan tot gevolg hebben dat in de cel 
een verkeerd eiwit wordt gemaakt, bv. een enzym dat niet werkzaam is. In dat 
geval spreekt men van een erfelijke stofwisselingsziekte. Van ongeveer 200 
erfelijke stofwisselingsziekten is thans bekend welk eiwit abnormaal is. Een 
bekend voorbeeld is Phenylketonurie (PKU). Alle pasgeborenen in Nederland 
worden tegenwoordig (met behulp van een hielprik) onderzocht op deze ziekte. 
Daarnaast is bij een aantal ziekten bekend dat erfelijke faktoren een rol 
spelen zonder dat precies is opgehelderd op welke manier. Voorbeelden zijn 
suikerziekte en jicht. 
De bovengenoemde nucleïnezuren zijn o.a. opgebouwd uit de bouwstenen 
purines en pyrimidines. Ook in de stofwisseling van deze purines en pyrimi-
dines zijn een aantal erfelijke afwijkingen bekend. Hiermee zijn we aange-
land op het terrein van onderzoek waarover dit proefschrift handelt. 
Onderzoek op het gebied van erfelijke stofwisselingsziekten is niet alleen 
van belang voor de betrokken patiënten, maar kan ook leiden tot een beter 
begrip van het verloop en de regulering van de normale stofwisseling. Zo is 
het met name uit de bestudering van aangeboren afwijkingen duidelijk gewor-
den dat er een sterke onderlinge samenhang bestaat tussen de pyrimidine-
stofwisseling en de punnestofwlsseling. Deze onderlinge samenhang is voor-
al een gevolg van de regulerende rol van phosphoribosylpyrophosphaat, afge-
kort PRPP. De vele reakties die betrokken zijn bij de vorming en het ver-
bruik van deze verbinding zijn weergegeven in Figuur 1.5 (proefschrift, pag. 
9 ). In de eerste hoofdstukken van dit proefschrift zijn de resultaten be-
schreven van onderzoekingen met betrekking tot deze verbinding PHPP. Onder 
andere werd onderzocht of er in de rode bloedcellen van jichtpatiénten af-
wijkingen zijn in de stofwisseling van PRPP. Vervolgens worden experimenten 
beschreven over de bijwerkingen van het geneesmiddel allopurinol. Dit ge-
neesmiddel wordt (o.a. bij jichtpatiénten) gebruikt om afwijkingen in de 
purinestofwisseling te korrigeren, maar heeft ook bijwerkingen met betrek-
king tot de stofwisseling van pynmidines, zoals blijkt bij onderzoek van 
de urine. De laatste hoofdstukken handelen over een tweetal erfelijke af-
wijkingen in de stofwisseling van de purines. Deze afwijkingen komen tot 
uiting in een gestoorde immunologische afweer en lijken veroorzaakt te wor-
den door een storing in de stofwisseling van de pynmidines. 
Men zal zich afvragen wat al deze onderzoekingen nu hebben opgeleverd. 
Welnu, wie denkt dat de verschijnselen van de onderzochte erfelijke ziekten 
nu volledig verklaard kunnen worden of dat er misschien zelfs een genees-
wijze kan worden aangegeven, komt bedrogen uit. Dit soort vraagstukken is 
meestal zo ingewikkeld dat ze alleen zijn op te lossen wanneer de gegevens 
die gedurende vele jaren zijn vergaard in talloze laboratoria over de gehele 
wereld worden gekombineerd. De hier beschreven onderzoekingen geven meer 
inzicht in de manier waarop allopurinol de stofwisseling van pynmidines 
beïnvloedt. Verder is aangetoond dat sommige enzymen van de purine- en pyri-
midinestofwisseling afwezig zijn in bloedcellen van bepaalde dieren. Bestu-
dering van deze cellen kan misschien bijdragen tot een beter begrip van deze 
stofwisseling bij de mens. Bovendien zijn methoden beschreven om op een be-
trouwbare manier erg lage concentraties van PRPP en van orootzuur te meten. 
Mogelijk komen deze methoden andere onderzoekers van pas bij hun experimenten. 
Nijmegen, november 1978. Wil Tax 
STELLINGEN 
I 
De op isotopenverdunning gebaseerde bepaling voor orootzuur zoals beschreven 
door Cohen et al. is niet korrekt wegens een onjuiste verhouding tussen de 
concentraties van phosphoribosylpyrophosphaat en [carboxyl-^dorootzuur. 
A.Cohen, G.E.J.Staal, Α.J.Ammann en D.W.Martin (1977) J.Clin.Invest. 60. 
491-494. 
Dit proefschrift, hoofdstuk 6. 
II 
De konklusie van Janeway en Cha dat er een orotidine Phosphorylase voorkomt 
in lymphoma-cellen wordt niet gerechtvaardigd door hun experimenten. 
C.M.Janeway en S.Cha (1977) Cancer Res. 37, 4382-4388. 
Ill 
Beardmore et al. houden bij de interpretatie van hun gegevens onvoldoende 
rekening met de instabiliteit van phosphoribosylpyrophosphaat. 
T.D.Beardmore, J.C.Meade en W.N.Kelley (1973) J.Lab.Clin.Med. 81, 43-52. 
Dit proefschrift, hoofdstuk 8. 
IV 
De hypothese van Grobner en Kelley dat de verhoogde aktiviteiten van oroot­
zuur phosphoribosyltransferase en orotidine-5'-phosphaat decarboxylase in 
hemolysaten na toediening van allopurinol een gevolg is van stabilisatie 
van deze enzymen gedurende de extractieprocedure, is onjuist. 
W.Grobner en W.N.Kelley (1975) Biochem.Pharmacol. 24, 379-384. 
Dit proefschrift, hoofdstuk 7. 
V 
De nummering van de pyrimidine-ring zoals die gehanteerd wordt door sommige 
leveranciers van radioaktieve verbindingen is niet in overeenstemming met 
de lUPAC-regels en werkt daardoor verwarrend. 
VI 
Het gebruik van strychnine als geneesmiddel bij niet-ketotische hyper-
glyclnemie toont opnieuw aan dat het verschil tussen geneesmiddel en gif 
voornamelijk bepaald wordt door de dosis. 
R.Gitzelmann, B.Steinmann en M.Cuenod (1978) N.Engl.J.Med. 298, 1424 
VII 
De snelheid waarmee de stofwisseling in zoogdieren plaatsvindt wordt in be-
langrijke mate bepaald door de snelheid waarmee het bloed substraten en 
zuurstof aanvoert. 
H.A.Coulson, T.Hernandez en J.D.Herbert (1977) Comp.Biochem.Physiol. 56A, 
251-262. 
Vili 
De opvatting dat de dalende perinatale sterfte een gevolg is van het stij-
gende percentage bevallingen in het ziekenhuis dient te worden betwijfeld. 
G.J.Kloosterman (1978) Ned.T.Geneesk. 122, 1161-1171. 
IX 
Bij de bestudering van de samenhang tussen zoutconsumptie en hypertensie 
dient meer aandacht te worden besteed aan de hoeveelheid kalium in het dieet. 
G.H.Meneely en H.D.Battarbee (1976) Am.J.Cardiol. 38, 768-785. 
X 
De term zwangerschapsonderbreking suggereert ten onrechte dat het hier een 
ingreep betreft die weer ongedaan gemaakt kan worden. 
XI 
Invoering van de bekende regel uit het straatvoetbal "driemaal hoekschop is 
strafschop" kan het voetbal als kijksport ten goede komen. 
XII 
Voor Amerikaanse toeristen kan binnenkort gelden: op de markt is Uw dollar 
een daalder waard. 
Nijmegen, 17 november 1978 W.J.M. Tax 


